CONFIDENTIAL –FOIA Exemptions Apply in U.S. 1
Status: Approved ,Date: 22 November 2020Janssen Research & Development *
Clinical Protocol
A Double -blind, Randomized, Psychoactive Placebo -controlled, Study to Evaluate the 
Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in 
Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of 
Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Subjects Assessed to 
be at Imminent Risk for Suicide
Protocol ESKETINSUI2002 ; Phase 2b
AMENDMENT 4
JNJ-54135419   (esketamine)
*Janssen Research & Development is a global organization that operates through different legal entities in
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen
Biologics, BV; Janssen -Cilag International NV; Janssen, Inc; Janssen Sciences Ireland UC; or Janssen
Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these
various legal entities; the sponsor is identified on the Contact [CONTACT_290075].
This compound is being investigated in Phase 3 clinical studies. 
This study  will be conducted under US Food & Drug Administration I NDregula tions (21 CFR 
Part 312).
EudraCT NUMBER:         2016 -004422 -42
Status: Approved
Date: 22November 2020
Prepared by: [CONTACT_12945] & Development   
EDMS number :EDMS- ERI-132382053, 5.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements . 
Confidentiality Statement
The information provided herein contains Company trade secrets, commercial or financial information that the Company 
customarily holds close and treats as confidential.  The information is being provided under the assurance that the recipi[INVESTIGATOR_23754], regulations, rules, protective orders or otherwise .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 2
Status: Approved , Date: [ADDRESS_461868] OF IN -TEXT T ABLES A ND FIGURES ................................................................................................ 5
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................. 37
TIME AND EVENTS SCHE DULE –DOUBLE -BLIND TREA TMENT PHA SE.......................................... 49
TIME AND EVENTS SCHE DULE –POST -TREA TMEN T FOLLOW -UP PH ASE..................................... 52
SIBAT TIME A ND EVENT S SCHEDULE –DOUBLE -BLIND TREA TMENT PHAS E.............................. 55
SIBAT TIME A ND EVENT S SCHEDULE –POST -TREATMENT FOLLOW -UP PH ASE......................... 55
ABBREVIA TIONS ...................................................................................................................................... 56
1. INTRODUCTION ................................................................................................................................ 58
1.1. Background .................................................................................................................................... 59
1.1.1. Nonclinical Studies ..................................................................................................................... 59
1.1.2. Clinical Studies ........................................................................................................................... 60
[IP_ADDRESS]. Completed and Ongoing Clinical Studies with Intranasal Esketamine .................................... 60
[IP_ADDRESS]. Human Pharmacokinetics and Product Metabolism ................................................................ 61
[IP_ADDRESS]. Efficacy .................................................................................................................................... 62
[IP_ADDRESS]. Safety and Tolerability ............................................................................................................. 63
1.2. Psychoactive Placebo Control ....................................................................................................... 66
1.3. Overall Rationale for the Study ...................................................................................................... 67
2. OBJECTIVES, ENDPOINT S, AND HYPOTHESIS ........................................................................... 67
2.1. Objectives and Endpoints .............................................................................................................. 67
2.1.1. Objectives ................................................................................................................................... 67
2.1.2. Endpoints .................................................................................................................................... 69
2.2. Hypothesis ..................................................................................................................................... 70
3. STUDY DESIGN A ND RA TIONA LE................................................................................................ .70
3.1. Overview of Study Design .............................................................................................................. 70
3.2. Study Design Rationale .................................................................................................................. 72
3.2.1. Study Population ......................................................................................................................... 72
3.2.2. Treatment and Study Duration ................................................................................................... 73
3.2.3. Control, Randomization and Blinding ......................................................................................... 73
3.2.4. Esketamine Dose ........................................................................................................................ 74
3.2.5. Psychoactive Placebo ................................................................................................................. 75
3.2.6. Efficacy  Measures ...................................................................................................................... 75
3.2.7. Safety Evaluations ...................................................................................................................... 78
3.2.8. Pharmacokinetic Assessments ................................................................................................... 79
3.2.9. Biom arker and Pharmacogenomic (DNA and RNA) Evaluations ............................................... 79
[IP_ADDRESS]. Biom arker ................................................................................................................................ 79
[IP_ADDRESS]. Pharmacogenomic/Epi[INVESTIGATOR_18193] (DNA and RNA )...................................................................... [ADDRESS_461869] POPUL ATION.................................................................................................................. 79
4.1. Inclusion Criteria ............................................................................................................................ 80
4.2. Exclusion Criteria ........................................................................................................................... 83
4.3. Prohibitions and Restrictions ......................................................................................................... 86
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 3
Status: Approved , Date: [ADDRESS_461870]- Treatment Follow -up Phases ............................................................................................. 96
9.1.5. Early W ithdrawal ......................................................................................................................... 96
9.2. Efficacy  Evaluations ....................................................................................................................... 97
9.2.1. Children’s Depression Rating Scale, Revised (CDRS -R).......................................................... 97
9.2.2. Suicide Ideation and Behavior Assessment Tool (SIBAT) ......................................................... 97
9.2.3. Montgomery -Asberg Depression Rating Scale .......................................................................... 98
9.2.4. Children’s Depression Inventory 2: Self -Report (Short) ............................................................. 98
9.3. Pharmacokinetics ........................................................................................................................... 99
9.3.1. Evaluations ................................................................................................................................ .99
9.3.2. Analytical Procedures ................................................................................................................. 99
9.3.3. Pharmacokinetic Parameters ..................................................................................................... 99
9.4. Pharmacokinetic/Pharmacodynamic Evaluations ........................................................................ 100
9.5. Biom arker and Pha rmacogenomic (DNA and RNA) Evaluations ................................................ [ADDRESS_461871] COMPLETION/DISCONTINUA TION OF STUDY TREA TMENT/ WITHDRA WAL 
FROM THE STUDY ......................................................................................................................... 108
10.1. Completion ................................................................................................................................... 108
10.2. Discontinuation of Study Treatment/ Withdrawal from the Study ................................................. [ADDRESS_461872] Information ...................................................................................................................... 110
11.2. Sample Size Determination ......................................................................................................... 110
11.3. Efficacy  Analyses ......................................................................................................................... 110
11.4. Pharmacokinetic Analy ses........................................................................................................... 112
11.5. Biom arker and Pharmacogenomic Analyses ............................................................................... 112
11.6. Safety Analyse s........................................................................................................................... 113
11.7. Independent Data Monitoring Committee .................................................................................... 115
12. ADVERSE EVENT REPORTING .................................................................................................... 115
12.1. Definitions .................................................................................................................................... 115
12.1.1. Adverse Event Definitions an d Classifications ......................................................................... 115
12.1.2. Attribution Definitions ................................................................................................................ 117
12.1.3. Severity Criteria ........................................................................................................................ 117
12.2. Special Reporting Situations ........................................................................................................ 118
12.3. Procedures ................................................................................................................................... 118
12.3.1. All Adverse Events .................................................................................................................... 118
12.3.2. Serious Adverse Events ........................................................................................................... 119
12.3.3. Pregnancy ................................................................................................................................ .120
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 4
Status: Approved , Date: [ADDRESS_461873] Quality .......................................................................... 121
14. STUDY DRUG INFORM ATION....................................................................................................... 121
14.1. Physical Description of Study Drug(s) ......................................................................................... [ADDRESS_461874] ................................................. 129
16.2.3. Informed Consent/Pediatric Assent Form ................................................................................. 130
16.2.4. Privacy of Personal Data .......................................................................................................... 131
16.2.5. Long- Term Retention of Samples for Additional Future Research .......................................... 132
16.2.6. Countr y Selection ..................................................................................................................... 132
17. ADM INISTRA TIVE REQUI REM ENTS ............................................................................................ 132
17.1. Protocol Amendments .................................................................................................................. 132
17.2. Regulatory Documentation .......................................................................................................... 133
17.2.1. Regulatory Approval/Notifi cation .............................................................................................. [ADDRESS_461875] Identification, Enrollment, and Screening Logs .............................................................. 134
17.4. Source Documentation ................................................................................................................. 134
17.5. Case Report Form Completion .................................................................................................... 135
17.6. Data Quality Assurance/Quality Control ...................................................................................... [ADDRESS_461876] Retention ......................................................................................................................... 136
17.8. Monitoring .................................................................................................................................... 137
17.9. Study Com pletion/Termination ..................................................................................................... 137
17.9.1. Study Com pletion/End of Study ................................................................................................ [ADDRESS_461877] OF A TTACHMENTS
Attachment 1: Prohibited/Permitted Concomitant Medications ....................................................... 146
Attachment 2: Growth Charts: Stature -for-Age Percentiles for Use in Blood Pressure 
Assessments ............................................................................................................ 149
Attachment 3: 95thPercentile Blood Pressure Levels For Sex by [CONTACT_46855] ......................... 151
Attachment 4: Postdose Blood Pressure: W ithdrawal Criteria Levels for Sex by [CONTACT_368977] ....................................................................................................................... 153
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 5
Status: Approved , Date: [ADDRESS_461878] OF IN -TEXT TA BLES A ND FIGURES
TABLES
Table 1: Dose administration of Intranasal Esketamine 28, 56, 84 mg or Placebo ................................ 90
Table 2: Approximate Volume of Blood to be Collected from Each Subject .......................................... 92
FIGURES
Figure 1: Schematic Overview of the Study ............................................................................................. 72
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 6
Status: Approved , Date: [ADDRESS_461879] recent amendment.
Amendment 4 (01 December 2020 )
The overall reason for the amendment: The overall reason for the amendment is to update the text related to 
statistical methods onsample size determination and multiple testing procedure. The multiple testing procedure 
has been modified to im prove pow er while controlling the overall Type I error rate when comparing the 
individual doses with psychoactive placebo.
Applicable Section (s) Description of Change(s)
Rationale: Text for sample size determination and multiple testing procedure w as updated to improve power 
while controlling the overall Type 1 error rate when comparing the individual doses with psychoactive placebo.
Synopsis, Sample 
Size Determination;
Section 11.2.Sample 
Size DeterminationText w as revised as follows:
The sample size for this study was calculated assuming an effect size of 0.65 between any 
dose of esketamine and psychoactive placebo for the change from baseline at 24 hours 
postdose for the CDRS -R total score and a 12-sided significance level of 0.025 0.05. A 
total of 145 subjects will be randomized in this study. Using a 1:1:1:2 randomization ratio 
(esketamine 28 mg: esketamine 56 mg: esketamine 84 mg: psychoactive placebo), 
approximately 58 subjects will need to be randomized to psychoactive placebo and 29 
subjects will need to be randomized to each esketamine treatment group to achieve 80% 
power for the comparison of each esketamine dose 94% power for the comparison 
of the pooled doses of esketamine 56 m g and esketamine 84 m g versus psychoactive 
placeb o and 92% power for at least one of the 2 esketamine higher dose s(56-mg and 
84-mg)  versus psychoactive placebo. The effect size of 0.65 is based on results from 
study ESKETINSUI2001 (mean difference between treatment groups of -7.2 and a pooled 
SD of 11.02) for MADRS total score.
Rationale: A pooled sequential multiple testing strategy will be implemented to contr ol Type 1 error.
Synopsis, Primary 
Efficacy Analysis;
Section 11.3.Efficacy 
AnalysisText w as revised as follows:
As the primary analysis, each dose will be compared to psychoactive placebo using the 
appropriate contrast at a 1sided significance level of 0.025. A fixed sequence test 
procedure will be applied where the 84mg dose will be tested first and the 56mg dose 
will be tested only if the 84 mg dose is shown to be significant.
A pooled sequential multiple testing procedure will be implemented to control for 
Type 1 error.  The esketamine 56-mg and 84-mg treatm ent groups will be pooled and 
compared with psychoactive placebo at a 2-sided significance level of 0.05. If this 
comparison achieves statistical significance in favor of esketamine, the 56-mg dose 
and the 84-mg dose will each be simultaneously tested versus psychoactive placebo 
at the 2-sided significance level of 0.05 based on the closed testing procedure. The 
28-mg dose will be tested only if both the individual doses of 56 mg and 84 mg are 
shown to be significant.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 7
Status: Approved , Date: 22 November 2020Applicable Section (s) Description of Change(s)
Rationale: An additional database lock (DBL) and analysis of efficacy and safety will be performed when the last 
subject completes the double- blind Day 25 visit. This analysis will enable selection of a dose for the planned Phase 
3 trial, facilitating Phase 3 trial design and preparation as early as possible. Database locks will also be performed 
at Days 81 and 200 (study completion)
Synopsis ,
Other Objectives
Section 2.1.1. 
Objective
Other ObjectiveText was revised as follows:
 To evaluate the safety and tolerability of intranasal esketamine at specified times 
through the initial 25 day double- blind treatment period (Day 25), the 8-week 
post-treatment follow -up (Day 81) and 6-month post-treatm ent follow -up, with 
special attention given to the follow ing assessments:
 Effects on suicidal ideation and behavior using the SIBAT
 Effects on cognitive function as measured by [CONTACT_368978] 5. 
TREATMENT 
ALLOCATION AND 
BLINDING
BlindingIn general, randomization codes will be disclosed fully only if the study is completed and 
the clinical database is closed. How ever, an analysis is planned after the last subject 
completes the Day 2581visit. Randomization codes will be disclosed to the sponsor in 
order to plan for Phase [ADDRESS_461880] Treatment Follow up p hase (Day 81)25-day Double -blind Treatment 
Period (Day 25). This analysis will enable selection of a dose for the planned Phase [ADDRESS_461881] completes the Day 81 Visit and Day 200 Visit , 
respectively.
Amendment 3 (20Novem ber 2018)
Overall reasons for the am endment: The protocol w as modified to 1) streamline the assessment schedule 
(number, type and timing of study visits and visit windows) to reduce burden for subjects who discontinue the 
study; 2) update Attachment 1  (Prohibited and Permitted Concomitant Medications) with new guidelines; 3) add 
blood pressure withdrawal criteria and clarify blood pressure exclusion criteria and guidance; 4) include changes 
to biomarker and pharmacogenomic assessmen ts;and 5) update consent/assent language to reflect the pediatric 
study population requirements. 
Applicable Section(s) Description of Change(s)
Rationale: Blood Pressure (BP) exclusionary criteri onwasupdated to include information for both Screening 
(Day  -1) and Day 1.  Attachment 2 “Weight Chart” w as replaced by a “Stature Chart” as the “Weight Chart” was 
erroneously included and stature is needed to determine the appropriate criteria for individual subject BP 
thresholds. Titles for At tachments 2 and 3 w ere revised accordingly, and Attachment 4 was added to include 
guidance for postdose BP w ithdraw al values. Language wasupdated for clarity.
Synopsis Key Exclusion 
CriteriaExclusion criterion was modified as follows:
On Day -1 (screening) or Day 1 of the double -blind phase prior to 
randomization, a supi[INVESTIGATOR_1662] -supi[INVESTIGATOR_368895]/or DBP ≥ the 95thpercentile 
for sex, age and height is exclusionary. Subjects who fall below  the 5thor above 
the 95thpercentile for their age, sex, and height should be evaluated using the 
parame ters for the 5thor 95thpercentile. Note that subjects whose SBP and/or 
DBP values are ≥ the 95thpercentile for sex, age and height may be reevaluated 
with a repeated measure once after [ADDRESS_461882] to assess eligibility.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 8
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
Section 4.2. Exclusion Cr iteria Exclusion criterion 7 was revised as follows:
Criterion modified per Amendment 3
7.2. On Day -1 (screening) or Day 1 of the double -blind phase prior to 
randomization, a s upi[INVESTIGATOR_1662] -supi[INVESTIGATOR_368895]/or DBP ≥ the 95thpercentile 
for sex, age and height is exclusionary. Subjects who fall below  the 5thor above 
the 95thpercentile for their age, sex, and height should be evaluated using the 
parameters for the 5thor 95thpercentile. Note that subjects whose SBP and/or 
DBP values are ≥ the 95thpercentile for sex, age and height may be reevaluated 
with a repeated measure once after [ADDRESS_461883] the new titles of Attachments 2 and3,andto add 
information for a new attachment (Attachment 4):
Attachment 2 (Grow th Charts: Stature -for-Age Percentiles for Use in Blood 
Pressure Assessments ) and Attachment 3 (95thPercentile Blood Pressure Levels 
For Sexby [CONTACT_46855]) will be used to determine the 95thpercentile for 
both the systolic (SBP) and diastolic blood pressures (DBP) by [CONTACT_4321], age and 
height percentile (refer to Attachment 3 for instr uctions).
On any dosing day , if either the postdose SBP or DBP levels are equal to or 
greater than the sex, age and height values in Attachment 4 ( Postdose Blood 
Pressure: Withdrawal Criteria Levels for Sex by [CONTACT_46855] ), the blood 
pressure should be repeated after the subject rests for at least 5 minutes (ie, 
sitting or supi[INVESTIGATOR_050]). If the values are still equal to or greater than the sex, age and 
height values in Attachment [ADDRESS_461884] should be w ithdrawn from the study
and appropriate follow -up clinical care should be initiated.
Rationale: Withdraw al criteria were updated to include 1) additional therapi[INVESTIGATOR_368896], 
and 2) to include the withdrawal of subjects whose postdose withdrawal values for systol ic and /ordiastolic blood 
pressure exceed sindividual thresholds thatare equal to or above the 99thpercentile for age, height and sex plus 
1.28 SD over the mean . These values are now added in Attachment 4. 
Section 10.2. Discontinuation 
of Stu dy
Treatment/With drawal from 
the StudyThe follow ing withdrawal criteria w ereadded:
Requires treatment with ECT, TMS, ketamine or esketamine
Subjects whose postdose SBP or DBP measures are equal to or greater than 
the sex, age and height values in Attachment 4 (after a repeated 
measurement).
Rationale: Text related to early withdraw al and discontinuation during the D ouble-B lind and Post-Treatment 
Follow -Up phase was updated in Section 9.1.5 . and deleted from Section 10.2. to avoid redundancy.
Changes were made to reduce burden while still thoroughly assessing safety parameters for subjects who 
discontinue the study .
Section 9.1.5. Early 
Withdraw alThe text w as revised as follows:
Subjects who discontinue Double -Blind Study treatment for reasons other than 
withdrawal of consent /assent , lost to follow -up or death w ill have the DB EW 
visit conducted at the time of discontinuation. In addition, if the DB EW visit 
occurs on Day [ADDRESS_461885] visit (eg, by [CONTACT_756]) will be 
conducted 5 days (+/ -2 day s) after the last dose of study medication. If remote 
contact D+5 occurs within 2 days of the early withdrawal visit, use the +[ADDRESS_461886] D+[ADDRESS_461887] visit will 
also be conducted on D ay 25 to assess PWC -20, CDRS -R and MADRS, and for 
collection of concomitant therapi[INVESTIGATOR_368897]. If the DB EW visit occurs on or 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 9
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
after Day 22 (assuming dose administered), D25 RC visit is not required, 
however, RC D+5 ([ADDRESS_461888] dose) should be perfo rmed.
Subjects who discontinue from the Post -Treatment Follow -Up phase for reasons 
other than withdraw al of consent/assent, lost to follow -up or death w ill have the 
Post-Treatment Early Withdrawal visit conducted at the time of discontinuation. 
In additio n, if the PT EW visit occurs prior to completion of the Day [ADDRESS_461889] (eg, by [CONTACT_756]) will be performed on Day 81 for PWC -20, 
CDRS -R and MADRS, and for collection of concomitant therapi[INVESTIGATOR_368897]. If 
the PT EW visit occurs within ±5 day s window  of Day 81 (Visit 18), then early 
withdrawal visit will be adequate, and the Day 81 RC visit is not required. If 
subjects discontinue anytime betw een Day 25 postdose and Day 28 RC of the 
PT phase, the PT EW visit is not required; how ever, Day 28 RC should be 
performed.
Section 10.2. Discontinuation 
of Study 
Treatment/Withdrawal from 
the StudyThe follow ing text was deleted, and instructions added to refer to Section 9.1.5. :
Subjects who discontinue study treatment prior to completion of the Double -
Blind Treatment phase (Day 25 visit), will have an Early Withdraw al visit 
conducted at the time of treatment discontinuation. Subjects who discontinue 
double- blind study treatment for reasons other than withdrawal of consent, lost 
to follow -up or de ath w ill be contact[CONTACT_112485] [ADDRESS_461890] (eg, by [CONTACT_756]) on Days 25 and 81 for CDRS -R 
and MADRS assessments and adverse event collection is acceptable. 
If the Earl y Withdrawal visit occurs within a window of ±1 days of the Day 25 
visit of the Double -Blind Treatment phase , or within a window  of ±[ADDRESS_461891] (eg, by [CONTACT_756]) on Day [ADDRESS_461892] -Treatment Early Withdrawal visit conducted at 
the time of discontinuation.
Rationale: TheCGI-SR-I was added to correct the inadvertent omission from the protocol as an objective and 
endpoint.
Synopsis , Other Objectives ,
Endpoints; Overvie w of Study 
DesignCGI-SR-I was added to “Other Objectives” and “Endpoints”:
To evaluate the efficacy of single and repeated doses of intranasal 
esketamine compared w ith psychoactive placebo in reducing symptoms of 
suicidal ideation, as assessed by [CONTACT_87793] –Imminent 
Suicide Risk (CGI -SR-I) from the Suicide I deation and Behavior 
Assessment Tool (SIBAT) at [ADDRESS_461893] dose and 
through the end of the Double -Blind Treatment phase (Day 25).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 10
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
CGI-SR-I from SIBAT
oChanges from baseline, post single and repeated doses, at [ADDRESS_461894] dose, through the end of the Double -Blind 
Treatment phase (Day  25).
CGI-SR-I was added as “other efficacy evaluation”:
The primary efficacy evaluation is the CDRS -R;other efficacy evaluations 
are SIBAT/CGI -SS-R and CGI -SR-I, MADRS, CDI 2:SR(S).
Section 2.1.1 . Objectives CGI-SR-I was added to “Other Objectives”
To evaluate the efficacy of single and repeated doses of intranasal 
esketamine compared w ith psychoactive placebo in reducing symptoms of 
suicidal ideation, as assessed by [CONTACT_87793] –Imminent 
Suicide Risk (CGI -SR-I) from the Suicide I deation and Behavior 
Assessment Tool (SIBAT) at [ADDRESS_461895] dose and 
through the end of the Double -Blind Treatment phase (Day 25).
Section 2.1.2 .Endpoints CGI-SR-I was added to “Other Efficacy Endpoints”
CGI-SR-I from SIBAT
oChanges from baseline, post single and repeated doses, at [ADDRESS_461896] dose, through the end of the Double -Blind 
Treatment phase (Day  25).
Section 3.1. Overview of 
Study Design
Section 3.2.6 .Efficacy 
MeasuresCGI-SR-I was added as “other efficacy evaluation”:
The primary efficacy evaluation is the CDRS -R; other efficacy evaluations 
are SIBAT/CGI -SS-R and CGI -SR-I, MADRS, CDI 2:SR(S).
Added description for “Clinical Global Impression of Imminent Suicide Risk 
(CGI -SR-I)”:
The CGI -SR-I is a scale summarizing the clinician’s best assessment of the 
likelihood that the subject w ill attempt suicide in the next 7 days (see Section 
9.2.2) . 
The CGI -SR-I will be used to evaluate other objectives by [CONTACT_58833]:
Change in imminent sui cide risk at 4 hours postdose on Day 1, 24 hours 
postdose on Day 2, and through the end of the Double -Blind Treatment 
phase
Synopsis , Other Efficacy 
Analyses; Section 11.3 . 
Efficacy Analyse sCGI-SR-I was added to the text for “Other Efficacy Analyses”:
The ranks of changes from baseline over time for both CGI -SS-R and CGI -SR-I 
will be analyzed using an ANCOVA model using last observation carried 
forw ard data with factors for treatment a nd center and baseline CGI -SS-R and 
CGI-SR-I (unranked) as a covariat e. Treatment differences will be estimated 
using the Hodges -Lehmann estimate, which is the median of all possible paired 
differences for the change from baseline for CGI -SS-Rand CGI-SR-I.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 11
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
Rationale: Clarifications were made to indicate that biological data w ill be used to predict inter -individual 
variability in esketamine treatment response. Additionally, text was modified to make it clear that the Day 4 
biomarker collection should occur at the same time as the PK collection during the 1.5 to 2.5 hour postdose 
window , thus reducing the number of separate venipunctures. Finally, text has been added to clarify the timing 
and duration of “fasting” prior to a blood sample collection, and to also make it clear that if fasting is not feasible,
subjects should try to eat a low -fat diet for at least 8 hours prior to the sample collection. Added “RNA” to the 
title of Section 9.5. Biomarker and Pharmacogenomic (DNA and RNA ) Evaluations .
Synopsis , Endpoints;
Section 2.1.2. EndpointsModified the text to include “biological predictors”:
Biomarkers
Characteristics of esketamine mechanism of action or biological 
predictors of inter -individual variability 
Time and Events Schedu le, 
Double -Blind Treatment 
Phase, footnote “ii”Added the following to the T&E table:
On Day 4, biomarker sampling to be performed during the 1.5 to 2.5 hour PK 
window .
Footnote “ii” was clarified as follows:
ii.  These samples will be collected along with the 1.5 to 2.5 hour PK collection.
Section 9.5. Biomarker and 
Pharm acogenomic (DNA and 
RNA ) EvaluationsThetext w as modified as follows :
If possible, blood samples should be collected under fasting conditions 
(minimum 8 hours prior to biomarker sample collection, water is permitted). 
When fasting is not feasible, subjects should follow  a low fat diet for at least 8 
hours prior to sample collection, if possible. Subjects should refrain from 
exercise/strenuous physical activity and the use of non -steroidal anti -
inflammatory drugs (NSAIDs) for 24 hours prior to blood collec tion. Not 
following these recommendations will not constitute a protocol violation.
Rationale: There is a large body of evidence that depression and antidepressant treatment response are both 
related to changes in gene transcription.  T hus,RNA collection was added to the study protocol to allow  for 
explorations of these relationships.  As a result, changes were made to the text to add collection of samples for 
RNA analyses, and to make clear that thes e samples will be collected pre dose.  Additionally, tex t was added to 
make clear that the RNA will be used for analyses of gene transcription both in the present study, and in 
combination with RNA samples from other studies, to investigate the biological bases of inter -individual 
variability in depression phen otypes. 
Synopsis ,
Overvie w of Study Design
andBiomarker and 
Pharm acogenomic (DNA and 
RNA ) EvaluationsThe text w as modified to include RNA:
Blood samples for DNA and RNA analyses will be collected from subjects who 
consent/assent separately to this component of the study (where local 
regulations permit). Subject participation in DNA and RNA research is 
optional.
Time and Events Schedule,
Double -Blind Treatment 
Phase [P harmacogenomic
(DNA & RNA) –Optional]Clarified in footnote “t” that blood sample collection for the pharmacogenomic 
blood sample collection at Day 25 w ill occur predose:
t. Performed predose
Section 3.2.9. Biomarker and 
Pharm acogenomic (DNA and 
RNA) Evaluations, Section 
[IP_ADDRESS]. Pharmacogenomic/
Epi[INVESTIGATOR_18193] (DNA and RNA)Added text for collection o f samples for RNA analyses:
The goal of the pharmacogenomic component is to collect DNA and RNA to 
allow  the identification of genetic and/or epi[INVESTIGATOR_368898] (PK), pharmacodynamics (PD), efficacy, safety, or 
tolerability of esketamine and to identify genetic factors associated w ith MDD 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 12
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
and suicidality in patients with MDD assessed to be at imminent risk for 
suicide. 
The DNA, RNA, protein and metabolic biomarker samples may be used to help 
address emerging issues and to enable the development of safer, more effective, 
and ultimately individualized therapi[INVESTIGATOR_014].
Section 9.5. Biomarker and 
Pharm acogenomic (DNA and 
RNA) Evaluations , 
Pharm acogenomics, 
Epi[INVESTIGATOR_7009], and Gene 
Transcription Evaluation sAdded text for collection of samples for RNA analyses and to clarify that RNA 
will be used fo r analyses of gene transcription:
Subject participation in pharmacogenomics/epi[INVESTIGATOR_18193]/gene transcription 
evaluations is optional. Whole blood samples for DNA and RNA analyses will 
be collected from all subjects who provide consent/assent for pharmacogenomic 
research at the time points indicated in the Time and Events Schedule.
DNA and RNA samples will be analyzed for the assessment of genetic variation 
and tr anscription of genes in pathways relevant to MDD and suicidality. 
Additional analyses may be conducted if it is hypothesized that this may help 
resolve issues with the clinical data. 
DNA and RNA samples will be used for research related to esketamine or 
MDD. They may also be used to develop tests/assays related to esketamine and 
MDD. Pharmacogenomic research may consist of the analysis of one or more 
candidate genes or of the analysis of genetic markers throughout the genome (as 
appropriate) in relation to esketamine or MDD clinical endpoints.
All genetic data obtained during this study may be included in ongoing cross -
study analyses to investigate the relationship between depression severity and 
phenotypes and biomarkers.
Synopsis , Statistical Met hods, 
Biomarker and 
Pharm acogenomic Analyses ; 
Section 11.5. Biomarker and 
Pharm acogenomic AnalysesAdded text for collection of samples for RNA analyses and to clarify that RNA 
will be used fo r analyses of gene transcription:
Pharm acogenomic analyses (DN A and RNA) may include candidate gene 
analyses, genome -wide association analyses, and gene transcription analyses in 
relation to treatment response, non -response, and MDD. Additional explora tory 
analyses may be performed.
Rationale: Text w as added to allow  for collection of menstrual cycle information.  Menstrual cycle phase can 
affect values for many biomarkers related to stress, metabolism, and inflammation. A line was added to the T&E 
table for clarity.
Time and Events Schedule, 
Double -Blind Treatment 
Phase (Biomarkers)In the Time and Events Schedule –Double Blind Treatment Phase , Menstr ual 
Cycle Tracking was added as a line in the T&E table to be conducted when 
biomarker samples are taken .
Section 9.5. Biomarker and 
Pharm acogenomic (DNA and 
RNA ) EvaluationsText w as added to indicate that menstrual cycle tracking was added to the Time 
and Events Schedule as a study procedure:
Per the Time and Events Schedule, information on menstrual cycle (date of first 
day of last period, average length of cycle) will be recorded at each visit when 
blood samples for biomarker analysis are collected.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 13
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
Rationale: Under “Clinical Laboratory Tests”, criteria w ere m odified to allow  standard of care local laboratory 
test results to be used for eligibility if performed up to 72 hours prior to signing of ICF (formerly 24 hours) to 
reduce the need for an additional blood draw  if the timeframe exceeds [ADDRESS_461897] was updated to add qualifier on how  UDS should be performed. Text was updated to 
clarify timing of assessments for Cogstate® computerized cognitive battery, pulse oximetry and MOAA/S.
Section 9.6.  Safety 
Evaluations ,
Clinical Laboratory TestsDeleted “random” from urine sample for urinalysis:
Blood samples for serum chemistry and hematology and a urine sample for 
urinalysis will be collected. 
Modified criteria for standard of care local laboratory test results:
A local laboratory will be used at screening to ensure results are available in 
enough time to determine subject eligibility. If standard of care clinical 
laboratory tests are performed within 72 hours prior to the screening visit (ie, 
signing of the ICF), r esults for those laboratory tests required per protocol at 
screening can be used for determination of subject eligibility. A local laboratory 
can also be used in any instance where safety follow -up is time -critical and the 
central laboratory results are no t expected to be available before actions need to 
be taken for safety reasons.
Added text to clarify that central laboratory samples must be collected at Day -1 
(screening), following ICF process:
At Day - 1 (screening), following ICF process , central lab oratory samples must 
also be collected.
Under the Urinalysis bullet point, clarified that urinalysis is performed at the 
centr al laboratory using a dipstick and added “specific gravity” to list. Central 
laboratory w ording added to sediment testing.
Urina lysis 
Dipstick performed at central laboratory
-specific gravitySediment (if central laboratory dipstick 
result is abnormal)
Section 9.6. Safety 
Evaluations , Clinical 
Laboratory Tests;
Section 5. Treatment 
Allocation and BlindingAdded qualifier on how urine drug screen (UDS) should be performed:
To maintain the integrity of the study blind, a urine drug screen (UDS) should 
not be performed during the DB period unless medically necessary. If deemed 
medically necessary, the medical monitor should be contact[CONTACT_368979].
Section 9.6. Safety 
Evaluations , Cogstate 
computerized cognitive 
batteryClarified timing of assessment s:
The Cogstate computerized cognitive battery is a validated set of assessments 
which wi ll be performed to assess verbal learning and memory and evaluate 
cognitive function. There are 4 in -study assessment times for these: between 
Day 4 and Day 8 (prior to discharge; predose if performed on dosing day), Day 
25 predose, DB EW, Day 81, Day 200, PT EW.
Section 9.6. Safety 
Evaluations , Vital Signs 
(Tem perature, Pulse/Heart 
Rate, Respi[INVESTIGATOR_13581], Blood 
Pressure)Clarified timing of assessment s:
Blood pressure, heart rate, and respi[INVESTIGATOR_368899] (should be 
performed between t = -15 m in and t = 0) and at t = 40 mins, 1 hr, and 1.5 hrs 
postdose; temperature at predose only.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 14
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
Section 9.6. Safety 
Evaluations , Pulse OximetryClarified timing and documentation of assessment:
On each dosing day, the device w ill be attached to the finger, toe, or ear, and 
SpO 2should be m onitored and documented once predose between t = - 15 m in 
and t =0 (first spray) and then every 15 minutes postdose for approximately 1.5 
hours .
Section 9.6. Safety 
Evaluations, Modified 
Observer's Assessment of 
Alertness/Sedation 
(MOAA/S )Clarified timing of assessment:
On each intranasal dosing day, the MOAA/S should be performed once predose 
betw een t = -15 m in and t = 0 (first spray), and every 15 min for approximately 
1.5 hr s postdose (or longer, if necessary).
Section 9.6. Safety 
Evaluations, Brief Psychiatric 
Rating Scale, Positive 
Symptom Subscale (BPRS+)Clarified timing of assessments:
On each dosing day, BPRS+ to be performed predose and at 40 minutes and 1.5 
hours postdose.
Section 16.2.1 .Investigator 
Responsibilities , Safety during 
StudyClarified timing of assessments:
Based on previous studies, it is known that certain adverse drug reactions occur 
postdose, peak around 40 minutes, and then dissipate, usually within 4 hours. 
The study includes careful monitoring following study drug dosing. Vital signs 
are performed at predose ( should be performed between t = -15 m inutes and t = 
0) and at 40 minutes, 1 hour, and 1.5 hours postdose. Oxygenation should be 
monitor ed predose (performed betw een t = -15 m inutes and t = 0), and every 
15minutes thereafter through to approximately 1.5 hours postdose, or longer, if 
necessary. Additionally, other known sideeffects of esketamine (eg, 
dissociation, sedation, conceptual dis orientation, hallucinogenic behavior, and 
abnormal thought content) are monitored closely during this time using specific 
assessment tools like CADSS, MOAA/S, and BPRS+. On each dosing day, 
CADSS and BPRS+ should be performed predose and at 40 minutes and 1.5 
hours postdose; MOAA/S should be performed predose (between t = -15 
minutes and t = 0) and every 15 minutes thereafter through to approximately 1.5 
hours postdose, or longer, if necessary.
Rationale: Textwas clarified with respect to the timing for r epeat B3 and B10 administration .
Section 9.7. Other 
Evaluations, Questions B3 and 
B10 from the MINI -KIDIf screening is longer than [ADDRESS_461898] be repeated to confirm eligibility.
Rationale: Footnotes w ere reord ered for clarity. Extraneous text was removed from footnotes. Visits and visit 
windows for subjects who discontinue treatment have been updated. Standard of care psychol ogical therapy line 
in the Post -Treatment Follow -Up T&E w as added. UDS removed from Day [ADDRESS_461899] burden. DNA 
collection was added to Day -1 to allow  for the acquisition of epi[INVESTIGATOR_18193] (methylation) markers prior to the first 
dose of esketamine. These epi[INVESTIGATOR_368900] (Day 25). Menstrual cycle tracking added as a line under Biomarkers in the Double -Blind T reatment 
T&E table. Errors i n the SIBAT T&E w ere corrected , some footnotes w ere deleted. Footnote “b” was added
modify instructions for SIBAT assessments if hospi[INVESTIGATOR_368901] a visit day.
Time and Events Schedule,
Double -Blind Treatment and 
Post-Treatment Follow -Up 
Phase ,SIBAT Time and Footnote “a” added:
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 15
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
Events Schedule ,Double -
Blind Treatment and Post-
Treatment Follow -Up Phasea. Day -[ADDRESS_461900] be performed both as part of the 
screening visit and as part of the Day 1 visit (predose).
Modif ied footnotes “e”, “f”and “g”pertaining to discontinuatio n and early 
withdrawal from th e Double -Blind Treatment phase:
e. Subjects who discontinue from the DB phase for reasons other than lost to 
follow  up, death, or w ithdrawal of consent/assent will have the DB EW visit 
conducted at the time of discontinuation . In addition , if the DB EW visit occurs 
on Day [ADDRESS_461901] visit (eg, by [CONTACT_756]) 
on Day 25 to assess PWC -20, CDRS -R and MADRS, and for collection of 
concomitant therapi[INVESTIGATOR_368897] (Refer to Sections 9.1.5 .and10.2).
f. If the DB EW visit occurs on or after Day 22 (assuming dose administered), 
D25 RC visit is not required, however, RC D+5 ([ADDRESS_461902] dose) should 
be performed. If subjects discontinue anytime between Day 25 postdose and 
Day 28 RC of the PT phase, the PT EW visit is not required; however, Day [ADDRESS_461903] to 
follow  up, death, or w ithdrawal of consent /assent , a remote contact [CONTACT_368980] 5 days (+/ -2 days) after the last dose of study medication. If RC D+5 
occurs within 2 days of the EW visit, use the +[ADDRESS_461904] the RC 
D+5 visit. 
Mod ified footnotes “mm”, “nn” and “oo” pertaining to discontinuation and 
early withdraw al from the Post-Treatment Follow -Up phase:
mm. Subjects who discontinue from the PT phase for reasons other than lost to 
follow  up, death, or w ithdrawal of consent/assent will have the PT EW visit 
conducted at the time of discontinuation. If the PT EW visit occurs prior to 
completion of the Day [ADDRESS_461905] will be performed on Day 81 
for PWC -20, CDRS -RandMADRS, and for collection of concomitant 
therapi[INVESTIGATOR_368897] . (refer to Sections 9.1.5 and 10.2).
nn. If the PT EW visit occurs wi thin ±5 days window  of Day 81 (V isit 18) of 
the PT phase, then EW visit will be adequate, and the Day [ADDRESS_461906] to follow up, death, or w ithdraw al of consent/assent after completion 
of the Day [ADDRESS_461907] the PT EW visit conducted at the time of 
discontinuation (refer to Section 10.2).
Footnote “o” for urine pregnancy test was modified to remove “drug screen” :
o.In addition to the scheduled time points, ad ditional pregnancy tests can be 
performed during the study at the investigator’s discretion (refer to Section 5).
UDS on Day 25 was removed in order to preserve the integrity of the study 
blind. Footnote “p”was added to clarify how UDS testing should be performed:
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 16
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
p. Due to the need to preserve the integrity of the study blind, a urine drug 
screen (UDS) should not be performed during the DB period unless medically 
necessary. If deemed medically necessary, the medical monitor should be 
contact[CONTACT_368981] s hould be performed predose on dosing days.
Weight measurement was added to Day 25.
Modified footnotes “u”, “x” and “z”to clarify timing of assessments:
u. Blood pressure, heart rate, and respi[INVESTIGATOR_368899] ( should
be performed betw een t = -15 min and t = 0) and at t = 40 mins, 1 hr, and 1.5 
hrs postdose; temperature at predose only (tympanic recommended).
x. On each dosing day, continuous arterial oxygen saturation monitoring by 
[CONTACT_406] (SpO 2) should be monitored and do cumented once predose 
betw een t = -15 m in and t = 0 (first spray), and then every 15 mins postdose for 
approximately 1.5 hrs (see Section 9.6). 
z. On each dosing day, MOAA/S should be performed once predose betw een t 
= -15 m in and t = 0 (first spray), an d every 15 min for approximately 1.5 hrs 
postdose (longer, if necessary; refer to Section 9.6). 
In the Double -Blind Treatment Phase, Menstrual Cycle Tracking was added as 
a line in the T&E table to be conducted when biomarker samples are taken.
Administrative and Standard of care psychological therapy row s were included 
in the Post-Treatment Follow -Up phase of the Time and Events Schedule.
The follow ing changes were made to the timing of sample collection:
Day 1 draw s for biomarkers moved to Day -1
DNA and RNA sampling added to Day -1
RNA sampling added to Day 25 /DB EW
On Day 4, biomarker sampling to be performed during the 1.5 to 2.5 
hour PK w indow
On Day 25, clinical labs moved from postdose to predose; DNA, RNA 
and biomarkers collected at the same time.
Updated the SIBAT Time and Events Schedule ( Double -Blind Treatment 
Phase and Post-Treatment Follow -Up Phase) to be consistent w ith the main 
Time and Events Schedule ( Double -Blind Treatment Phase and Post-Treatment 
Follow -Up Phase). Footnote “b” is new:
b. If the actual day of discharge coincides with another scheduled study visit, all 
study procedures for the scheduled visit should be completed and duplicate 
assessments are not required.
Section 3.2.2. Treatment and 
Study DurationText w as aligned with changes to the visit schedule per Section 9.1.4. Post -
Treatment Follow -Up Phases:
Visits will continue to occur twice a week for the first 2 w eeks (Days 28, 32, 
35, 39), after which visits will occur w eekly (Days 46 and 53), then every 2 
weeks (Days 67 and 81). The Day [ADDRESS_461908] -Treatment Follow -
Up phase (Days 81 -200), during which they will have monthly visits to assess 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 17
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
safety. Investigators may add follo w-up visits as dictated by [CONTACT_423]’s 
clinical condition and the investigator’s clinical judgment.
Section 9.1.[ADDRESS_461909] -Treatment 
Follow -Up PhasesText w as aligned w ith the Time and Events schedule:
The Day [ADDRESS_461910] concomitant therapi[INVESTIGATOR_368897].
Rationale: PCP was added to the below  sections to correct omissions. Mentions of esketamine w ereremoved and 
sites will be directed to capture this information under ketamine.
Synopsis , Objectives; Section 
2.1.1. ObjectivesText modified as follows:
To evaluate the potential for ketamine or PCP abuse during the follow -up as 
measured by [CONTACT_9859] -Back (TLFB).
Synopsis, E ndpoints ; Section 
2.1.2. EndpointsText mo dified as follows:
Safety endpoints will be evaluated throughout the study, as follow s: 
TLFB methodology to evaluate use of ketamine or PCP.
Section 9.6. Safety 
Evaluations , Tim eline Follow -
Back (TLFB)Text modified as follows:
The TLFB w ill be used to assess the potential for ketamine and PCP abuse 
during the follow -up phase. The Timeline Follow -Back (TLFB), a clinical and 
research tool used to obtain a variety of quantitative estimates of alcohol and 
drug use, will be used to evaluate the potential for ketamine or PCP abuse 
during the follow -up.
Rationale: Updated the informed consent/pediatric assent language to accurately reflect the pediatric study 
population requirements.
Section 4.1. Inclusion Criteria; 
Section 9.1.2. Screening 
Phase; Section 10.3. 
Withdraw al from the Use of 
Research Samples; Section 
16.1. Study -Specific Design 
Considerations; Section 
16.2.1. Investigator 
Responsibilities; Section 
16.2.3. Informed 
Consent/Pediatric Assent 
Form ; Section 16.2.4. Privacy 
of Personal Data ; Section 
16.2.5. Long -Term  Retention 
of Samples for Additional 
Future ResearchAdded “subject(s) and/or parent(s)/LAR(s)” and “pediatric assent/informed 
consent” wherever applicable.
Section 16.2.3. Informed Consent/Pediatric Assent Form : Entire section was 
modified.
Rationale: Text wasadded to selectively permit subjects to be rescreened .
Section 4. Subject Population Text w as modified as follows:
Requests to rescreen an individual subject must be evaluated and approved by 
[CONTACT_368982] a case -by-case basis.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 18
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
Rationale:  To clarify standard of care psychotherapy guidanc e, text was included to provide guidance on 
acceptable types of psychotherapi[INVESTIGATOR_014], and to state that the frequency of psychotherapy visits should be determined 
based on clinical need at the discretion of the treatment team .
Section 6. Dosage and 
Administration ; Section 9.1.3. 
Double -Blind Treatment 
PhaseText w as modified as follows:
Treatment with a psychological intervention is also required, at least through 
the initial [ADDRESS_461911]-Treatment Follow -Up phase (Day 81). The specific 
antidepressant and type of psychological intervention selected for a given 
subject w ill be based on the treating physician(s) clinical judgment, knowledge 
of the subject ’s prior treatment history, and practice guidelines. Acceptable 
types of psychological interventions include individual cognitive behavioral 
therapy (CBT) , interpersonal therapy, family therapy, and psychodynamic 
psychotherapy. Other evidence - based psycho therapi[INVESTIGATOR_368902].  The frequency of psychotherapy visits 
should be determined based on clinical need ,at the discretion of the treatment 
team.
Rationale: Text w as modified t o clarify the num ber of nights associated with the 5 day sof recommended 
inpatient hospi[INVESTIGATOR_059] , and to specify order of SIBAT administration .
Section 9.1.3 .Double -Blind 
Treatment PhaseText w as modified as follows:
Subjects will remain in the inpatient psychiatry unit or other permitted setting 
for a recommended duration of 5 days (4 nights) from randomization, with 
shorter or longer hospi[INVESTIGATOR_368903].
Specified the order of SIBAT as follows:
SIBAT 
Patient Portion
Clinician Portion
Rationale: Text w as revised to clarify that theTLFB includes a paper calendar.
Section 17.[ADDRESS_461912] w as revised as follows:
Subject -and investigator -completed scales and assessments designated by [CONTACT_103] w ill be considered source data. The CDRS -R, MADRS, SIBAT, CDI 
2:SR(S), MOAA/S, YMRS, PWC -20, BPRS+, MINI -KID, Cogstate
computerized cognitive battery, TLFB (including paper calendar ), nasal 
symptom questionnaire, and CADSS will be considered source data.
Rationale: Redundant text was deleted.
Section 3.2.7. Safety 
EvaluationsThe follow ing text was deleted:
A list of prohibited therapi[INVESTIGATOR_313276] 1 for general guidance 
for the investigator; however, this list is not all -inclusive.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 19
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
Rationale: Text related to prohibitions and restrictions was clarified.
Section 4.3. Prohibitions and 
Restrictions; Section 8. 
Prestudy and Concomitant 
TherapyThe text w as modified as follows:
Subjects may not receive electroconvulsive therapy (ECT), trans -cranial 
magnetic stimulation (TMS) , ketamine or other antidepressant therapi[INVESTIGATOR_014] (aside 
from those allowed ) during the study.
A list of concomitant therapi[INVESTIGATOR_368904], permitted, and permitted 
with restrictions is provided in Attachment 1 for general guidance for the 
investigator; however, this list is not all -inclusive.
Rationale: Table [ADDRESS_461913] during each study phase. Added DNA sampling at Day -1 and added RNA 
sampling to Day -1 and Day 25/ DB EW.
Section 9 .Study Evaluations The text w as modified as follows:
The Time and Events Schedule summarizes the frequency and timing of 
efficacy, PK, biomarker, pharmacogenomic (DNA and RNA), and safety 
measurements applicable to this study.
The maximum total blood volume to be collected from eac h subject w ill be 
approximately 56.5 mL for subjects who are particip ating in 
pharmacogenomics/epi[INVESTIGATOR_368905] (see Table 2 ); total blood volume 
will be less for subjects who are not participating in these evaluations, as 
presented in Table 2 .
Table 2 f ootnotes “b” and “d” were modified as follows:
b.At screening, 2 samples will be collected for analysis – 1 sample each for the 
SoC local laboratory (to have results prior to Day 1 dose) and the central 
laboratory (see Section 9.6for further details). Volume is approximate for local 
laboratories. 
d.Pharmacogenomi c (DNA and RNA) blood sample(s) will be collected only 
from subjects who have consented to provide an optional sample for genetic 
research.
Rationale: Attachment [ADDRESS_461914] of prohibited/permitted concomitant medications and the 
guidelines for concomitant medication use. 
Attachment 1 :
Prohibited/Permitted 
Concomitant Medications Table of Prohibited/Permitted Concomitant Medications was edited to include 
new guidelines for w ashout timing, updated information on medications that are 
prohibited, permitted and permitted with restrictions and clarify the reasons in 
the c omments c olumn for some therapi[INVESTIGATOR_368906] .
Information was reorder ed for clarity ( therapi[INVESTIGATOR_368907] ) and additional medications were added.
Rationale: “Weight Chart” was replaced by a “Stature Chart” as the “Weight Chart” was erroneously included 
and stature is needed to determine individual blood pressure thresholds.
Attachment 2:Grow th Charts: 
Stature -for-Age Percentiles 
for Use in Blood Pressure 
AssessmentsAdded the following tables:
Grow th Charts: Stature -for-Age Percentiles for Use in Blood Pressure 
Assessments (Boys and Gi rls, 2 to 20 years)
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 20
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
Rationale: Attachment (95thpercentile blood pressure levels) was revis edto be used with grow th charts to 
determine appropriate criteria for exclusion.
Attachment 3: 95thPercentile 
Blood Pressure Levels For 
Sex by [CONTACT_368983] (for boys and girls):
95thPercentile Blood Pressure Levels for Sex by [CONTACT_368984]: New attachment ( postdose blood pressure w ithdraw al criteria) was added to be used to determine 
individual postdose blood pressu re thresholds.
Attachment 4:Postdose Blood 
Pressure: Withdrawal Criteria 
Levels for Sex by [CONTACT_368985] (for boys and girls):
Postdose Blood Pressure: Withdraw al Criteria Levels for Sex by [CONTACT_368977] . 
Rationale: Minor errors w ere noted
Throughout the protocol Minor grammatical, formatting, or spelling changes were made
Amendment 2 (14June 2017 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union 
The overall reason for the amendment: The protocol w as modified to 1) permit the initiation of standard of care 
antidepressant during the 1st7 days  of double -blind treatment, to reflect local standard of care in regions where it 
is not routine to initiate two medications simultaneously; 2) remove cognitive assessment at baseline and replace 
the RAVLT with the Internat ional Shoppi[INVESTIGATOR_220037] (ISLT); 3) expand description of safety evaluations; and 4) 
clarify within the Time & Events schedule the different recall periods for efficacy assessments used at certain study 
visits
Applicable Section(s) Description of Change(s)
Rationale: Modification that subjects will receive standard of care antidepressant medication that may be 
initiated or optimized during the first 7 days of the double -blind phase if starting tw o medication ssimultaneously 
is not consistent with local clinical practice .
Time & Events Schedule, 
Double -Blind Treatment 
Phase, footnote (kk)Revision indicating that antidepressant treatment maybe initiated or optimized 
within the first 7 days of the Double-Blind Treatm ent Phase if starting tw o 
medications simultaneously is not consistent with local clinical practice.
T&E Schedule: Standard of Care Antidepressant Assignment: Predose :footnote 
(kk)added.
3.1. Overview  of Study 
Design, 
Figure 1, legend, footnote (a)The text w as revised as follows (bold text added; strikeout text deleted):
Standard of care Antidepressant treatment medication willshould be initiated or 
optimized on Day 1. However initiating standard of care antidepressant 
medication up to [ADDRESS_461915] dose of study m edication (Day 1) is 
permitted if starting two m edications simultaneously is not consistent with 
local clinical practice.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 21
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
6. Dosage and 
Administration;
9.1.3. Double- Blind 
Treatment PhaseAntidepressant therapy should be chos en and started on or before Study
medication should be initiated or optim ized on Day 1. However initiating 
standard of care antidepressant m edication up to [ADDRESS_461916] dose 
of study m edication (Day 1) is permitted if starting two medications 
simultaneously is not consistent with local clinical practice.
16.[ADDRESS_461917] dose of study medication (Day 1) is perm itted if starting two 
medications simultaneously is not consistent with local clinical practice.
Rationale: Clarification that subjects must agree to take one of the prescribed antidepressant therapi[INVESTIGATOR_368908] -blind treatment phase (Day 25).
Synopsis, Subject 
Population;
4.1. Inclusion CriteriaInclusion Criterion No. 7 was revised as follows (bold text added; strikeout text 
deleted) :
As part of the newly initiated or optim ized standard of care treatment, subject 
must agree to take one of the prescribed non -investigational antidepressant 
medications (fluoxetine, escitalopram, sertraline) forat least the duration of
during the double -blind treatment phase (Day  25).
Rationale: Modification to reflect that the Cogstate safety assessment will no t beperformed at screening as 
subject sin acute crisis may not be able to be accurate ly assessed . 
Time & Events Schedule,
Double -Blind Treatment 
PhaseThe follow ing Safety Assessment will no tbe performed at screening:
Cogstate test battery cognitive assessment
Rationale: Modification to reflect that instead of the Re y Auditory Verbal Learning Test (RAVLT) the ISLT will 
used to evaluate verbal learning and memory to accommodate all languages in countries where the study is being 
conducted.
Synopsis, Objectives, Endpoints, 
Hypothesis;
Synopsis, Safety Evaluations;
Synopsis, Statistical Methods, 
Safety Analyses;
Time & Events Schedule, 
Double Blind Treatment Phase, 
Post-Treatment Follow -up 
Phase,
footnote (bb);
2.1.1. Objectives;
2.1.2. Endpoints;
3.1. Overview  of Study Design;
3.2.7. Safety Evaluations;
9.6. Safety Evaluations;
11.6. Safety Analyses;
17.4. Source DocumentationThe Re y Audito ry Verbal Learning Test (RAVLT), designed to assess verbal 
learning and memory ,will not be used to evaluat ecognitive function as part 
of the safety and tolerability assessment for this study
Text referring to the Rey Auditory Verbal Learning Test (RAVLT) 
has been deleted and has been replaced w ith text referring to the ISLT 
where appropriate .
The “Cogstate test battery cognitive assessment ” has been changed to :
“Cogs tatecomputerized cognition battery ”.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 22
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
9.6. Safety Evaluations The follow ing additional information is provided on safety evaluations: 
Young Mania Rating Scale (YMRS) 
YMRS will be administered to assess treatment -emergent occurrence and 
severity of manic epi[INVESTIGATOR_1841]. The YMRS is an eleven -item multiple choice 
questionnaire which is used to measure the severity of manic epi[INVESTIGATOR_368909]. It is based on the patient’s subjective report of his or her 
clinical condition over the previous hour s. Additional information is based upon 
clinical observations made during the clinical interview. The scale is completed 
by a clinician or other trained rater and takes 15 -30minutes to complete. The 
symptom items were selected based upon published descrip tions of the core 
symptoms of mania; the YMRS is a reliable, valid and sensitive rating scale to 
measure the severity of mania.[ADDRESS_461918] (PWC -20)
The PWC -20 w ill be administered by [CONTACT_368986]. The PWC -20 
is a 20 -item simple and accurate method to assess potential development of 
discontinuation symptoms after stoppi[INVESTIGATOR_368910]. The PWC -20 is a 
reliable and sensitive instrument for the assessment of anxiolytic discontinuation 
symptoms.106Discontinuation symptoms occur early and disappear rather 
swiftly, depending upon speed of taper, daily medication dose, and drug 
elimination half -life.106
Cogstate computerized cognitive battery  
The Cogstate computerized cognitive battery, is a validated set of assessments 
which will be performed to assess verbal learning and memory and evaluate 
cognitive function. 12, 28, 64There are 4 in -study assessment times for these: 
betw een Day 4 and Day 8 (prior to discharge; pre- dose if performed on dosing 
day), Day [ADDRESS_461919] -treatment follow -up phase.
The battery will provide assessment of mult iple cognitive domains, including 
attention, visual and verbal learning and memory, and executive function. The 
tests use culture neutral stimuli, enabling use in multilingual/multicultural 
settings. The computerized battery includes:
Simple and choice rea ction time tests; scored for speed of response: 
oDetection (DET; Psychomotor Function)
oIdentification (IDN; Attention)
Visual epi[INVESTIGATOR_10682]; visual recall test 
oOne Card Learning (OCL; Visual Learning)
Working memory (n back task); scored for speed of correct response 
oOne Back (ONB; Working Memory)
Verbal learning and memory assessment
oInternational Shoppi[INVESTIGATOR_96063] (ISLT)
Executive function; maze/sequencing test, scored for total number of errors:
oThe Groton Maze Learning Test (GML; Executive Function)
All measures in the cognitive battery have been validated against traditional 
neuropsychological tests and are sensitive to the effects of various drugs on 
cognitive performance, including alcohol and b enzodiazepi[INVESTIGATOR_1651]. The subject 
completed computerized cognitive test battery has been used for cognitive 
assessment in several child and adolescent research trials including attention 
deficit hyperactivity disorder,7and demonstrates good reliability and vali dity in 
child and adolescent populations.6The ISLT has also been used in adolescent 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 23
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
trials, demonstrating sensitivity, reliability and validity. The subject completed 
cognitive battery requires approximately 25 minutes; the clinician administered 
ISLT req uires approximately [ADDRESS_461920] Task (ISLT), that will be 
administered by [CONTACT_15370]. The ISLT is a [ADDRESS_461921] w ill also complete a series of other tasks for 15- 20 
minutes, before being asked to recall the 12 w ords from the ISLT again –this is 
called a Delayed Recall trial. The subject will also be shown a list of words and 
asked to recognize previously presented words, a Word Recognition trial.
Timeline Follo w-Back (TLFB)
TLFB w ill be used to assess the potential for ketamine, esketamine, and PCP 
abuse during the follow -up phase. The Timeline Follow  Back (TLFB),35a 
clinical and research tool used to obtain a variety of quantitative estimates of 
alcohol and drug use, will be used to evaluate the potential for ketamine or 
esketamine or PCP abuse during the follow -up. The Timeline Follow -Back 
method has been used in studies to quantify ketamine use in adults, as well as to 
evaluate substance use in various adolescent populations.62
11.6. Safety Analyses The text w as revised as follows (bold text added; strikeout text deleted):
Cogstate Computerized Cognitive Battery RAVLT and Cogstate test 
battery
Cognitive function data from the RAVLT Cogstate computerized cognitive 
battery and Cogstate test battery cognitive screening assessment will be 
summarized descriptively at each designated scheduled visit by [CONTACT_1570].
TimeLine Follow -Back (TLFB)
The TLFB, a clinical and research tool used to obtain a variety of quantitative 
estimates of ketamine and PCP abuse, w ill be summarized descriptively at each 
scheduled visit by [CONTACT_1570].
Rationale: Clarification that in addition to nasal examination, a nasal symptom questionnaire w ill be performed 
to monitor for any signs of adverse effects on the nasal mucosa, as part of the safety evaluations .
Synopsis, Overview of Study 
Design;
Synopsis, Safety 
Evaluations;
3.1. Overv iew of Study 
Design;
3.2.7. Safety Evaluations ;Safety Evaluations revised to include nasal symptom questionnaire 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 24
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
Rationale: Clarification that the Children’s Depression Inventory 2, Self- Report (Short Form) (CDI 2:SR[S]) is a 
12-item patient rated self -assessment of depressive symptoms in youth .A 24 -hour recall period w ill be used on 
Day 2; a 2 -week recall period will be used at all other assessments .
3.2.6. Efficacy Measures The text w as revised as follows (bold text added; strikeout text deleted)
Children’s Depression Inventory 2, Self -Report (Short Form ) (CDI 2:SR[S])
The CDI 2:SR(S) assessment is a multi rater patient rated assessment of 
depressive symptoms in youth aged 7 to 17 years and an efficient screening 
measure that contains 12 items and takes 5 to 10 minutes to administer.
9.2.3. Children’s Depression 
Inventory 2, Self -Report 
StudyDescriptive text regarding the multi -rater CDI 2 has been deleted since it is not 
applicable to this study. 
The CDI 2: SR(S) is based on the Children’s Depression Inventory 2 (CDI 2) 
and Children’s Depression Inventory 2 Self -Report (CDI 2:SR). The CDI 2 is a 
comprehensive multirater assessment of depressive symptoms in youth aged 7 to 
17 years. When used w ith other sources of verified information, the CDI 2 can 
aid in the early identification of depressive symptoms, the diagnosis of 
depression and related disorders, and the monitoring of treatment effectiveness. 
The CDI 2 quantifies depressive symptomatology using reports from 
children/adolescents (full length and short), teachers, and parents (or alternative 
caregivers).
9.2.3. Children’s Depression 
Inventory 2, Self -Report 
StudyCorrection to description of CDI 2 :SR assessment:
The CDI 2:SR is a 1228-item self-reported assessment.
Time & Events Schedule Footnote (u) CDI 2:SR(S) –Subject -completed assessment. A 24 -hour recall 
period applies on Day 12; a 2-week recall period applies at all other assessments.
Rationale: Clarification of the recall periods in this study used for assessment of the Efficacy Evaluations: 
CDRS -R and MADRS
9.2.1. Children’s Depression 
Rating Scale R evised 
(CDRS -R)Efficacy Evaluations: CDRS -R and MADRS: clarification of the recall periods in 
this study
The text w as revised as follows (bold text added; strikeout text deleted)
9.2.1. Children’s Depression Rating Scale, Revised (CDRS -R)
The typi[INVESTIGATOR_368911] -R is [ADDRESS_461922] assessment recall, a 4 hour recall on 
Day 1 and Day 25 postdose, and a 24 hour recall on Day 2. The 4 recall 
periods: a 7 -day recall on Day 1 (predose) ; a 4-hour recall at the 4 -hour 
postdose assessment on Days 1 and 25 ;a 24-hour recall at t he post-dose 
assessment on Day 2 ; and a “since last assessment” recall predose on Day 4 
through Day 25 dosing days . “Since last assessment” recall will also be used 
in Post-Treatm ent Follow -up assessments on Days 28, 32, [ADDRESS_461923] to calculate the total score.
9.2.2. Montgomery -Asberg 
Depression Rating Scale9.2.2. Montgom ery-Asberg Depression Rating Scale
The typi[INVESTIGATOR_154881] 7 days. In this study, the MADRS 
will be adm inistered using 4 recall periods: a 7 -day recall on Day 1 
(predose); a 4 -hour recall at the 4 hour postdose assessment on Days 1 and 
25; a [ADDRESS_461924] -dose assessment on Day 2; and a “since last 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 25
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
assessment” recall predose on Day 4 through Day 25 dosing days. “Since last 
assessment” recall will also be used in Post -Treatm ent Follow -up 
assessments on Days 28, 32, [ADDRESS_461925] to calculate the total 
score.
9.1.3. Double- Blind 
Treatment PhaseMADRS and CDRS -R will be perform ed at both predose and 4 -hour 
postdose assessments on Day 25 (visit 10) of the double -blind treatm ent 
phase.
Rationale: Clarification of the recall periods for the MADRS and CDRS -R efficacy assessments during the 
Double -Blind Treatment Phase and the Post -Treatm ent Follow -up Phase
Time & Events Schedule The CDRS -R and MADRS assessments were expanded to indicate each of the 
four recall periods in order to clarify for the site.
The follow ing changes were made to the Time & Events Schedule:
Double -Blind Treatment Phase : Efficacy Assessments
Children’s Depression Rating Scale Revised (CDRS -R)oand Montgomery -
Asberg Depression Rating Scale (MADRS)z: assessments on Days 1 (predose 
and 4 hours), 2, 4, 8, 11, 15, 18, 22, 25, D/C and DB EWweremodified.
The follow ingchanges were made: 
-Children’s Depression Rating Scale Revised (CDRS -R)o (recall: 7 days): 
assessment predose on Day 1 ;
-Montgomery -Asberg Depression Rating Scale (MADRS)z (recall :7 days): 
assessment predose on Day 1; 
-CDRS -R (recall: 4 -hours postdose): D ay 1, 4 -hours (visit 2) and Day 25 
(visit 10);
-MADRS (recall: 4 hours postdose): Day 1, 4 -hours (visit 2) and Day 25 
(visit 10);
-CDRS -R (recall: 24 hours postdose): Day 2;
-MADRS (recall: 24 hours postdose): Day 2;
-CDRS -R (recall: since last assessment predose ): Day 4 through to Day 
25, D/C and DB E W;
-MADRS (recall: since last assessment predose ): Day 4 through to Day 25, 
D/C and DB E W
Post-Treatm ent Follow -up Phase: Efficacy Assessments
Children’s Depression Rating Scale Revised (CDRS -R)oand Montgomery -
Asberg Depression Rating Scale (MADRS)z: assessments on Days 32, 39, 46, 
53, 67, 81, every 4 weeks up to and including Day 200, and PT E Wwere
modified
The follow ingchanges were made:
-Children’s Depression Rating Scale Revised (CDRS -R): (recall: 7 days)o: 
Day 46, 53, 67, 81, every 4 weeks up to including Day 200, and PT E W
-Montgomery -Asberg Depression Rating Scale (MADRS) (recall: 7 
days)z: Day 46, 53, 67, 81, every 4 weeks up to including Day 200, and 
PT E W
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 26
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
-CDRS -R (recall: since last assessment): Days 28 RC, 32, 35 RC, 39
-MADRS (recall: since last assessment): Days 28 RC, 32, 35 RC, 39
Time & Events Schedule, 
Double -Blind and Post -
Treatment Follow -up Phase, 
FootnotesThe follow ing changes were made to the Time & Events Schedule Footnotes 
(text added in bold; strikethough text deleted):
-Day 22 and Day 25 of the Double- Blind Treatment Phase: footnote (a) 
“visit can be performed ±3 days” changed to footnote (b) “visit can be 
performed ±1 day”
-Footnote (a) Intranasal treatment sessio ns should not be given on 
consecutive days.
-The statement above in footnote (a) is made in Section 6. Dosage and 
Administration
-Footnote (d) Subjects w ho discontinue study treatment prior to 
completion of the double -blind treatment phase (Day 25 visit), w ill have 
an EW visit conducted at the time of treatment discontinuation. Subjects 
who discontinue double- blind study treatment for reasons other than 
withdrawal of consent, lost to follow -up or death will be contact[CONTACT_368987] (eg, by [CONTACT_756]) [ADDRESS_461926] (eg, by [CONTACT_756]) on Days 
25 and 81 for CDRS -R and MADRS assessment sand adverse event 
collection is acceptable.  
-Footnote (o) CDRS -R –Clinician -administered assessment. A predose 
total score of ≥[ADDRESS_461927] eligibility. There are 4 recall 
periods: a 7 -day recall period applies predose on Day 1 (predose); a4-
hour recall at the 4 -hour postdose assessment on Day 1 and Day 25; 
anda24-hour recall at the 4hour postdose assessment on andDay 2; 
assessments respectively. A and a “since last assessment” recall period 
applies predose on Day 4 through Day 25 dosing days. “Since last 
assessment” recall will also be used in Post-Treatm ent Follow -up all 
other CDRS Rassessments performed on Days 28, 32, 35, and 39. A 
7-day recall will be used for Post -Treatm ent Follow -up assessments 
on Days 46 -200. at an interval <7 days. For all assessments performed at 
intervals ≥7 days, th e 7 day recall version of the CDRS R will be used 
(eg, Post Treatment Follow up visits 12 and 14 22). At the Day 1, 4 hour 
postdose time point and on Day 25, the sleep item score is not assessed .
-Footnote (z) MADRS -Clinician -administered assessment. There are 4 
recall periods: a A 7-day recall period applies on Day 1(predose); a 4-
hour recall at the 4 -hour postdose assessment on Day 1 and Day 25; a 
24-hour recall at the post -dose assessment on Day 2; and a “since last 
assessment” recall period applies predose on Day 4 through Day 25 
dosing days. “Since last assessment” recall will also be used in Post -
Treatm ent Follow -up assessments on Days 28, 32, [ADDRESS_461928] -Treatm ent Follow -up assessments on Days 
46-200.at all oth er assessments. At the Day 1, 4 hour time point and on 
Day 25, the sleep item score is not assessed.
Time & Events Schedule, 
Double -Blind Treatment 
PhaseThe follow ing footnote was added:
Footnote (nn): MADRS and CDRS -R will be performed at both predose and 4 -
hour postdose assessments on Day 25 (visit 10) of the double- blind treatment 
phase
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 27
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
SIBAT Time & Events 
ScheduleDay 22 and Day 25 of the Double- Blind Treatment Phase: footnote (a) “visit can 
be performed ±3 days” changed to footnote (b) “visit can be performed ±1 day”
Rationale: Time and Events Schedule was modified to include a Remote Contact (RC) visit during the 
Double -Blind Phase for CDRS -R, MADRS, PWC -[ADDRESS_461929] to follow -up, death, or w ithdrawal of consent .
Time & Events Schedule, 
Double -Blind Treatment 
Phase;The follow ing changes were made to the Time and Events Schedule –Double -
Blind Treat ment Phase :
Column added to the Double -Blind Treatment Phase for Remote Contact (DB 
RC) for the following assessments:
-CDRS -R (recall: since last assessment) 
-MADRS (recall: since last assessment)
-Physician Withdraw al Checklist (PWC -20)
-Adverse event collection. 
The follow ing footnote was added:
Footnote (oo): For subjects who discontinue from double -blind treatment for
reasons other than lost to follow up, death, or w ithdraw al of consent, Remote 
Contact (RC) will be implemented [ADDRESS_461930] dose of intranasal 
study medication to assess adverse events, withdraw al symptoms using PWC 20 
and rebound using CDRS -R and MADRS assessments. If the EW visit is > [ADDRESS_461931] dose, the 3 day RC will not be done.
Rationale: Study Evaluations, Table [ADDRESS_461932] for total blood volume collected during the 
Double -Blind Treatment Phase , and to delete statemen t that site participation in biomarker evaluations is 
optional.
9.1.1. Study Evaluations, 
Overvie wTable 2 : Approxim ate Volume of Blood to be Collected from  Each Subject
The follow ingchanges were made:
Correction of Approximate total blood volume for DB treatment phase with 
biomarker and pharmacogenomics/epi[INVESTIGATOR_313252]: from 26.[ADDRESS_461933] -Treatment Follow -up Phase
-Central Serum Chemistry (Day 81, Day 200/EW): Total blood vol. 2.2 
mL 
-Central Hematology (Day 81, Da y 200/EW): Total blood vol. 2.[ADDRESS_461934] -Treatm ent Follow -up Phase: 4.[ADDRESS_461935] -Treatment Follow -up Phase:
-Including biomar ker and pharmacogenomic samples: from 44.9 to 49.5
mL
-Without pharmacogenomic samples: 47.[ADDRESS_461936]- treatment
Changes to footnotes (bold text added, strikeout text deleted):
-Footnote (c) Biom arker samples are as s cheduled in the Time and 
Events Schedule Optional site participation (based on operational 
capabilities) .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 28
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
-Footnote (d) Pharm acogenomic b Blood sample(s) will be collected only 
from subjects who have consented to provide an optional sample for 
genetic researc h.
9.5. Biomarker and 
Pharm acogenomic (DNA) 
EvaluationsBiom arker Evaluations
The follow ing text was deleted for consistency with Table 2, footnote (c) above:
“Site participation in biomarker evaluations is optional based on operational 
capabilities; subjects at participating sites are required to participate.”
Rationale: Correction of error. Revised text states that s ubject w ill have completed study if assessments up to 
and including Week 29 are completed .
10.1 Completion The follow ing text was revised (bold text added; strikeout text deleted):
A subject w ill be considered to have completed the study if he or she has 
completed assessments up to and including Week 2529.
Rationale: Clarification that the Post -Treatment Early Withdraw al visit will be conducted at the time of 
discontinuation for subjects who discontinue from the Post -Treatment Follow -up Phase
10.2 Discontinuation of 
Study Treatment/Withdraw al 
from the studyWithdraw al from the Study During the Post -Treatment Follow -up Phase
The follo wing text was added (bold text) :
Subjects who discontinue from  the Post -Treatment Follow -up Phase after 
completion of the Day [ADDRESS_461937] is appropriately transitioned and/or follow ed 
for any additional care required when a subject discontinues participation in 
the study for any reason.
Rationale: Clarification as to which safety and efficacy assessments will be performed for subjects who 
discontinue treatment prior to completion of the Double -Blind treatment phase.
9.1.5. Early Withdrawal;
10.2 Discontinuation of 
Study Treatm ent/Withdraw al 
from the studyDiscontinuation from study treatment prior to completion of the Double -Blind 
treatment phase.
The text w as revised as follows (bold text added):
Subjects who discontinue study treatment prior to completion of the double -blind 
treatment phase (Day 25 visit), w ill have an EW visit conducted at the time of 
treatment discontinuation. Subjects w ho discontinue double -blind study 
treatment for reasons other than withdraw al of consent, lost to follow -up or death 
will be contact[CONTACT_112485] (eg, by [CONTACT_756]) [ADDRESS_461938] (eg, by [CONTACT_756]) on Days [ADDRESS_461939] is appropriately transitioned 
and/or followed for any additional care required when a subject 
discontinues participation in the study for any reason.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 29
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
Rationale: Clarification as to which efficacy assessments will be performed for subjects who discontinue 
treatment prior to completion of the Post -Treatm ent Follow -up phase.
9.1.5. Early Withdrawal;
10.2 Discontinuation of 
Study Treatment/Withdraw al 
from the study
9.1.5. Early WithdrawalDiscontinuation from study treatment prior to completion of the Post -Treatment 
Follow -up phase.
The text w as revised as follows (bold text added):
For subjects who refuse to return for in -person assessment, remote contact (eg, 
by [CONTACT_756]) on Day [ADDRESS_461940] is appropriately transitioned/followed for any additional care 
required.
Rationale: Clarification of timing of the Early Withdrawal visit and assessments in relation to the Day 25 and 
Day 81 visits.
Time & Events Schedule, 
Double -Blind Treatment 
Phase ,
footnote (ll)The follow ing text was added:
If the Early Withdrawal visit occurs within a window of ± 1day of Day 25 (visit 
10) of the double- blind treatment phase, then the E arly Withdraw al visit will be 
adequate and the Day [ADDRESS_461941] still 
complete the Day 81 clinic visit.
Time & Events Schedule, 
Post-Treatment Follow -up 
Phase, footnote (mm)If the Early Withdrawal visit occurs within a window of ±5 days of Day 81 (visit 
18) of the follow -up phase, then the Early Withdrawal visit will be adequate and 
the Day 81 visit is not require d.
9.1.5. Early Withdrawal;
10.2. Discontinuation of 
Study Treatment/Withdraw al 
from the StudyIf the Early Withdrawal visit occurs within a window of ±1 days of the Day 25 
visit of the double -blind treatment phase, or w ithin a window of ±5 days of the 
Day 81 visit of the follow -up phase, then the Day 25 or Day 81 visits, 
respectively, are not required.
Time & Events Schedule, 
footnote (d);
SIBAT Time & Events 
Schedule, footnote (f)
9.1.5 Early Withdrawal;
10.2. Discontinuation of 
Study Treatment/Withd rawal 
from the StudyThe text w as revised as follows (bold text added):
Additionally, these subjects will return for the Day 25 and Day 81 visit 
assessments .
9.1.5. Early Withdrawal The follow ing text was added:
Subjects who discontinue from the Post-Treatment Follow -Up phase after 
completion of the Day [ADDRESS_461942] -Treatm ent Early Withdrawal 
visit conducted at the time of discontinuation only.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 30
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
Rationale: Correction of investigational drug treatment dose in Table 1
6.2 Intranasal Study Drug, 
Table 1The follow ing changes were made to the heading in Table 1 (bold text added ; 
strikeout text deleted ):
Dose administration of Intranasal Esketamine 28, 54,56, 84 mg or Placebo
Rationale: Changes to permit use of Isotretinoin, only in consultation with the medical monitor
Attachment 1 Prohibited Concomitant medications with Intranasal Study Medication 
(esketamine or placebo)
The follow ing addition was made to the table:
Isotretinoin may only be used in consultation with the medical monitor 
Restrictions: no epi[INVESTIGATOR_81532], only continuous use.
Rationale: Clarification of text regarding Justification for use of Psychoactive Placebo , and aspects of the 
Investigators responsi bilities for Safety, including monitoring potential adverse drug reactions. 
16.1. Study -Specific Design 
ConsiderationsThe follow ing text was deleted ( bold text added; strikeout text deleted ):
Justification for Using Psychoactive Placebo
Subjects and their consenting parent or legal guardian will be informed of the 
equal chance of receiving esketamine or psychoactive placebo .
16.2.1. Investigator 
ResponsibilitiesSafety during study
Blood volumes used for testing in pediatric populations are monitored closely 
and Aall phlebotomy volumes for this study have been minimized to adhere to 
the Committee for Human Medicinal Products (CHMP) and Paediatric 
Committee (PDCO) guideline recommendations. To increase subject comfort, an 
indwelling catheter has been recommended.
Based on previous studies, it is known that certain adverse drug reactions occur 
postdose, peak around [ADDRESS_461943] spray (t = 0), and every 15 m inutes thereafter through to 
approximately 1.5 hours postdose, or longer, if necessary . Additionally, other 
known after effects of esketamine (eg, dissociation, sedation, conceptual 
disorien tation, hallucinogenic behavior, and abnormal thought content) are 
monitored closely during this time using specific assessment tools like CADSS, 
MOAA/S, and BPRS. On each dosing day, CADS S and BPRS+ will be 
perform ed predose and at 40 minutes and 1.5 hours postdose, whereas 
MOAA/S will be perform ed every 15 minutes, from  15 minutes predose to 
1.5 hours postdose, or longer, if necessary.
Rationale: Text updated to include complete list of assessments to be considered source data
17.4. Source Documentation The text w as revised as follows (bold text added; strikeout text deleted):
Subject -and investigator -completed scales and assessments designated by [CONTACT_103] w ill be considered source data. The CDRS -R, MADRS, SIBAT, CDI 2 
SR(S ),MOAA/S, YMRS, PWC -20, RAVLT, BPRS+, MINI -KID, Cogstate
computerized cognitive battery Cogstate test battery , TLFB, nasal symptom 
questionnaire and CADSS will be considered source data
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 31
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
Rationale: Clarification of subject and site staff entry of assessments and patient reported outcomes.
9.1.3. Double- Blind 
Treatment PhaseThe text w as revised as follows (bold text added):
Subjects and site staff will complete the clinician -administered assessment s and 
patient -reported outcomes using an electronic tablet device provided for this 
study or using a paper version if electronic entry is not functioning .
Rationale: Minor errors w ere noted
Throughout the protocol Minor grammatical, formatting, or spelling changes were made
Amendment 1(28April 2017 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.  
The overall reason for the amendment: The overall reason for the amendment is to revise the protocol to 
address feedback from Health Authorities , improve clarity, enhance safety, and align the protocol wi th currently 
ongoing studies in a related population.
Applicable Section(s) Description of Change(s)
Rationale: Revisions were made to minimize risk to subjects.
Treatment Time and 
Events Schedule; 
3.2.7, Safety 
Evaluations; 
9.1.5, Early 
Withdraw al; 
10.2, Discontinuation 
of Study TreatmentText w as revised to indicate that monitoring visits w illoccur [ADDRESS_461944] 
treatment to assess adverse events and withdrawal symptoms .
4.1. Inclusion Criteria Inclusion criterion #[ADDRESS_461945] be willing 
and able to participate in all study activities.
10.2. Discontinuation 
of Study TreatmentWorsening of underlying condition and a change from voluntary to involuntary 
hospi[INVESTIGATOR_368912].
Rationale : Exclusion criteria were revised to more precisely define the study population.
Synopsis, Key 
Exclusion Criteria; 
4.2, Exclusion 
CriteriaExclusion Criterion #[ADDRESS_461946] meet DSM -5 severity criteria of moderate to severe in order to be considered 
exclusionary ; and that a lifetime history of ketamine, phencyclidine (PCP), lysergic acid 
diethylamide (LSD), or 3, 4 -methylenedioxy -methamphetamine (MDMA) hallucinogen -
related use disorder is exclusionary.
Exclusion Criterion #6 w as revised to include examples of clinically significant cardiac 
and endocrine conditions.
Exclusion Criterion #7 w as revised to indicate the following:
-elevated blood pressure in children is based on a single measurement, rather than an 
average of 3 or more measurements; 
-on Day 1, prior to randomization, a supi[INVESTIGATOR_1662] -supi[INVESTIGATOR_368895]/or DBP ≥ the 
95th percentile for sex, age and height is exclusionary; 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 32
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
-an abnormal blood pressure measurement at screening may be repeated once after [ADDRESS_461947] eligibility; 
-subjects with conditions in which blood pressure elevation could pose a serious risk 
are excluded. 
Synopsis, Key 
Exclusion Criteria; 
4.2, Exclusion 
Criteria Exclusion Criterion #8 w as revised to include methamphetamines, 3,4-methylenedioxy 
methamphetamine (MDMA) and heroin as drugs that result in exclusion from the study 
at screening, and that subjects who have a positive urine test result for cannabinoids may 
be eligible to participate in the study ,provided they do not meet DSM -5 severity criteria 
for a moderate to severe substance abuse disorder.
3.2.1. Overview of 
Study DesignText w as revised to align with revisions related to exclusion criteria #4, 6, 7 and 8.
6.2.1. Guidance on 
Blood Pressure 
MonitoringGuidance on blood pressure monitoring was revised to align with revisions related to 
Exclusion Criterion #7.
Rationale: Text w as revised t o correct and expand the description of procedures for pulse oximetry and Modified 
Observer’s Assessment of Alertness/Sedation data.
9.6. Safety 
Evaluations, Pulse 
Oximetry ; Safety 
Evaluations, 
Modified Observer’s 
Assessment of 
Alertness and 
Sedation (MOAA/S)The text describing collection of data for pulse oximetry , and MOAA/ S was revised as 
follows ,respectively, and text was added to inform site personnel as to how to proceed 
in the event a subject’s oxygen saturation level falls below 93% (bold text added and 
strike out text deleted) :
Pulse oximetry will be used to measure arterial oxygen saturation (SpO2). On each 
dosing day, the device will be attached to the finger, toe, or ear at approximately [ADDRESS_461948] nasal 
spray is administered (ie, SpO2 w ill be measured at t = 15 minutes, 0 [after 
administration of the first intranasal device], 15 minutes, 30 minutes, etc.). If oxygen 
saturation levels are <93% at any time during the 1.5 hour postdose interval, pulse 
oximetry will be recorded every 5 minutes until levels return to 93% or until the 
subject is referred for appropriate medical care, if clinically indicated. If oxygen 
saturation levels are <9 5% predose, dosing should be postponed, and the subject 
should be evaluated by [CONTACT_368988] y to 
continue in the study .
On each intranasal dosing day, the MOAA/S will be performed every 15 minutes from t 
= 15 minutes ( predose )to 1.5 hours postdose (ie, at t = 15 minutes, 0 [after 
administration of the first intranasal device], 15 minutes, 30 m inutes, etc.)
Rationale: The text was updated to clarify that the duration of hospi[INVESTIGATOR_368913], based on the clinical needs of a given subject and local practice; and that discharge before
[ADDRESS_461949].
Footnote “c” was revised to indicate that continued hospi[INVESTIGATOR_368914] [ADDRESS_461950] be discussed with the sponsor’s medical monitor on a weekly basis.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 33
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
9.1.3. Double- blind 
Treatment PhaseText w as revised as follows (bold text added):
Subjects will remain in the inpatient psychiatry unit for a recommended duration of [ADDRESS_461951] from the hospi[INVESTIGATOR_368915] b e based 
upon the investigator’s judgment that the subject is no longer imminently suicidal and 
meets standard discharge criteria per local practice. Discharge before [ADDRESS_461952] be 
discussed and approved by [CONTACT_456]’s medical monitor. The investigator m ust 
discuss the need for continued hospi[INVESTIGATOR_60613] 10 days and thereafter on a 
weekly basis with the sponsor’s m edical monitor.
Time and Events 
Schedule –Post-
Treatment Follow -Up 
Phase; SIBAT Time 
and Events Schedule 
–Post-Treatment 
Follow -Up Phase; Text in the footnotes was revised for consistency with the changes described above in 
Section s 3.1 and 9.1.3.
Rationale: The descr iption of the urine drug test was revised to reflect the full range of drugs evaluated in the 
urine drug screen.
9.6. Safety 
Evaluations, Clinical 
Laboratory TestsThe list of drugs screened in the urine drug test was replaced w ith the following list of 
drugs: amphetamine, barbiturates, benzodiazepi[INVESTIGATOR_1651], cocaine, marijuana (THC), 
methadone, methamphetamine, methylenedioxymethamphetamine (MDMA), opi[INVESTIGATOR_858], 
phencyclidine (PCP), and tricyclic antidepressants.
Rationale: Text w as revised t o improve clarity.
Treatment Time and 
Events Schedule Footnotes “o” and “u” were revised to better describe the recall periods used for CDRS -
R and CDI 2:SR, respectively, at each time point they are administered.
Treatment and 
SIBAT Time and 
Events Schedule s; 
3.2.7. Safety
EvaluationsAll references to “remote contact” and “telephone contact” were revised to “remote 
contact (eg, by [CONTACT_756]).”
Synopsis, Overview 
of Study Design; 
Time and Events 
Schedule –Double -
blind Treatment 
Phase; 
3.1. Overview  of 
Study Design; 
9.1.2. Screening 
Phase;
9.1.3 Double- Blind 
Treatment PhaseAs applicable for each section, the following changes were made:
-The location “inpatient psychiatric unit” was revised to “inpatient psychiatric unit or 
other permitted setting”.
-The number of anticipated sites (45) w as added.
-A statement was added to clarify that the d uration of hospi[INVESTIGATOR_368916].
Section [IP_ADDRESS]. 
EfficacyText w as revised to more clearly present efficacy results from Study 
ESKETINTRD2003.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 34
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
9.1.3. Double -blind 
Treatment Phase
9.1.4. Post -treatment 
Follow -up Phases
9.1.[ADDRESS_461953] was added to 
Section 9.1:
If a subject dies, the date and cause of death will be collected and documented on the 
eCRF.
Also, procedur al instructions related to early withdrawal weremoved within Section 9.[ADDRESS_461954] 
treatment for the assessment of adverse events and withdrawal symptoms .
9.6. Safety 
Evaluations, Targeted 
Nasal Examination 
and Nasal Symptom 
QuestionnaireText describing the Nasal Examination and Nasal Symptom Questionnaire was revised 
as follows (bold text added and strikeout text deleted):
Subsequent examinations will consist of a visual inspection of the nostrils, nasal 
mucosa, and throat for nasal erythema, rhinorrhea, rhinitis, capi[INVESTIGATOR_1396]/blood vessel 
disruption and epi[INVESTIGATOR_3940] , and the presence and severity of sym ptoms will be graded as 
follows: none, mild, moderate, or severe . 
In addition, subjects a clinician or designated study staff will be asked to complete a 
nasal symptom questionnaire.
Rationale : Text w as revised t o accommodate differences in antidepressant prescribing practice s.
6. Dosage and 
Administration; 
9.1.3. Double- blind 
Treatment PhaseClarified that unless clinical judgment dictates otherwise, it is recommended that 
subjects who have not previously been treated with an antidepressant receive standard of 
care antidepressant treatment with fluoxetine.
Rationale : Text w as revised to include evaluat ion of the post -treatment occurrence of PCP use .
9.6. Safety 
Evaluations, Timeline 
Follow -backPCP w as added as a drug to be assessed by [CONTACT_9859] -back assessment for 
abuse potential.
Rationale: Text w as revised t o allow  for collection and analysis of final laboratory values from subjects who 
withdraw from the study before the Day 81 visit.
Treatment Time and 
Events Schedule –
Post-treatment 
Follow -up Phase
9.6. Safety 
Evaluations, Timeline 
Follow -backSchedule revised to indicate the collection of laboratory analytes at the post -treatment 
early withdraw al visit, including a footnote to indicate this collection only applies if the 
patient withdraws before the Day 81 visit.
Rationale: The recommended sequence in which patient -reported outcomes are performed was revised to include 
the Children’s Depression Inventory 2: Self -Report (short version) (CDI 2 -SR(S)).
9.1.3. Double- blind 
Treatment PhaseThe text describing the recommended sequence for performing patient -reported 
outcomes was revised as follows (bold text added):
When multiple patient -reported outcomes and clinician -administered assessments are 
scheduled for the predose time point, it is recommended they be performed in the 
following sequence:
SIBAT
MADRS and CDRS -R 
CDI 2 -SR(S)
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 35
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
Rationale: Text w as added to support statistical methodology.
Synopsis, Sample 
Size Determination; 
11.2. Sample Size 
DeterminationTo support the assumed effect size of 0.65, the mean difference betw een treatment 
groups (-7.2) and pooled SD (11.02) observed in MADRS total score in Study 
ESKETINSUI2001 were added .
Synopsis, Primary 
Efficacy Analyses; 
Synopsis, Other 
Efficacy Analyses; 
11.3. Efficacy 
AnalysesText w as revised to indicate that point estimates and 95% confidence intervals for 
treatment differences will be provided w ith the primary and other efficacy analyses; that 
the Hodges -Lehmann estimate w ill be used to estimate treatment differences; and tha t 
descriptive statistics will be provided, as appropriate.  
Synopsis, 
Pharm acokinetics 
Analyses; 
11.4. 
Pharm acokinetic 
AnalysesText w as revised to indicate that standard errors and 95% confidence intervals will be 
provided as part of the pharmacokineti c analysis.  
Rationale: To avoid unnecessary restriction of study participation.
Attachment 1. 
Prohibited 
Concomitant 
MedicationsText w as revised to define the parameters around the use of corticosteroid and opi[INVESTIGATOR_281539].
Rationale: To correct m inor errors .
Synopsis Literature references were deleted in the synopsis.
Synopsis, Safety 
EvaluationsTimeline Follow -Back (TLFB) was added to the list of safety evaluations.
[IP_ADDRESS]. Human 
Pharm acokinetics and 
Product Metabolism;
3.2.4. Esketamine 
DoseDescription of subjects in Study ESKETINTRD2003 w as revised to state “adult 
subjects” instead of “subjects”.
4.1. Inclusion Criteria The repeated text (“sexually active subjects”) w as deleted in Inclusion Criterion #12 as 
shown below (strikeout text deleted):
During the double- blind treatment phase (from Day [ADDRESS_461955] dose of 
study drug) and for a minimum of [ADDRESS_461956] dose of study drug, sexual abstinence is strongly 
recommended; however, sexually active subjects heterosexually active male subjects
must:…
The last four inclusion criteria w ere renumbered as 13, 14, 15, and 16 (instead of 14, 15, 
16, and 17).
9.1.2. Screening 
PhaseText w as revised as follows (strikeout text deleted):
The clinician -administered assessments at screening can be performed in the order 
preferred by [CONTACT_977] .: MINI KID, Questions B3 and B10 from MINI KID 
(current status). If the screening phase is longer than 24 ho urs, Question B3 and B10 
from MINI -KID (current status) must be repeated to confirm eligibility.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 36
Status: Approved , Date: 22 November 2020Applicable Section(s) Description of Change(s)
12. Adverse Event 
Reporting, Solicited 
Adverse EventsMissing w ord added to the follow ing sentence (bold text added): 
Solicited adverse events are predefine d local and systemic events for which the subject 
is specifically questioned .
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 37
Status: Approved , Date: 22 November 2020SYNOPSIS
A Double -blind, Randomized, Psychoactive Placebo -controlled, Study to Evaluate the Efficacy and Safety 
of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensive 
Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including 
Suicidal Ideation, in Pediatric Subjects Assessed to be at Imminent Risk for Suicide
Esketamine is the S-enantiomer of ketamine, which has been widely used for the induction and maintenance 
of anesthesia since the 1970s. Because of its ability to block the N-methyl -D-aspartate (NMDA ) glutamate 
receptor, ketamine has shown efficacy in the treatment of symptoms of major depressive disorder (MDD). 
This study is intended to evaluate the efficacy , safety and dose response of 3doses of esketamine in subjects 
12 to <[ADDRESS_461957] commonly associated with suicide. Epi[INVESTIGATOR_368917] 12-month 
prevalence of MDD is 2% in children and 4% to 8% in adolescents ;that MDD is the main predictor of 
suicidal ideation among children and adolescents ;and that 40% to 80% of adolescents meet the diagnostic 
criteria for depression at the time of suicide attem pt. Similar to adults, there is a substantial link between 
clinical depression and suicide in adolescents with up to 60% of adolescent suicide victims having a 
depressive disorder at the time of death. Therefore, MDD with imminent risk for suicide is a serious, 
potentially lethal condition that requires immediate intervention.
Although MDD with immi nent risk for suicide is a potentially lethal condition that requires immediate 
intervention, there is no approved treatment. The current standard of care for depressed adolescents at 
imminent risk for suicide is hospi[INVESTIGATOR_313254] ,combined with 
psychotherapy. However, hospi[INVESTIGATOR_368918], and the risk for suicide 
remains high in the weeks after discharge. For example, one study found that 13.9% of hospi[INVESTIGATOR_368919] (12- 15 years of age) reattempted suicide within 3 months of discharge.
According to several treatment guidelines, 3 antidepressants are recommended as pharmacologica l 
treatment options in children and adolescents with MDD: fluoxetine (Prozac®), escitalopram ( Lexapro®), 
and sertraline (Zoloft®). However, because standard of care antidepressants may take up to [ADDRESS_461958] to 
decrease depressive symptomatology, including suicidal ideation.
Ketamine and esketamine (the S-enantiomer of ketamine) are approved and widely used in children and 
adults for the induction and maintenance of anesthesia via intramuscular (IM) or intravenous (IV) 
administration. The desired analgesic -anesthetic effects of esketamine are attributed to the blockade of 
ionotropic N-methyl -D-aspartate (NMDA) glutamate receptors. Affinity for the NMDA receptor is 
approximately 3-to 4-fold greater for esketamine than for its enantiomer, arketamine (R ketamine, the R -
enantiomer of ketamine).
Several pi[INVESTIGATOR_368920]. In addition, 2 independent 
randomized, double -blind trials in subjects with MDD suggested that doses of IV ketamine could rapi[INVESTIGATOR_368921] 
(MADRS- SI).
The mechanism of action of esketamine is distinct from conventional antidepressant treatments, which 
target modulatory monoaminergic neurotransmitters (serotonin, norepi[INVESTIGATOR_238], and/or dopamine), and 
esketam ine profoundly affects fast excitatory glutamate transmission, increases brain -derived neurotrophic 
factor (BDNF) release, and stimulates synaptogenesis. In addition, a higher NMDA receptor binding 
affinity of esketamine compared to ketamine allows a lower volume of medication to be administered via 
the non- invasive and rapi[INVESTIGATOR_375] -absorbed intranasal route.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 38
Status: Approved , Date: 22 November 2020Administered intranasally, esketamine is rapi[INVESTIGATOR_368922] -absorbed, and can offer patients better 
convenience . Janssen Research & Development is developi[INVESTIGATOR_368923] -
resistant depression (TRD) and for the rapid reduction of the symptoms of MDD, including suicidal 
ideation, in adult patients who are assessed to be at imminent risk for suicide. As part of the pediatric 
developmen t program, this study is evaluating the efficacy, safety and dose response of esketamine in 
subjects 12 to <[ADDRESS_461959] ing esketamine (JNJ-54135419), 
refer to the latest version of the Investigator's Brochure for esketamine , and associated addenda.
OBJECTIVE S, ENDPOINTS, AND HYPOTHESIS
Objectives
Primary Objective
The primary objective is to assess the efficacy of a single (first) dose of 3 fixed doses of intranasal 
esketamine (28 mg, 56 mg, and 84 mg) compared with psychoactive placebo (oral midazolam) in rapi[INVESTIGATOR_368924], including suicidal ideation, in subjects 12 to <18 years of age who are 
assessed to be at imminent risk for suicide. Efficacy will be assessed by [CONTACT_368989]’s Depression Rating Scale, Revised (CDRS -R) total score at [ADDRESS_461960] dose (Day 2).
Other Objectives
The other objectives are the following: 
 Toevaluate the dose response of intranasal esketamine compared with psychoactive placebo in 
reducing the symptoms of MDD, including suicidal ideation, as assessed by [CONTACT_368990] -R total score at [ADDRESS_461961] dose (Day 2) and Day 25 .
 To evaluate the efficacy of single and repeated doses of intranasal esketamine compared with 
psychoactive placebo in reducing symptoms of suicidal ideation, as assessed by [CONTACT_368991], revised version (CGI -SS-R) from the Suicide Ideation and 
Behavior Assessment Tool (SIBAT) at [ADDRESS_461962] dose and through the end of the 
Double- Blind Treatment phase (Day 25). 
 To evaluate the effica cy of single and repeated doses of intranasal esketamine compared with 
psychoactive placebo in reducing symptoms of MDD as assessed by [CONTACT_716]:
 CDRS -R total score at [ADDRESS_461963] dose, through the end of the Double -Blind Treatment 
phase (Day 25 ), and during the [ADDRESS_461964]-Treatment Follow -Up phase .
 Montgomery -Asberg Depression Rating Scale ( MADRS )total score at [ADDRESS_461965] dose, through the end of the Double -Blind Treatment phase (Day 25), and during the 6-month 
Post-Treat ment Follow -Up phase .
 Children’s Depression Inventory 2: Self-Report (short version )(CDI 2:SR[S])TM score at 24hours 
post first dose and through the end of the Double -Blind Treatment phase (Day 25).
 To evaluate the efficacy of single and repeated doses of intranasal esketamine compared with 
psychoactive placebo in reducing symptoms of suicidal ideation, as assessed by [CONTACT_87789] –Imminent Suicide Risk (CGI -SR-I) from the Suicide I deation and Behavior Assessment 
Tool (SIBAT) at [ADDRESS_461966] dose and through the end of the Double -Blind 
Treatment phase (Day 25).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 39
Status: Approved , Date: 22 November 2020 To evaluate the efficacy of single and repeated doses of intranasal esketamine compared with 
psychoactive placebo in reducing suicidal thoughts, as assessed by [CONTACT_716]:
 Change from baseline in SIBAT Module 3 (My Current Thinking) and Module 5 (My Risk) 
Question 3 (patient -reported frequency of suicidal thinking) through the end of the Double- Blind 
Treatment phase (Day 25) and during the [ADDRESS_461967]-Treatment Follow -Up phase . 
 To characterize the pharmacokinetics of intranasal esketamine and its metab olite noresketamine.
 To evaluate the safety and tolerability of intranasal esketamine through the end of the Double -Blind 
Treatment phase (Day 25) using the following assessments:
 Effects on suicidal ideation and behavior using the SIBAT 
 Effects on dissoc iative symptoms using the Clinician -Administered Dissociative States Scale 
(CADSS)
 Occurrence of psychosis -like side effects using a 4-item positive symptom subscale (consisting 
of: suspi[INVESTIGATOR_23703], hallucinations, unusual thought content, and conceptual disorganization) of 
the Brief Psychiatric Rating Scale, positive symptom subscale (BPRS+)
 Occurrence of potential treatment -emergent symptoms of mania using the Young Mania Rating 
Scale (YMRS)
 Effects on cognitive funct ion as measured by [CONTACT_368992]® comput erized cognitive battery
 Effect on sedation using the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) 
scale
 Local nasal tolerability, using targeted nasal examinations coupled with a nasal symptom 
questionnaire
 To evaluate the safety and tolerability of intranasal esketamine at specified times through the initial 
25day double -blind treatment period (Day 25), the 8-week post-treatment follow -up (Day 81) and 
6-month post -treatment follow -up, with special attention given to the following assessm ents:
 Effects on suicidal ideation and behavior using the SIBAT
 Effects on cognitive function as measured by [CONTACT_368993]
 To evaluate potential withdrawal symptoms during the post-treatment follow -up as measured by [CONTACT_368994] (PWC -20) on Days 25, 28, 32, 35 and 39.
 To evaluate the potential for ketamine orphencyclidine (PCP) abuse during the follow -up as measured 
by [CONTACT_9859] -Back (TLFB) .
 To evaluate whether pretreatment concentrations of MDD -related biomarkers (eg, HPA axis function, 
immune system activation, growth factors, metabolic markers) correlate with clinical response or non-
response ,as measured by [CONTACT_368995].
 To explore the change in MDD -related biomarkers in relation to clinical response or non- response to 
intranasal esketamine.
Endpoints
The primary efficacy evaluation will be the change from baseline (Day 1, predose) at [ADDRESS_461968] 
dose in depressive symptoms, including s uicidal ideation, as measured by [CONTACT_368996] -R total score.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 40
Status: Approved , Date: 22 November 2020 Other efficacy endpoints will be evaluated throughout the study, as follows:
 CDRS -R 
o Dose response at [ADDRESS_461969] dose, through the 
end of the Double -Blind Treatment phase (Day 25), and during the [ADDRESS_461970]-Treatment 
Follow -Up phase .
 MADRS
o Changes from baseline, post single and repeated doses, at [ADDRESS_461971] 
dose, through the end of the Double -Blind Treatment phase (Day 25), and during the 
6-month Post -Treatment Follow -Up phase . 
 CGI-SS-R from SIBAT
o Changes from baseline ,post single and repeated doses ,at [ADDRESS_461972] 
dose, through the end of the Double- Blind Treatment phase (Day 25).
 CGI-SR-I from SIBAT
o Changes from baseline, post single and repeated doses, at [ADDRESS_461973] 
dose, through the end of the Double- Blind Treatment phase (Day 25).
 SIBAT
o Changes from baseline, post single and repeated doses, through the end of the Double -Blind 
Treatment phase (Day 25) and during the 6-month Post-Treatment Follow -Up phase in 
depressive symptoms and suicidal ideation (subject -completed modules 3, 4, and 5) and 
clinician impression of suicidality and judgment about management of suicidal thinking 
(clinician -completed modules 7 and 8) .
 CDI 2:SR (S)
o Changes from baseline, post single and repeated doses, at [ADDRESS_461974] dose and 
through the end of the Double -Blind Treatment phase (Day 25). 
 Safety endpoints will be evaluated throughout the study, as follows: 
 Monitoring of treatment -emergent adv erse events (TEAEs) 
 Clinical laboratory tests, physical examination, nasal examination and nasal symptom 
questionnaire, 12- lead electrocardiogram ( ECG ), vital signs, pulse oximetry and body weight
 SIBAT 
 BPRS+ score 
 CADSS 
 Cogstate computerized cognitive battery
 YMRS score
 Modified Observer’s Assessment of Alertness/Sedation (MOAA/S) score
 Physician Withdrawal Checklist (PWC -20)
 TLFB methodology to evaluate use of ketamine or PCP .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 41
Status: Approved , Date: 22 November 2020 Pharmacokinetics
 Plasma esketamine and noresketamine concentrations will be summarized; plasma concentrations 
of esketamine (and noresketamine concentrations, if warranted) will be included in a population 
analysis. Plasma concentrations of other esketamine metabolites andmidazolam may also be 
measured, if warranted .
 Biomarkers
 Characteristics of esketamine mechanism of action or biological predictors of inter-individual 
variability.
Refer to Section 9, Study Evaluations, for evaluations related to endpoints.
Hypothesis
The primary hypothesis of this study is that, in addition to standard of care, intranasal esketamine is superior 
to psychoactive placebo in rapi[INVESTIGATOR_313257], including suicidal ideation, as assessed 
by [CONTACT_368997]- R at [ADDRESS_461975] dose in subjects 12 to <18 years of age who 
are assessed to be at imminent risk forsuicide.
OVERVIEW OF STUDY DESIGN
This Phase 2 study is a randomized, double -blind, double -dummy, psychoactive placebo -controlled, 
multicenter trialwith 45 anticipated global sites . A target of 145pediatric subjects, 12 to <18 years of age, 
will be enrolled in this study and randomized in a 1:1:1:2 ratio to one of 3 doses of intranasal esketamine 
(28, 56 or 84 mg) or a psychoactive placebo (oral mida zolam 0.125 mg/kg), with approximate ly 29subjects 
assigned to each dose of intranasal esketamine and approximately [ADDRESS_461976] presented to an emergency room 
(ER) or other permitted setting and been assessed to be at imminent risk for suicide. Given the vulnerability 
of the population, this study will be conducted in the context of standard of care treatment. This includes 
initial hospi[INVESTIGATOR_51531] a n inpatientpsychiatr icunit or other permitted setting for a recommended duration 
of [ADDRESS_461977] of care; initiation or optimization of allowed antidepressant medication 
therapy, participation in a specific psychological intervention (individual cognitive behavioral therapy  
[CBT]), interpersonal therapy, family therapy or psychodynamic psychotherapy), and close outpatient 
follow -up.
There is only 1 a pproved antidepressant for the treatment of MDD in children and adolescents in both the 
[LOCATION_002] (US) and European Union (EU): fluoxetine; however , iftreatment with fluoxetine is 
unsuccessful or is not tolerated because of side effects, guidelines recommend treatment with escitalopram 
and sertraline. E scitalopram (the S -enantiomer of citalopram) is also approved for use in adolescents in the 
US. Therefore, this multi -national study will permit the use of fluoxetine, escitalopram or sertraline as the 
standard of care antidepressants.
The study will be conducted in 4 phases: a screening evaluation performed within 48 hours prior to Day 1 
intranasal dose (if possible, screening should occur within 24 hours prior to the Day 1 intranasal dose); a 
25-day Double- Blind Treatment phase (Days 1- 25), during which study drug will be administered 2 times 
per week for 4 weeks on Days 1, 4, 8, 11, 15, 18, 22, and 25;an 8-week initial post-treatment follow -up
phase (Days 25-81); and a subsequent phase to complete a full 6-month post-treatment follow -up 
(Days 81-200). During post -treatment follow -up phases, no study drug will be administered. The duration 
of the subject’s participation will be approximately [ADDRESS_461978] participating in the study.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 42
Status: Approved , Date: 22 November 2020Efficacy, safety, pharmacokinetic, biomarker, and pharmacogenomic (DNA and RNA) evaluations will be 
performed as described in the Time and Events Schedule.
 The primary efficacy evaluation is the CDRS -R; other efficacy evaluations are SIBAT/CGI -SS-Rand 
CGI-SR-I, MADRS, CDI 2:SR (S).
 Safety evaluations include monitoring and collection of adverse events and concomitant therapi[INVESTIGATOR_014], 
physical examination, nasal examination and nasal symptom questionnai re, measurements of body 
weight and vital signs, 12-lead electrocardiogram (ECG), pulse oximetry, clinical laboratory tests, 
SIBAT, MOAA/S, CADSS, BPRS+, YMRS, PWC-20, TLFB, Cogstate computerized cognitive
battery .
 Blood samples will be collected for measu rement of plasma concentrations of esketamine, 
noresketamine, and other metabolites (if warranted).
 Blood samples will be collected for biomarker evaluations.
 Blood sample s for DNA and RNA analyses will be collected from subjects who consent/assent 
separat ely to this component of the study (where local regulations permit). Subject participation in 
DNA and RNA research is optional.
An Independent Data Monitoring Committee will be commissioned for this study.
SUBJECT POPULATION
The key inclusion and exclusion criteria for enrolling subjects in this study are described below.
Key Inclusion Criteria
 Male and female adolescents (12 to <18 years of age) .
 Subject must meet DSM -5 diagnostic criteria for MDD, without psychotic features, based upon 
clinical assessment and confirmed by [CONTACT_368998] (MINI -KID).
 Subject must have current suicidal thinking with intent at the time of screening, confirmed by “Yes” 
responses to both MINI -KID Question B3 (Think about hurting yourself with the possibility that 
you might die. Or did you think about killing yourself?)   AND Question B10 ( Expect to go thr ough 
with a plan to kill yourself?) . 
Note: the response to B3 must refer to the present, whereas the response to B10 may reflect the past 
[ADDRESS_461979] be repeated to confirm eligibility.
 In the physician’s opi[INVESTIGATOR_1649], acute psychiatric hospi[INVESTIGATOR_368925] y warranted due to subject’s 
imminent risk of suicide.
 Subject must have a CDRS -R total score of ≥ 58 predose on Day 1.
 As part of standard of care treatment, subject must agree to be hospi[INVESTIGATOR_368926] a 
recommended period of 5 days after randomization (may be shorter or longer if clinically warranted 
in the investigator’s opi[INVESTIGATOR_1649]). 
 As part of the newly initiated or optimized standard of care treatment, subject must agree to take 
one of the prescribed non-investigational antidepressants medic ations (fluoxetine, escitalopram, 
sertraline) during the Double -Blind Treatment phase (Day 25).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 43
Status: Approved , Date: 22 November 2020 As part of standard of care treatment, subject must agree to participate in a specific psychological 
intervention (individual cognitive behavioral therapy [CBT], interpersonal therapy , family therapy 
or psychodynamic psychotherapy) at least through the initial 8 -week follow -up period (Day 81).
Key Exclusion Criteria
 Subject has a current DSM -5 diagnosis of bipolar (or related disorders), intellectual disabi lity, 
autism spectrum disorder, conduct disorder, anorexia nervosa, oppositional defiant disorder, or 
obsessive compulsive disorder. 
 Subject currently meets DSM- 5 criteria for borderline personality disorder. 
Subjects not meeting full DSM -5 criteria forborderline personality disorder but exhibiting recurrent 
suicidal gestures, threats, or self -mutilating behaviors should also be excluded.
 Subject has a current or prior DSM -5 diagnosis of a psychotic disorder orMDD with psychosis.
 Subject meets the DS M-5 severity criteria for moderate or severe substance or alcohol use disorder
(except for nicotine or caffeine) within the 6 months before screening.
A history (lifetime) of ketamine, phencyclidine (PCP), lysergic acid diethylamide (LSD), or 3, 
4-methyle nedioxy- methamphetamine (MDMA) hallucinogen -related use disorder is exclusionary.
 Subject has a history of seizure disorder .
 Subject has a history or current signs and/or symptoms of liver or renal insufficiency; has a current 
diagnosis of clinically significant cardiac (eg, congenital heart disease, cardiomyopathy, or 
tachyarrhythmias) , vascular, pulmonary, gastrointestinal, endocrine (including severe 
dehydration/hypovolemia) , neurologic, hematologic, rheumatologic, or metabolic disturbances; 
based on investigator judgment.
 On Day -1 (screening) or Day 1 of the double -blind phase prior to randomization, a supi[INVESTIGATOR_1662] -
supi[INVESTIGATOR_368895]/or DBP ≥ the 95thpercentile for sex, age and height is exclusionary. Subjects who 
fall below the 5thor above the 95thpercentile for their age, sex, and height should be evaluated using 
the parameters for the 5thor 95thpercentile. Note that subjects whose SBP and/or DBP values are ≥ 
the 95thpercentile for sex, age and height may be reevaluated with a repeated measur e once after 
5minutes of rest to assess eligibility.
Subjects with conditions in which blood pressure elevation could pose a serious risk (including 
severe cardiovascular disease, recent cerebral injury, increased intracranial pressure / intracranial 
mass lesion, intracranial bleeding or acute stroke, primary developmental or secondary acquired 
glaucoma or perforating eye injury) are excluded.
DOSAGE AND ADMINISTRATION
Intranasal Study Drug 
For each intranasal esketamine or placebo dose, subjects will s elf-administer 1 spray into each nostril (ie, a 
total of 2 sprays using 1 intranasal device) at each of the following 3 time points: t = 0, 5 minutes and 
10minutes; time = [ADDRESS_461980] 100-μl spray. Sprays to each nostril should be 
delivered in rapid succession at each of the 3 scheduled time points. A total of 3 devices will be used by [CONTACT_368999] 3 doses of esketamine or placebo.
Oral Study Drug
Oral midazolam solution (2mg/ml) will be provided as a psychoactive pl acebo at a dose of 0.125mg/kg to 
all subjects randomized to intranasal placebo. A designated pharmacist (or other qualified healthcare 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 44
Status: Approved , Date: 22 November 2020professional) will be unblinded in order to prepare the oral study drug. Subjects randomized to oral 
psychoactive placebo (midazolam) will receive a weight -based dose using a 2mg/m Lsolution; those 
randomized to intranasal esketamine will receive an oral placebo solution in an equivalent volume to that 
which they would receive if randomized to the psychoactive placebo.
EFFIC ACY EVALUATIONS
The primary efficacy evaluation wil l be the CDRS -Rtotal score. 
The other efficacy evaluations include SIBAT, MADRS ,and CDI 2:SR (S).
PHARMACOKINETIC EVALUATIONS
Venous blood samples will be collected for measurement of plasma concentrations of esketamine , 
noresketamine, and other metabolites (if warranted).
BIOMARKER AND PHARMACOGENOMIC (DNA AND RNA) EVALUATIONS
Blood samples will be collected for exploratory an alysis of biomarkers (protein and metabolites) related to 
immune system activity, HPA axis activation, neurotrophic and metabolic factors. Exploratory analyses 
may be performed for additional biomarkers as well. Results may be presented in a separate bioma rkers 
report.
Blood samples for DNA and RNA analyses will be collected from subjects who consent/assent separately 
to this component of the study (where local regulations permit). Subject participation in DNA and RNA 
research is optional.
SAFETY EVALUATION S
Safety evaluations include monitoring and collection of adverse events and concomitant therapi[INVESTIGATOR_014], physical 
examination, body weight, height, vital signs, 12 -lead ECG, pulse oximetry, clinical laboratory tests, nasal 
examination and nasal symptom questionnaire , MOAA/S, CADSS, BPRS+, YMRS, TLFB, Cogstate
computerized cognitive battery , and PWC-20. 
Although the SIBAT will be an efficacy evaluation, it will also inform the safety evaluation to detect 
potential effects on suicidal ideation and behavio r throughout the study.
STATISTICAL METHODS
Subject Information
The primary efficacy and safety analysis sets are defined below.
 Full analysis set: The full analysis set will include all randomized subjects who receive at least [ADDRESS_461981] both a baseline and a postdose evaluation for the CDRS -R 
total score.
 Safety analysis set: The safety analysis set will include all randomized subjects who receive at least 
one dose of double -blind study medication .
Sample Size Determi nation
The sample size for this study was calculated assuming an effect size of 0.65 between any dose of 
esketamine and psychoactive placebo for the change from baseline at 24 hours postdose for the CDRS -R 
total score and a 2-sided significance level of 0.05. Atotal of 145 subjects will be randomized in this study. 
Using a 1:1:1:2 randomization ratio (esketamine 28 mg: esketamine 56 mg: esketamine 84 mg: 
psychoactive placebo), approximately 58 subjects will need to be randomized to psychoactive placebo and
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 45
Status: Approved , Date: 22 November 202029 subjects will need to be randomized to each esketamine treatment group to achieve 94% power for th e 
comparison of the pooled doses of esketamine 56 mgandesketamine 84 mgversus psychoactive placebo
and 92% power for at least one of the 2 esketamine higher doses(56-mg and 84 -mg) versus psychoactive 
placebo. The effect size of 0.65 is based on results from study ESK ETINSUI2001 (mean difference between 
treatment groups of - 7.2 and a pooled SD of 11.02) for MADRS total score .
Efficacy Analyses
Primary Estimand
The primary estimand, the main clinical quantity of interest to be estimated in the study, is defined by [CONTACT_14504] 3 components:
Population: subjects with MDD who are at imminent risk of suicide
Endpoint: change from baseline to [ADDRESS_461982] dose (Day 2) in the CDRS -R total score 
Measure of Intervention: the effect of the initially randomized treatment that would have been observed
had all subjects remained on their treatment until Day 2 of the double -blind phase. 
The primary analysis will be based on the full analysis set and the CDRS -R total scores collected at Day 2 
([ADDRESS_461983] dose). 
Primary Efficacy Analysis
The primary analysis will be based on the full analysis set. The primary efficacy variable, change from  
baseline in CDRS -R total score at [ADDRESS_461984] dose, will be analyzed using an analysis of covariance 
(ANCOVA) model. The model will include factors for treatment and center, and baseline CDRS -R total 
score as a covariate A pooled sequential multiple testing procedure will be implemented to control for 
TypeIerror. The esketamine 56-mg and 84-mgtreatment groups will be pooled and compared with 
psychoactive placebo at a 2-sided significance level of 0.05. If this comparison achieve s statistical 
significance in favor of esketamine, the 56 -mg dose and the 84 -mg dose will each be simultaneously tested 
versus psychoactive placebo at the 2-sided significance level of 0.05 based on the closed testing procedure.
The esketamine 28-mg dose will be tested only ifboth the individual doses of 56-mg and 84 mg are shown 
to be significant. Point estimates and 95% confidence intervals for treatment differences will be provided.
Since subjects are hospi[INVESTIGATOR_313260], itis anticipated that missing data will 
be infrequent. However, if a subject has a CDRS -R total score at a time earlier than [ADDRESS_461985] dose 
and at Day 25 will be conducted with various dose response models being explored. Details of the dose 
response analysis will be provided in the statistical analysis plan(SAP) .
Changes from baseline over time in CDRS -R total score, MADRS total score, and CDI 2:SR[S]TM score 
will be analyzed based on last observation carried forward (LOCF) data using an ANCOVA model with 
treatment and center as factors and baseline value as a covariate. Additionally, the change from baseline in 
CDRS -R total score at Day 25 will be analyz ed using a mixed model for repeated measures (MMRM) 
analysis with baseline CDRS -R total score as a covariate, and treatment, center, day, and day -by-treatment 
interaction as fixed effects, and a random subject effect. Comparison of each esketamine dose versus 
placebo will be performed using the appropriate contrast. Point estimates and 95% confidence intervals for 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 46
Status: Approved , Date: 22 November 2020treatment differences will be provided. Missing data will be closely monitored and additional sensitivity 
analyses will be specified in the SAP, if necessary.
The ranks of changes from baseline over time for both CGI-SS-Rand CGI -SR-Iwill be analyzed using an 
ANCOVA model using LOCF data with factors for treatment and center and baseline CGI-SS-Rand
CGI-SR-I(unranked) as a covariate. Treatment differences will be estimated using the Hodges -Lehmann 
estimate, which is the median of all possible paired differences for the change from baseline for CGI -SS-R
and CGI-SR-I.
SIBAT Module 3 (My Current Thinking )andModule 5 (My Risk )Question 3 (patient -reported frequency 
of suicidal thinking) will be summarized over time.
Additionally, scores of all efficacy endpoints will be summarized for all visits. Descriptive statistics (N, 
mean, standard deviation, median, minimum and maximum) will be provided for c ontinuous variables and 
frequency distributions will be provided for categorical variables.
Pharma cokinetic A nalyses
Data will be listed for all subjects with available plasma concentrations per treatment group. Subjects will 
be excluded from the pharmacok inetic (PK)analysis if their data do not allow for accurate assessment of 
the PK (eg, incomplete administration of the study drug; missing information of dosing and sampling times; 
concentration data not sufficient for PK parameter calculation). Concentra tions below the lowest 
quantifiable concentration or missing data will be labeled as such in the concentration database. All subjects 
and samples excluded from the analysis will be clearly documented in the study report.
The plasma concentration -time data of esketamine (and noresketamine, if warranted) will be analyzed using 
population PK modeling. Data may be combined with those of other selected studies to support a relevant 
structural model. Available baseline subject characteristics (demographics, labor atory variables, genotypes, 
race, etc.) will be tested as potential covariates affecting PK parameters. 
Details will be given in a population PK analysis plan and the results of the population PK analysis will be 
presented in a separate report. In addition to the final population PK parameter estimates, the corresponding 
standard errors and 95% confidence intervals will be provided.
The relationship between CDRS -R total score (and possibly other efficacy endpoints such as MADRS and 
selected adverse events and additional pharmacodynamic parameters), and PK metrics of esketamine may 
be evaluated. The results of such analyses may be reported separately.
Biomarker and Pharmacogenomic Analyses
Changes in biomarkers over time will be summarized by [CONTACT_1570]. Associations between baseline 
levels and changes from baseline in selected biomarkers and clinical endpoints will be explored.
Exploratory analyses may be performed for additional biomarkers. Results may be presented in a separate 
Biomarkers repor t. 
Pharmacogenomic analyses (DNA and RNA) may include candidate gene analyses or genome -wide 
association analyses , and gene transcription analyses in relation to treatment response, non-response, and 
MDD. Additional exploratory analyses may be performed.
Safety Analyses
The primary population for safety analysis will consist of all randomized subjects who receive at least one 
dose of double -blind study medication. The safety data from the follow -up phase will be summarized 
separately.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 47
Status: Approved , Date: 22 November 2020The verbatim terms used in the electronic case report form (eCRF )by [CONTACT_154923] (MedDRA). Treatment -
emergent adverse events are adverse events with onset during the Double -Blind Treatment phase or that 
are a consequence of a pre -existing condition that has worsened since baseline. All reported adverse events 
with onset during the Double -Blind Treatment phase (ie, TEAEs and adverse events that have worsened 
since baseline) will be included in the analysis. For each adverse event, the percentage of subjects who 
experience at least 1occurrence of the given event will be summarized by [CONTACT_1570]. In addition, 
comparisons between treatment groups will be provi ded if appropriate. Adverse events during the follow -
up phase will be summarized separately.
The TEAEs of special interest will be examined separately grouped in the following Medical Dictionary 
for Regulatory Activities (MedDRA) based categories: drug abuse, dependence and withdrawal 
(standardized MedDRA queries [MedDRA SMQ]), transient dizziness/vertigo, impaired cognition, anxiety, 
cystitis, and suicidality. Treatment -emergent adverse events of special interest will be further listed in the 
SAP.
Laborat ory data will be summarized by [CONTACT_154924]. Markedly abnormal results (specified in the 
SAP) will be used in the summary of laboratory data. Descriptive statistics will be calculated for each 
laboratory analyte at baseline and for observed values and changes from baseline at each scheduled time 
point. A listing of subjects with any markedly abnormal laboratory results will also be provided.
The effects on cardiovascular variables will be evaluated by [CONTACT_369000]. These tables will include observed values and changes from baseline values (the predose ECG 
will be used as baseline).
Electrocardiogram data will be summarized by [CONTACT_105292]. Descriptive statistics will be calculated at 
baseline and for observed values and changes from baseline at each scheduled time point. Frequency 
tabulations of the abnormalities will be made.
The ECG variables that will be analyzed are heart rate, PR interval, QRS interval, QT interval, and corrected 
QT (QTc) interval using the following correction methods: QT corrected according to Bazett's formula 
(QTcB), QT corrected according to Fridericia's formula (QTcF). 
Descriptive statistics of QTc intervals and changes from baseline will be summarized at each scheduled 
time point. The percentage of subjects with QTc interval >450 milliseconds, >480 milli seconds, or 
>500 milliseconds will be summarized, as will the percentage of subjects with QTc interval increases from 
baseline >30 milliseconds or >60 milliseconds.
All clinica lly relevant abnormalities in ECG waveform that are changes from the baseline readings will be 
reported (eg, changes in T -wave morphology or the occurrence of U -waves. )
Descriptive statistics of temperature, pulse/heart rate, respi[INVESTIGATOR_697], pulse oximet ry measurements, body 
weight measurements, and blood pressure (systolic and diastolic) values and changes from baseline will be 
summarized at each scheduled time point. The percentage of subjects with values beyond clinically 
important limits will be summarized.
Changes in findings from the baseline nasal examination (including the upper respi[INVESTIGATOR_4352]/throat) will 
be listed by [CONTACT_1570]. Examinations will provide ratings of severity that are based on a visual 
inspection of the nostrils, nasal muco sa, and throat for nasal erythema, rhinorrhea, rhinitis, capi[INVESTIGATOR_1396]/blood 
vessel disruption and epi[INVESTIGATOR_3940]. A shift table for changes from baseline in ratings for each examination will 
be presented by [CONTACT_313311].
Scoring from the nasal symptom questionnaire will be summarized descriptively by [CONTACT_1570].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 48
Status: Approved , Date: 22 November 2020Sedation data from the MOAA/S and dissociative symptoms data from the CADSS will be summarized 
descriptively at each scheduled visit by [CONTACT_1570]. Data on suicidal ideation and behavior from the 
SIBAT ;psychosis -like side effect sfrom the BPRS+ ;and potential treatment -emergent symptoms of mania 
from the YMRS will be summarized descriptively at each scheduled visit by [CONTACT_1570]. Cognitive 
function data from theCogstate computerized cognitive battery , and withdrawal symptom data from the 
PWC-20 will be summarized descriptively at designated scheduled visit sby [CONTACT_1570].
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 53
Status: Approved , Date: 22 November 2020Footnotes:   
aDay -[ADDRESS_461986] be performed both as part of the screening visit 
and a s part of the Day 1 visit (predose).
bSubject should be screened within 48 hrs (if possible, 24 hrs) prior to study drug dosing on Day 1.
cVisit can be performed +/ -[ADDRESS_461987] to follow up, death, or w ithdraw al of consent/assent will have the DB EW visit conducted at 
the time of discontinuation. In addition, if the DB EW visit occurs on Day [ADDRESS_461988] visit (eg, by [CONTACT_756]) on Day 25 to 
assess PWC -20, CDRS -R and MADRS, and for collection of concomitant therapi[INVESTIGATOR_368897] (Refer to Sections 9.1.5and 10.2).
fIf the DB EW visit occurs on or after Day 22 (assuming dose administered), D25 RC visit is not required, however, RC D+5 ([ADDRESS_461989] dose) should be 
performed. If subjects discontinue anytime between Day 25 postdose and Day 28 RC of the PT phase, the PT EW visit is not required; how ever, Day [ADDRESS_461990] to follow  up, death, or w ithdrawal of consent /assent , a remote contact [CONTACT_369001] 
5days (+/ -2 day s) after the last dose of study medication. If RC D+5 occurs within 2 day s of the EW visit, use the +[ADDRESS_461991] the RC D+5 visit.
hDay 1, 4-hr assessments should be performed within a 30 min window . Day 2, 24 -hr assessments should be performed within a 2 hr w indow .
iNot applicable for subjects admitted directly into the inpatient psychiatric unit or other permitted setting (refer to Sectio n 3.1).
jIt is recommended that subjects dosed in the ER not be transferred to the inpatient psychiatric unit or other permitted setting unt il after the 4 -hr postdose assessments 
are completed.
k Refer to Section 3.1.
lSubjects requiring psychiatric re -hospi[INVESTIGATOR_368927].
m Antidepressant medication should be initiated or optimized on Day 1. If starting 2 medications simulta neously is not consistent with local clinical practice, initiating 
SOC antidepressant medication up to 7 days after Day 1 is permitted (refer to Section 6).
n Outpatient psychotherapy should be initiated as soon as possible upon discharge from the hospi[INVESTIGATOR_307].
o In addition to the scheduled time points, additional pregnancy tests can be performed during the study at the investigator’s discretion (refer to Section 5).
p Due to the need to preserve the integrity of the study blind, a urine drug screen (UDS) should not be performed during the DB period unless medically necessary. If 
deemed medically necessary, the medical monitor should be contact[CONTACT_369002].
q Subjects will be asked to respond to Questions B3 and B10 of the MINI -KID regarding their current state. Response to B3 must refer to the present, response to B10 
may reflect the past [ADDRESS_461992] be repeated to confirm eligibility.
r CDRS -R and BP should be p erformed prior to randomization in order to evaluate eligibility.
sRefer to Section 6.
tPerformed predose.
u Blood pressure, heart rate, and respi[INVESTIGATOR_368899] (should be performed betw een t = -15 m in and t = 0) and at t = 40 mins, 1 hr, and 1.5 hrs 
postdose; temperature at predose only (tympanic recommended).
v At screening, the ECG tracing w ill be sent to the central ECG l aboratory, but the investigator or sub -investigator is required to review  the ECG locally to determine 
subject eligibility.
w Performed 1 hr postdose.
x On each dosing day, continuous arterial oxygen saturation monitoring by [CONTACT_406] (SpO 2) should be m onitored and documented once predose betw een 
t= -15 min and t = 0 (first spray), and then every 15 mins postdose for approximately 1.5 hrs (see Section 9.6).
yOnly weight will be recorded at the Day  25 and the DB EW visit.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 54
Status: Approved , Date: 22 November 2020z On each dosing day, MOAA/S should be performed once predose betw een t = -15 min and t = 0 (first spray), and every 15 min for approximately 1.5 hrs postdose 
(longer, if necessary; refer to Section 9.6).
aaOn each dosing day, CADSS and BPRS+ to be performed predose and at [ADDRESS_461993]’s discharge from the inpatient unit. On a dosing day, comp lete 
predose.
ccNasal symptom questionnaire performed predose and at 1 hr postdose.
ddIf a dose is administered, SIBAT is performed predose. Not all modules are completed at every visit; see SIBAT Time &Events S chedule.
eeMADRS and CDRS -R will be performed at both predose and 4 -hr postdose on Day 25 (visit 10) of the DB phase.
ffCDI 2:SR[S] Completed predose at all timepoints. A 24 -hr recall period applies on Day 2; a 2 -week recall period applies at Day 1 and Day 25 or DB EW.
ggSamples will be collected for analysis by [CONTACT_12117] (for eligibility) and central laboratory (refer to Section 9.6)
hhWindow  for PK collect ion as follow s: 30 -50 mins; 1.5 hr to 2.5 hrs; and 4 hrs to 12 hrs on Day 1 and Day 4.
iiThese samples will be collected along with the 1.5 to 2.5 hour PK collection.
jj Visit can be performed +/ - 3days.
kkVisit can be performed +/ -5 day s.
llVisit c an be performed +/ -[ADDRESS_461994] to follow up, death, or w ithdraw al of consent/assent will have the PT EW visit conducted at 
the time of discontinuation. If subjects discontinue anytime betw een Day 25 postdose and Day 28 RC of the PT phase, the PT EW visit is not required; however, 
Day [ADDRESS_461995] will be performed on Day 81 for PWC -20,
CDRS -RandMADRS, andforcollection of concomitant therapi[INVESTIGATOR_368897] . (refer to Sections 9.1.5 and 10.2).
nnIf the PT EW visit occurs within ±5 days window  of Day 81 (visit 18) of the PT phase, then EW visit will be adequate, and the Day [ADDRESS_461996] to follow  up, death, or w ithdrawal of consent/assent after completion of the 
Day [ADDRESS_461997] the PT EW visit conducted at the time of discontinuation (refer to Section 10.2).
ppHem atology, chemistry and urinalysis are done only if the subject has w ithdrawn from the study prior to the Day 81 visit.
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 56
Status: Approved , Date: 22 November 2020ABBREVIA TIONS
AAP American Academy of Pediatrics
AD antidepressant
ADHD Attention -deficit hyperactivity disorder
AE adverse event
ANCOVA analysis of covariance
BP blood pressure
BPRS+ Brief Psychiatric Rating Scale, positive symptom subscale 
CADSS Clinician -Administered Dissociative States Scale 
CBT cognitive behavioral therapy
CDI 2:SR Children’s Depression Inventory 2 Self -Report
CDI 2:SR(S) Children’s Depression Inventory 2: Self -Report (short version) 
CDRS -R Children’s Depression Rating Scale -Revised
CGI-SR-I Clinical Global Impression –Imminent Suicide Risk
CGI-S Clinical Global Impression Severity Scale
CGI-SS Clinical Global Impression Severity of Suicidality
CGI-SS-R Clinical Global Impression of Severity of Suicidality, revised version 
eCRF electronic case report form 
DB double -blind
DBP diastolic blood pressure
D/C hospi[INVESTIGATOR_368928] -5 Diagnostic and Statistical Manual of Mental Disorders ( 5th edition)
ECG electrocardiogram
eDC electronic data capture
ER emergency room
EU European Union
EW early withdraw al
FDA Food and Drug Administration
GCP Good Clinical Practice
ICF informed consent form
ICH International Co uncil for Harmonisation
IDMC Independent Data Monitoring Committee
IEC Independent Ethics Committee
IM intramuscular
IND Investigational New Drug
InterSePT International Suicide Prevention Trial
IRB Institutional Review Board
IV intravenous
IVRS interactive voice response system
IWRS interactive web response system
LAR Legally acceptable representative
LC-MS/MS liquid chromatography/mass spectrometry/mass spectrometry
MADRS Montgomery -Asberg Depression Rating Scale 
MADRS -SI Montgomery -Asberg Depression Rating Scale –Suicidal Ideation
MedDRA Medical Dictionary for Regulatory Activities
MDD major depressive disorder
MINI Mini International Neuropsychiatric Interview
MINI -KID Mini International Neuropsychiatric Interview for Children and Adolescents
MOAA/S Modified Observer's Assessment of Alertness/Sedation 
NICE National Institute for Health and Clinical Excellence
NSAID non-steroidal anti -inflammatory drug
PD pharmacodynamic (s)
PDCO Paediatric Committee
PWC -[ADDRESS_461998] 
PK pharmacokinetic (s)
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 57
Status: Approved , Date: [ADDRESS_461999] Quality Complaint
PRO patient -reported outcome(s) (paper or electronic as appropriate for this study)
RC remote contact
[CONTACT_369003] -cranial magnetic stimulation
TLFB Timeline Follow -Back 
UDS urine drug screen
US [LOCATION_002]
USP [LOCATION_002] Pharmacopeia
YMRS Young Mania Rating Scale 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 58
Status: Approved , Date: 22 November [ZIP_CODE]. INTRODUCTION
Esketamine is the S-enantiomer of ketamine, which has been widel y used for the induction and 
maintenance of anesthesia since the 1970s. Because of its ability  to block the N-methy l-D-
aspartate (NMDA )glutamate receptor, ketamine has shown efficacy  in the treatment of sy mptoms 
of major depressive disorder (MDD).85This study  is intended to evaluate the efficacy , safety  and 
dose response of 3 doses ofesketamine in subjects 12 to <[ADDRESS_462000] commonly  associated with suicide.54,91Epi[INVESTIGATOR_368929]
12-month prevalence of MDD is 2% inchildren and 4% to 8% inadolescents,2that MDD is the 
main predictor of suicidal ideation among children and adolescents ,37,93and that 40% to 80% of 
adolescents meet the diagnostic criteria for depression at the time of suicide attempt .10,37Similar 
to adults, there is a substantial link between clinical depression and suicide in adolescents with up 
to 60% of adolescent suicide victims having a depressive disorder at the time of death.14,[ADDRESS_462001] of care for depressed 
adolescents at imminent risk for suicide is hospi[INVESTIGATOR_368930] y.91However, hospi[INVESTIGATOR_368931], and the risk for suicide remains high in the weeks after discharge. For 
example, one study found that 13.9% of hospi[INVESTIGATOR_253243] (12-15 yearsof age) reattempt ed 
suicide within 3 months of discharge.102
According to several treatment guidelines, 3 antidepressants are recommended as pharmacological 
treatment option sin children and adolescents with MDD : fluoxetine (Prozac®), escitalopram 
(Lexa pro®), and sertraline (Zoloft®) .20,21However, b ecause standard of care antidepressants may 
take up to [ADDRESS_462002] to decrease depressive symptomatology , including suicidal 
ideation .30
Ketamine and esketamine (the S-enantiomer of ketamine) are approved and widel y used for the 
induction and maintenance of anesthesia via intramuscular (IM) or intravenous (IV) 
administration. The desired analgesic -anesthetic effects of esketamine are attributed to the 
blockade of ionotropic NMDA glutamate receptors.112Affinity  for the NMDA receptor is 
approximately  3-to 4-fold greater for esketa mine than for its enantiomer, arketamine (R-ketamine, 
the R -enantiomer of ketamine ).58,[ADDRESS_462003] s are involved in the pathophysiology  of depression, 
IV-administered ketamine has been investigated for antidepressant properties.68,88In animal 
models, blockage of NMDA receptors was shown toresult in antidepressant -like effects3; and in 
humans, a single subanesthetic dose infusion of ketamine has been shown to have rapid ,potent 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 59
Status: Approved , Date: [ADDRESS_462004].4,84,85,100Several pi[INVESTIGATOR_368932].4,31,60,101,103,123In addition, 2 independent randomized, 
double -blind trials in subjects with MDD suggested that doses of IV ketamine could rapi[INVESTIGATOR_2478] y 
decrease suicidal ideation as evaluated b y assessments such as the MADRS suicidal thoughts item 
(MADRS -SI).5,[ADDRESS_462005] from conventional antidepressant treatments, 
which target modulatory  monoaminergic neurotransmitters (serotonin, norepi[INVESTIGATOR_238], and/or 
dopamine), and esketamine profoundl y affects fast excitatory  glutamate transmission, increases 
brain -derived neurotroph ic factor (BDNF) release, and stimulates synaptogenesis. In addition, a 
higher NMDA receptor binding affinity  of esketamine compared to ketamine allows a lower 
volume of medication to be administered via the non-invasive and rapi[INVESTIGATOR_375] -absorbed intranasal 
route. 
Administered intranasally , esketamine is rapi[INVESTIGATOR_2478] y and well -absorbed, and can offer patients better 
convenience . Janssen Research & Development is developi[INVESTIGATOR_368933] s ymptoms of MDD, includin g suicidal ideation, in adult patients 
who are assessed to be at imminent risk for suicide. As part of the pediatric development program, 
this study  is evaluating the efficacy , safet y and dose response of esketamine in subjects 12 to 
<18years of age with MDD who are assessed to be at imminent risk for suicide .
For the most comprehensive nonclinical and clinical information regarding esketamine
(JNJ-54135419), refer to the latest version of the Investigator's Brochure for esketamine , and 
associated addenda .48,49,50
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
1.1. Backgro und
1.1.1. Nonclinical Studies
Safety Pharmacology 
The effects of ketamine on myocardial contractility  and blood pressure varied with species and 
experimental conditions.48,49,50In these studies, the dog was most predictive of the cardiovascular 
effects of ketamine in man. I n dogs, ketamine produced increases in arterial blood pressure, heart 
rate and cardiac output as well as a decrease in total peripheral resistance.55Results from animal 
studies suggest that the increase in blood pressure produced by [CONTACT_313331].55
Toxicology 
Repeated- dose Toxicity: Repeated- dose toxicity  studies with intranasall y-administered
esketamine were performed in rats for up to [ADDRESS_462006] dose tested (ie, 9mg/day  in rats,and 72 mg/day  in dogs).48,49,50
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 60
Status: Approved , Date: 22 November 2020The Cmax-based exposure ratios for esketamine compared to the 84 mg human dose ranged from
1.3-and 0.7-fold. The AUC -based exposure ratios for es ketamine compared to the 84 mg human 
dose ranged from 0.7 -to 1.1 -fold.48,49,50
Neurotoxicity: Racemic ketamine has been reported to induce neurotoxicity in animal fetuses, and 
in juvenile, adolescent, and adult anima ls, as evidenced by [CONTACT_369004]. The precise thresholds for dose and duration of ketamine exposure causing 
neurotoxicity  in animals remain to be established. The relevance to humans of ketamine’s 
neurotoxic actio n in animals is unknown.
In animal studies with intranasall y-administered esketamine no evidence of neurotoxicity  was 
found. In single -dose and 14-day repeat -dose neurotoxicity  studies in rats, no histopathological 
brain lesions were noted up to 54 mg/day  in the 14-day study, and 72 mg as a single intranasal 
dose. In the 14-day rat study  the Cmax-and AUC -based safet y margins for esketamine compared 
to the 84 mg human dose were approximately  17-and 11- fold, respectivel y. At a single intranasal 
dose of 72 esketamine the Cmax-and AUC -based safet y margins compared to the 84mg human 
dose were approximately 60 -and 86-fold, respectively48,49,50In the 6 -month rat and 9 -month do g 
repeat -dose toxicity  studies with intranasall y-administered esketamine, where the animals were of 
adolescent age at initiation of treatment, and in the pre-and postnatal developmental toxicity  study 
in rats, no morphological or functional evidence of ne urotoxicity  was observed either.48,49,50  
Reproductive and Developmental Toxicity: In a  fertility  and early embry onic developmental 
study , no adverse effects of intranasal esketamine on the fertility  and reproductive capacities of 
adult male and female rats were observed.48,49,50Rat and rabbit embryo -fetal developmental 
toxicity  studies with intranasall y-administered racemic ketamine did not reveal evidence of 
reproductive toxicity .48,49,50High dose levels of racemic ketamine, however, induced neuronal cell 
death in the brain when administered to earl y postnatal rat pups.48,49,50Also, when monkey  fetuses 
were exposed in utero to high dose levels of racemic ketamine, neuro nal cell death was found in 
the brain .48,49,50Ketamine anesthesia during the first week of life caused long-lasting cognitive
deficits in monkey s.48,49,50
Genotoxicity: In vitro and in vivo genotoxicity  studies have been performed with ketamine and 
esketamine, and the overall weight of evidence demonstrates the absence of significant genotoxic 
risk.48,49,50
Abuse potential: The results of self- administration and withdrawal experiments in several animal 
models suggest that esketamine would have abuse potential in humans.9,24,25,57,77,120,121
1.1.2. Clinical Studies
[IP_ADDRESS]. Completed and Ongoing Clinical Studies with Intranasal Esketamine
A total of 10Phase [ADDRESS_462007] been reported .48,49,50
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 61
Status: Approved , Date: [ADDRESS_462008]: 2short -term double -blind, randomized, active -controlled studies, 
1maintenance -of-effect study , [ADDRESS_462009]. Further information about the completed and ongoing studies with esketamine 
is provided in the I nvestigator’s Brochure.48,49,50
[IP_ADDRESS]. Human Pharmacokinetics and Product Metabolism
Racemic Ketamine
The pharmacokinetics of IV ketamine has been examined in several studies with pediatric patients 
1.5 to 14 years of age who were administered single doses of 1 to 6 mg/kg.38,41,66The PK estimates 
of key parameters, namely  clearance and distribution volume, in children were similar relative to 
estimates in adult patients who received IV ketamine after standardization for body  size. The 
absolute bioavailability  of intranasall y administered esketamine was estimated to be 50%, which 
is similar to the 42% and 45% bioavailability  estimated in adults.98,119
It is evident from the published studies that racemic ketamine and esketamine are metabolized in 
children (1-9 years of age) to norketamine and noresketamine, respectivel y, based on the measured 
concentrations of each in plasma. A population PK analy sis which included norketamine 
concentration -time data from 57 pediatric patients (1.5-14 years of age) and adults who received 
IV ketamine indicated that estimates were indistinguishable from each other when standardized to 
a 70 kg person.42
Ketamine (and esketamine) undergoes extensive metabolism by  [CONTACT_313332] P450 
(CYP). In humans, N-demethy lation to the active metabolite norketamine is a major route of 
metabolism. Norketamine has a half-life in plasma of approximately  5 hours in humans.40The 
major human hepatic cytochromes that catal yze ketamine N- demeth ylation in vitro were CYP2B6 
and CYP3A4,43,99,118and those that were responsible for the formation of norketamine metabolites 
included CYP2A6 and CYP2B6.99Pharmac okinetic (PK) results after IV administration of 
racemic ketamine and esketamine to human subjects suggest that inversion of esketamine to 
arketamine (the R -enantiomer of ketamine) does not occur.[ADDRESS_462010] been shown to be predominantly excreted in the urine. 
An average of 91% of a dose of ketamine administered to healthy  subjects was recovered in urine.18
Less than 3% of an administered dose was excreted in urine as parent drug.115
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 62
Status: Approved , Date: [ADDRESS_462011] been characterized in healthy  adult subjects (elderl y and 
younger adults), subjects with a history  of allergic rhinitis, subjects with treatment -resistant 
depression (TRD),48,49,50and subjects with MDD at imminent risk for suicide. In healthy  adult 
subjects, intranasally -administered esketamine (28 mg to 112 mg) was rapi[INVESTIGATOR_368934] 7minutes after the first spray ; the plasma esketamine maximum 
concentration and area under the concentration -time curve increased in a dose-related manner 
following intranasal administration, and the mean terminal half-life of esketamine ranged from 
5.86 to 9.83 hours (ESKETINTRD1001).48,49,50When administered in healthy adult subjects via 
the intranasal route, esketamine was rapi[INVESTIGATOR_2478] y absorbed and had an absolute bioavailability  of 
approximately  48% (ESKTINTRD1009).48,49,50In a Phase [ADDRESS_462012] 
(ESKETINTRD2003), there was a dose-dependent increase in mean plasma esketamine 
concentrations from subjects in Panel A who were administered 28-, 56-, or 84-mg doses of 
intranasal esketamine.48,49,50Furthermore, the mean esketamine concentrations in plasma samples 
collected at corresponding time points on Day s 1, 11, and 25 we re similar suggesting that the PK 
was consistent after repeated intranasal administration.48,49,50The PK results from subjects with 
MDD at imminent risk of suicide (ESKETINSUI2001) who received 84-mg doses of intranasal 
esketamine were consistent with the PK results in healthy  adults and those with TRD.
[IP_ADDRESS]. Efficacy  
Several small clinical studies and case reports suggested that subanesthetic doses of ketamine 
could improve symptoms of depression within hours ,even in subjects who responded poorl y to 
conventional antidepressants.67Further, results from Panel A, part of a Phase 2, 2-panel, double -
blind, doubly -randomized, placebo -controlled clinical study  in subjects with TRD 
(ESKETINTRD2003) ,demonstrated that treatment with intranasal esketamine 28, 56, and84mg 
rapi[INVESTIGATOR_368935] s ymptoms of depression at [ADDRESS_462013] dose, as assessed 
by [CONTACT_313333] -Asberg Depression Rating Scale (MADRS) total score from 
baseline.48,49,50In addition, after 1 week of treatment ,the analysis showed that all 3 esketamine 
dose groups were statistically  superior to the placebo group using a one-sided significance level of 
0.05 (mean differences [SE] between each esketamine group and the placebo group 
were -4.2[2.09], p=0.021; -6.3 [2.07], p=0.001; and -9.0 [2.13] ,p<0.001 for esketamine 28, 56, 
and 84 mg, respectivel y). Additionally , there was a significant relationship between esketamine 
dose and change in MADRS total score (p<0.001) .48,49,50The major secondary  analyses of results 
from Panel A provided preliminary  evidence suggesting that improvements in depressive 
symptoms resulting from esketamine treatment could be sustained with repeated dosing for 
74days, the duration of the study  in Panel A.48,49,50In Panel B (conducted in Japan), subjects were 
treated with placebo or 14 or 56 mg of intranasal esketamine for up to 25 days. Greater 
improvements in MADRS total score were observed in the esketamine 56-mg group compared 
with the placebo group using a one -sided significance level of 0.10 (least squares mean difference 
[SE]: -3.7 [2.81]; p=0.096), and a dose response was detected during the first week of treatment 
(p=0.097).48,49,50Although there was a statisticall y significant difference between the esketamine 
56-mg and placebo groups during the first week of treatment, the results from Panel B must be 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 63
Status: Approved , Date: [ADDRESS_462014] week of treatment (p=0.052).4849,50
Several pi[INVESTIGATOR_368936].31,60,101,103,123In addition, 
2independent randomized, double -blind trials in subjects with MDD suggested that doses of IV 
ketamine could rapi[INVESTIGATOR_368937] (MADRS -SI).5,87
Recently , a Phase 2,double -blind, randomized, placebo- controlled, proof -of-concept study 
(ESKETINSUI2001) evaluated the efficacy  and safety  of intranasal esketamine for the rapid 
reduction of the symptoms of MDD, including suicidal ideation . Adult subjects with a diagnosis
of MDD assessed to be at imminent risk for suicide from the USwere randomly  assigned to 
treatment with placebo (n=31) or esketamine 84 mg (n=35) for up to [ADDRESS_462015] dose (primary  
endpoint; least squares mean differ ence [SE] between esketamine 84 mg and placebo: -5.3 [2.10]; 
p=0.015), at approximately  [ADDRESS_462016] dose (least squares mean difference [SE]: -7.2 
[2.85]; p=0.015). At the end of the double -blind phase esketamine [ADDRESS_462017] (least squares mean difference [SE]: -4.5 
[3.14]; p=0.159).16The changes from baseline in suicidal thoughts based on the MADRS -SI score 
also favored esketamine [ADDRESS_462018] dose (p=0.002) , at approximately  24hours 
after the first dose (p=0.129) , and at the end of the double -blind phase (p=0.143) .16Additionally , 
changes from baseline in the Clinical Global Judgment of Suicide Risk (CGJ -SR), which 
summarized the clinician’s overall judgment of suicide risk, provided evidence ofa potential 
therapeutic effect of esketamine 84 mg compared with placebo at both 4 hours (p=0.112) and 
24hours (p=0.150) after the first dose.16The results support the hypothesis that esketamine, 
administered intranasally, is an efficacious treatment for the rapid reduction of the symptoms of 
MDD, including suicidality , in subjects assessed to be at imminent risk for suicide. 
[IP_ADDRESS]. Safety  and Tolerability
Ketamine was first introduced as an anesthetic in [ADDRESS_462019] an excellent 
medical safety  profile.39,56,105,110The following adverse reactions are listed as very common, 
common, or frequent occurrences for ketamine and esketamine when administered as an 
anesthetic: emergence or recover y reactions, elevated blood pressure and pulse rate, stimulation of 
respi[INVESTIGATOR_1516], nausea, and vomiting.[ADDRESS_462020] in Panel A in Study  ESKET INTRD2003, received placebo or 28, 56, or 84 mg 
of intranasal esketamine, and subjects in Panel B received placebo or 14 or 56 mg of esketamine. 
All doses of esketamine generall y appeared to be tolerated, and no new safety  concerns were raised 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 64
Status: Approved , Date: [ADDRESS_462021] dose of study  medication.48,49,50A total of 4 non -fatal 
serious adverse events (SAEs) occurred in 3 subjects during the study ; oesophagitis (during 
placebo treatment), ectopic pregnancy  (during esketamine treatment, leading to treatment 
withdrawal), general physical health deterioration (follow -up phase) and confusional state (follow -
up phase).48,49,50The investigator assessed the SAE of confusional state as probabl y related to 
study  medication and SAEs of esophagitis, ectopic pregnancy , and general physical health 
deterioration, and completed suicide as not related to study  medication. In total, 4subjects 
experienced treatment -emergent adverse events (TEAEs) which led to withdrawal of study 
medication while receiving esketamine treatment (ectopic pregnancy  [described above], sy ncope, 
headache, and dissociative disorder).48,49,50The investigator assessed the events of headache and 
dissociative disorder as very likely related to study  medication. The investigator considered the 
event of syncope possibly  related to the study  medication, and the sponsor considered this event 
not related to the study  medication based on the short half -life of esketamine and the onset of the 
event of s yncope. 
In Panels A and B combined, the common TEAEs ( ≥10% the total esketamine or placebo groups) 
that occurred more frequently  in the total esketamine group compared with the placebo group 
during the double -blind phase were: dizzi ness, headache, dissociation, nausea, feeling abnormal, 
and hypoaesthesia.23A majority  of subjects in Panels A and B experienced elevations in blood 
pressure measurements after receiving esketamine doses; the maximum elevations from predose
in blood pressure measurements on each dosing day were observed in most cases within 1 hour 
postdose, with the majority  returning within the normal range by 2 hours postdose.23The blood 
pressure changes observed did not appear to attenuate over time with multiple doses. A majorit y 
of subjects in the esketamine treatment groups in Panels A and B experienced an increase in 
dissociative sy mptoms after dosing as assessed using the CADSS. Dissociative sy mptoms peaked 
at approximately  40 minutes after dosing and typi[INVESTIGATOR_313268] 2 hours after dosing.23The 
magnitude of postdose dissociative symptoms decreased over time with repeated consecutive 
doses for all esketamine doses.
Short -term Use of Intranasal Esketamine in Adult Subjects with MD D at Imminent Risk 
for Suicide
In the Phase 2 stud y in adult subjects with MDD at imminent risk for suicide (ESKETINSUI2001 , 
esketamine 84 mg versus placebo), the TEAEs reported by [CONTACT_313335]-treated subjects were 
consistent with the safet y profile of esketamine observed in earlier studies. Esketamine 84 mg was 
generall y tolerated, and no new safet y signals emerged in this population. There were no deaths 
during the study . There were 4 SAEs in the double -blind phase, all in the esketamine 84 mg group. 
Three of these events were related to re -hospi[INVESTIGATOR_313269] -emergence of suicidal 
ideation (n=2) or depression (n=1) in subjects who had improved and had been discharged from 
the hospi[INVESTIGATOR_307]. In all 3instances, the subjects recovered and complete d both the double -blind and 
follow -up phases. One subject experienced an event of increased agitation, and the study 
medication was withdrawn. With the exception of re-emergence of depressive symptoms, which 
was considered possibly  related to study  medicat ion, none of the other SAEs were considered to 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 65
Status: Approved , Date: 22 November 2020be related to study  medication by [CONTACT_093]. During the follow -up phase, 5 subjects in the 
placebo group experienced SAEs, including suicidal ideation (n=1) and attempted suicide (n=3) 
and cellulitis (n=1), compared with only [ADDRESS_462022] common ( ≥20%) individual TEAEs in the esketamine [ADDRESS_462023] findings were that frequent ketamine users (more than 5 times a week) exhibited 
impairments in both short -and long-term memory .80Although dosages varied, the dosages 
reported by [CONTACT_369005]. The memory  impairments were 
not found in ex-users who had been abstinent for at least a year, thus impairments may be 
reversible.[ADDRESS_462024] demonstrated a decline in 
cognitive function shortly  after a single 84-mg dose administration (40 minutes postdose) that 
return edto comparable baseline levels by  [ADDRESS_462025] cases were in near-daily recrea tional ketamine users; the majority  of cases 
resolved after stoppi[INVESTIGATOR_154852], and one-third remained static. The ketamine dose, dosing 
frequency , and duration of chronic ketamine use at which cystitis may develop are not known. 
Compared with the doses and dosing frequency  of esketamine proposed in this study , the 
equivalent ketamine dose in published reports of interstitial cystitis and bladder -related s ymptoms 
was typi[INVESTIGATOR_1306] y much higher; ketamine was dosed more frequently, and often there was concomita nt 
use of other substances.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 66
Status: Approved , Date: 22 November 2020Abuse Liability, Dependence and Withdrawal
There are reports of ketamine dependence in the litera ture but no large -scale studies.46,52,79,76,95
One study  found that ketamine users and ex-users expressed concerns about ketamine addiction, 
and the majorit y of frequent users reported using the drug without stoppi[INVESTIGATOR_154853], 
so compulsive patterns of behavior are a concern.83A few published reports describe craving and 
somatic and psychological aspects of anxiety  as symptoms of withdrawal from ketamine; however, 
a specific ketamine withdrawal s yndrome has not y et been described.27,63,79
1.2. Psychoactive Placebo Control
Midazolam 
Oral midazolam solution, 0.125 mg/kg, will be used as a psychoactive placebo in a double -dummy 
study  design. Given the transient dissociative and sedative side effects of esketamine, midazolam 
was selected as a psychoactive placebo in order to maintain blinding.86Midazolam is a short -acting 
benzodiazepi[INVESTIGATOR_368938], with pharmacokinetic characteristics similar to 
those of ketamine; that is, fast onset of action and short eliminat ion half-life. It also possesses 
psychoactive effects such as sedation and disorientation.72,73Oral midazolam is indicated for use 
in pediatric subjects for sedation, anxioly sis, muscle relaxation, and amnesia prior to a medical 
procedure, and before induction of anesthesia. Common reported effective doses range from 
0.25 mg/kg to 1 mg/kg in children 6 months to <16 years of age.71While midazolam is anxioly tic, 
it has not been shown to be efficacious as a treatment for depression. Midazolam has been 
previously  used as a ps ychoactive placebo in studies of ketamine .86
The midazolam dose of 0.125 mg/kg is based on a study  of IV ketamine in adult subjects with 
TRD in which midazolam 0.045 mg/kg IV was used.86Assuming 36% bioava ilability  of the oral 
formulation in pediatric patients,104an oral dose of 0.125 mg/kg was calculated to be equivalent to 
the IV dose of 0.045 mg/ kg. The midazolam dose selected for this study  isapproximately 25% of 
that recommended for pre -anesthetic use in pediatric populations.
Midazolam exhibits linear pharmacokinetics between oral doses of 0.25 to 1 mg/kg (up to a 
maximum dose of 40 mg) across the age groups ranging from 6 months to <16 years. The 36% 
absolute bioavailability  of orally  administered midazolam in pediatric patients is not affected by 
[CONTACT_369006]. Midazolam is rapi[INVESTIGATOR_368939]  0.5 and 3 hours. The half-life of midazolam ranges between 2and6 hours. 
Midazolam is primarily  metabol ized to1 hydroxy midazolam by [CONTACT_097]3A4 and is considered a 
sensitive probe of CYP3A4 activity . Fluoxetine, escitalopram or sertraline are not expected to 
influence the metabolic clearance of midazolam. 
The sedative effects of midazolam are accentuated by [CONTACT_369007], particularly  narcotics, secobarbital and droperidol. 
Caution is also advised when midazolam is administered with drugs that are known to inhibit the
P450 -3A4 enzyme system such as(not ranitidine), diltiazem, verapamil, ketoconazole, and 
itraconazole. These drug interactions may result in prolonged sedation due to a decrease in plasma 
clearance of midazolam.70
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 67
Status: Approved , Date: 22 November 2020Adverse events associated with midazolam administration include sedation, vomiting, nausea, 
hypoxia, laryngospasm, respi[INVESTIGATOR_2477], rhonchi, congestion, agitation, involuntary  
movements (including tonic -clonic movements and muscle tremor), bradycardia, bigeminy , and 
skin rash.71Benzodiazepi[INVESTIGATOR_1651], including midazolam, are contraindicated in patients with acute 
narrow -angle glaucoma. Flumazenil is a specific reversal agent for midazolam .70
1.3. Overall Rationale for the Study
The current study  is being conducted to evaluate the efficacy , safety  and dose response of 3 fixed 
doses of intranasal esketamine (28, 56 and 84 mg)compared with a psychoactive placebo, each 
given in addition to comprehensive standard of care in subjects 12 to <18 years of age with MDD 
who are at imminent risk for suicide in support of regulatory  agency  requirements for registration 
of intranasal esketamine.
2. OBJECTIVES , ENDPOINTS, AND HYPOTHES IS
2.1. Objectives and Endpoints
2.1.1. Objectives
Primary Objective
The primary objective is to assess the efficacy  of a single (first) dose of 3 fixed dosesof intranasal 
esketamine (28 mg, 56 mg, and 84 mg) compared with psy choactive placebo (oral midazolam) in 
rapi[INVESTIGATOR_368940] , including suicidal ideation, in subjects 12 to <18 years
of age who are assessed to be at imminent risk for suicide. Efficacy  will be assessed by [CONTACT_369008]’s Depression Rating Scale, Revised (CDRS -R) total score at 24hours 
post first dose (Day  2).
Othe rObjective s
The other objective s are the following: 
To evaluate the dose response of intranasal esketamine compared with psychoactive placebo 
in reducing the symptoms of MDD, including suicidal ideation, as assessed by [CONTACT_369009] -R total score at [ADDRESS_462026] dose (Day  2)and at Day  25.
To evaluate the efficacy  of single and repeated dosesof intranasal esketamine compared with 
psychoactive placebo in reducing symptoms ofsuicidal ideation ,as assessed by [CONTACT_369010] , revised version (CGI -SS-R)from the Suicide 
Ideation and Behavior Assessment Tool (SIBAT) at [ADDRESS_462027] dose and 
through the end of the Double -Blind Treatment phase (Day 25).
To evaluate the efficacy of single and repeated doses of intranasal esketamine compared with 
psychoactive placebo in reducing s ymptoms of MDD as assessed by  [CONTACT_716]:
-CDRS -R total score at [ADDRESS_462028] dose,through the end of the Double- Blind 
Treatment phase (Day 25), and during the [ADDRESS_462029] dose, through the end of the Double-
Blind Treatment phase (Day 25), and during the 6-month Post-Treatment Follow -Up phase.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 68
Status: Approved , Date: 22 November 2020-Children’s Depression Inventory  2: Self -Report (Short) version (CDI 2:SR[S])TMscore at 
[ADDRESS_462030] dose and through the end of the Double -Blind Treatment phase (Day 25).
To evaluate the efficacy of single and repeated doses of intranasal esketamine compared with 
psychoactive placebo in reducing symptoms of suicidal ideation, as assessed by [CONTACT_369011] –Imminent Suicide Risk (CGI -SR-I) from the SIBAT at [ADDRESS_462031] dose and through the end of the Doub le-Blind Treatment phase (Day 25).
To evaluate the efficacy  of single and repeated doses of intranasal esketamine compared with 
psychoactive placebo in reducing suicidal thoughts, as assessed b y the following:
-Change from baseline in SIBAT Module 3 (My Current Thinking) and Module 5 (My Risk) 
Question 3 (patient -reported frequency  of suicidal thinking) through the end of the Double-
Blind Treatment phase (Day 25)and during the 6-month Post-Treatment Follow -Up phase .
To characterize the pharmacokinetics of intranasal esketamine and its metabolite 
noresketamine.
To evaluate the safet y and tolerability  of intranasal esketamine through the end of the Double-
Blind Treatment phase (Day 25) using the following assessments:
-Effects on suicidal ideation and behavior using the SIBAT 
-Effects on dissociative symptoms using the Clinician- Administered Dissociative States 
Scale (CADSS)
-Occurrence of psychosis -like side effects using a 4-item positive symptom subscale 
(consisting of: suspi[INVESTIGATOR_23703], hallucinations, unusual thought content, and conceptual 
disorganization) of the Brief Psychiatric Rating Scale , positive symptom subscale (BPRS+)
-Occurrence of potential treatment -emergent symptoms of mania using the Young Mania 
Rating Scale (YMRS)
-Effects on cognitiv e function as measured b y the Cogstate computerized cognitive battery  
-Effect on sedation using the Modified Observer's Assessment of Alertness/Sedation 
(MOAA/S) scale
-Local nasal tolerability , using targeted nasal examinations coupled with a nasal symptom
questionnaire
To evaluate the safety and tolerability of intranasal esketamine at specified times through the 
initial 25 day double -blind treatment period (Day  25), the8-week post-treatment follow -up 
(Day  81) and [ADDRESS_462032]-treatment follow -up, with special attention given to the following 
assessments:
-Effects on suicidal ideation and behavior using the SIBAT
-Effects on cognitive function as measured b y the Cogstate computerized cognitive battery  
To evaluate potential withdrawal s ymptoms during the pos t-treatment follow -up as measured 
by [CONTACT_369012] (PWC -20)on Day s 25, 28, 32, 35 and 39.
To evaluate the p otential for ketamine or PCP abuse during the follow -up as measured b y the 
Timeline Follow -Back (TLFB) .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 69
Status: Approved , Date: 22 November 2020To evaluate whether pretreatment concentrations of MDD -related biomarkers (eg, HPA axis 
function, immune system activation, growth factors, metabolic markers) correlate with 
clinical response or non-response ,as measured by [CONTACT_369013].
To explore the change in MDD -related biomarkers in relation to clinical response or non-
response to intranasal esketamine.
2.1.2. Endpoints
The primary  efficacy  evaluation will be the change from baseline (Day  1, predose) at [ADDRESS_462033] dose in depressive symptoms, including suicidal ideation, as measured by [CONTACT_368996] -R 
total score.
Other efficacy  endpoints will be evaluated throughout the study , as follows :
-CDRS -R
oDose response at [ADDRESS_462034] dose, 
through the end of the Double- Blind Treatment phase (Day 25), and during the 
6-month Post-Treatment Follow -Up phase .
-MADRS
oChanges from baseline, post single and repeated doses ,at [ADDRESS_462035] dose, through the end of the Double- Blind Treatment phase (Day  25), and during 
the 6- month Post-Treatment Follow -Up phase .
-CGI-SS-R from SIBAT
oChanges from baseline ,post single and repeated doses at [ADDRESS_462036] dose, through the end of the Double- Blind Treatment phase (Day  25).
-CGI-SR-I from SIBAT
oChanges from baseline, post single and repeated doses at [ADDRESS_462037] dose, through the end of the Double- Blind Treatment phase (Day  25).
-SIBAT
oChanges from baseline, post single and repeated doses, through the end of the 
Double- Blind Treatment phase (Day  25)and during the 6-month Post-Treatment 
Follow -Up phase in depressive symptoms and suicidal ideation (subject -completed 
modules 3, 4, a nd 5) and clinician impression of suicidality  and judgment about 
management of suicidal thinking (clinician -completed modules 7 and 8) .
-CDI 2:SR (S)
oChanges from baseline ,post single and repeated doses, at [ADDRESS_462038] dose 
and through the end of the Double- Blind Treatment phase (Day  25).
Safety  endpoints will be evaluated throughout the study , as follows:
-Monitoring of TEAEs
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 70
Status: Approved , Date: 22 November 2020-Clinical laboratory  tests, physical examination, nasal examination and nasal symptom 
questionnaire , 12-lead ECG, vital signs , pulse oximetry and bod y weight
-SIBAT
-BPRS+ score 
-CADSS 
-Cogstate computerized cognitive battery  
-YMRS score
-Modified Observer ʼs Assessment of Alertness/Sedation (MOAA/S) score
-Physician Withdrawal C hecklist (PWC -20)
-TLFB methodology  to evaluate use of ketamine or PCP .
Pharmacokinetics
-Plasma esketamine and noresketamine concentrations will be summarized; plasma 
concentrations of esketamine (and noresketamine concentrations, if warranted) will be 
included in a population analysis. Plasma concentrations of other esketamine metabolites 
andmidazolam may also be measured , if warranted.
Biomarkers
-Characteristics of esketamine mechanism of action or biological predictors of inter-
individual variability .
Refer to Section 9, Study Evaluations ,for evaluations related to endpoints.
2.2. Hypothesis
The primary  hypothesis of this study  is that ,in addition to standard of care, intranasal esketamine 
is superior to psy choactive placebo in rapi[INVESTIGATOR_368941] s ymptoms of MDD, including suicidal
ideation , as assesse d by [CONTACT_368997] -R at [ADDRESS_462039] dose in subjects 
12 to <18 y ears of age who are assessed to be at imminent risk forsuicide .
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This Phase 2 study  is a randomized, double -blind, double -dummy , psychoactive placebo -
controlled, multicenter trial with 45 anticipated global sites. A target of 145 male and female 
subjects , 12 to <18 years of age, will be enrolled in this study and randomized in a 1:1:1:2 ratio to 
one of 3 doses of intranasal esketamine (28, 56 or 84 mg) or a psychoactive placebo (oral 
midazolam 0.125 mg/kg) , with approximately  [ADDRESS_462040] presented to an emergency room (ER) or other 
permitted setting and been assessed to be at imminent risk for suicide. Given the vulnerability  of 
the population, this study will be conducted in the context of standard of care treatment . This
includes initial hospi[INVESTIGATOR_368942] a 
recommended duration of 5 dayscounted from randomization, with shorter or longer 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 71
Status: Approved , Date: [ADDRESS_462041] of care;initiation or 
optimization of allowed antidepressant treatment; participation in a specific ps ychological
intervention (indivi dual cognitive behavioral therap y [CBT]), interpersonal therap y, family 
therap y or ps ychody namic psy chotherapy );and close outpatient follow -up.
There is only  1 approved antidepressant for the treatment of MDD in children and adolescents in 
both the [LOCATION_002] (US) and European Union (EU): fluoxetine; however , if treatment with 
fluoxetine is unsuccessful or is not tolerated because of side effects, guidelines recommend treatment 
with citalopram and sertraline .20,22,61,91Escitalopram (the S-enantiomer of citalopram) is also 
approved for use in adolescents in the US. Therefore, this multi- national study  will permit the use 
of fluoxetine, escitalopram or sertraline as the standard of care antidepressants.
The study  will be conducted in 4 phases: a screening evaluation performed within 48 hour s prior 
to Day 1 intranasal dose (if possible, screening should occur within 24 hours prior to the Day 1 
intranasal dose) ;a 25-day Double- Blind Treatment phase (Day s 1-25), during which study  drug 
will be administered 2 times per week for 4 weeks on Days 1, 4, 8, 11, 15, 18, 22, and 25; an
8-week initial post-treatment phase (Day s 25- 81);and asubsequent phase to complete a full 
6-month post-treatment follow-up(Day s 81-200).During post-treatment follow -up phases, no 
study  drug will be administered. The duration of the subject’s participation will be approximately 
29 weeks . 
Efficacy , safety , pharmacokinetic, biomarker, and pharmacogenomic (DNA and RNA) 
evaluations will be performed as described in the Time and Events Schedule.
The primary  efficacy evaluation is the CDRS -R; other efficacy evaluations are 
SIBAT/CGI -SS-R and CGI -SR-I, MADRS, CDI 2:SR (S).
Safety  evaluations include monitoring and collection of adverse event s and concomitant 
therapi[INVESTIGATOR_014], physical examination, nasal examination and nasal symptom questionnaire, 
measurements of body  weight and vital signs, 12-lead electrocardiogram (ECG), pulse 
oximetry , clinical laboratory  tests, SIBAT, MOAA/S, CADSS, BPRS+, YMRS, PWC- 20, 
TLFB, and Cogstate computerized cognitive battery .
Blood samples will be collected for measurement of plasma concentrations of esketamine, 
noresketamine, and other metabolites i f warranted.
Blood samples will be collected for biomarker evaluations.
Blood samples for DNA and RNA analyseswill be collected from subjects who consent/assent 
separately  to this component of the study  (where local regulations permit). Subject 
participat ion in DNA and RNA research is optional.
An Independent Data Monitoring Committee (IDMC) will be commissioned for this study  (refer 
to Section 11.7,Data Monitoring Committee , for details).
A diagram of the stud y design is provided in Figure 1.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 72
Status: Approved , Date: 22 November 2020Figure 1: Schematic Overview of the Study
Abbreviations: AD , antidepressant; SoC, standard of care.
aAntidepressant medication should be initiated or optimized on Day 1. How ever, initiating standard of care
antidepressant medication up to [ADDRESS_462042] dose of study medication (Day  1), is perm itted if starting 
two medications simultaneously is not consistent with local clinical practice .
bIf possible, screening should be performed within 24 hours prior to Day 1 intranasal dose.
cHospi[INVESTIGATOR_307] d ischarge before 5 days (from randomization) must be discussed with and approved by [CONTACT_456]’s 
medical monitor. The investigator must discuss the need for continue d hospi[INVESTIGATOR_60613] 10 days and 
thereafter on a weekly basis with the sponsor’s medical monitor.
d Remote contact.
3.2. Study Design Rationale
3.2.1. Study Population
This study  will enroll subjects 12 to <[ADDRESS_462043] commonly  associated with suicide.54,91Depression is 
the main predictor of suicidal ideation.37,93In the US, the age standardized suicide rate increased 
24.2% over the 12-year period from 2000 to 2012, rising from 9.8% to 12.1% per 
100,[ADDRESS_462044] affected. Globally , suicide accounts for 
8.5% of all deaths among young adults (15−29 years of age) and is ranked as the second leading 
cause of death .92In the US, suicide is the third leading cause of death for y oung people between the 
ages of [ADDRESS_462045] y during adolescence and young adulthood.92Older adolescents (13 –18years)are at higher 
risk of MDD than those younger than 13 years (overall point prevalence estimates [±SE] 5.6±0.3% 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 73
Status: Approved , Date: 22 November 2020versus 2.8±0.5%, respectively ).17,117The age range of subjects 12 to < 18 was chosen due to the 
significant unmet need for effective treatment in this particularl y vulnerable population . 
The MINI-KID 7.0.2 will be utilized to identify  adolescents with a primary  diagnosis of MDD 
without psychotic features. Affirmative responses to questions B3 and B10 of the MINI-KID, 
along with clinical need for hospi[INVESTIGATOR_059], will confirm that subjects are experiencing active 
suicidal ideatio n with intent, and thus are considered to be at imminent risk for suicide. A 
requirement for a CDRS -R total score of ≥[ADDRESS_462046] disorder, anorexia nervosa, oppositional defiant disorder, obsessive compulsive 
disorder, borderline personality  disorder ,or those who meet Diagnostic and Statistical Manual of 
Ment al Disorders (5thedition) ( DSM -5)severit y criteria of moderate or severe substance or alcohol 
use disorders within the [ADDRESS_462047]’s 
depression is not attributed to a disorder other than MDD, and to allow accurate assessment of 
efficacy  and/or safet y data of the stud y drug in the context of MDD.
3.2.2. Treatment and Study  Duration
Patients with MDD with suicidal thoughts and behaviors are at risk for increased suicidality  both 
in the first several days after initiating treatment with a standard antidepressant53and post-
hospi[INVESTIGATOR_059].11,102,114The dosing regimen in this study  includes administration of esketamine 
twice a week for 4 weeks (Day s 1, 4, 8, 11, 15, 18, 22, and 25). This duration of repeated dosing 
is consistent with the timeframe in which standard antidepressants take to exert their action, and 
will allow for the evaluation of depression and assessment of suicide risk during this period of 
increased vulnerability .The duration of follow -up in this study  covers the period of greatest risk 
for recurrent suicidality  post initial attempt and/or hospi[INVESTIGATOR_059].11,15,[ADDRESS_462048] 2 weeks (Day s 28, 32, 35, 39), after which visits will occur weekl y (Days46 
and 53), then every  2 weeks (Day s 67 and 81). The Day [ADDRESS_462049]-Treatment Follow -Up phase 
(Day s81-200), during which they will have monthly visits to assess safety. Investigators may add 
follow -up visits as dictated by [CONTACT_423]’s clinical condition and the investigator’s clinical 
judgment. Additionally ,throughout the follow -up period, suicide attempts, hospi[INVESTIGATOR_134577] -admissions 
for suicidality , and ER visits will be followed and noted as part of safet y outcomes .
3.2.3. Control, Randomization and Blinding
Randomization will be used to minimize bias in the assignment of subjects to treatment groups, to 
increase the likelihood that known and unknown subject attributes (eg, demographic and baseline 
characteristics) are evenly  balanced across treatment groups, and to enhance the validity  of 
statistical comparisons across treatment groups. Randomization will be stratified by  [CONTACT_91294] .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 74
Status: Approved , Date: [ADDRESS_462050] of a placebo response is of particular concern in clinical trials of MDD .97Because a 
lower likelihood of randomization to placebo has been shown to be associated with placebo 
response,97atreatment allocation of 1:1:1:2 for 28 mg: 56 mg: 84 mg: psychoactive placebo is 
being used to minimize expectancy  bias and to mitigate placebo response .
A double -dummy  design will be used in order to preserve the blind since the active study  drug 
(intranasal esketamine) and the psychoactive placebo (oral midazolam) are administered via 
different routes. Therefore, [ADDRESS_462051] and sustained efficacy  observ ed at the 84mg dose. 
The primary  efficacy  endpoint (change in MADRS total score from baseline to Day 8) 
demonstrated statistically significant improvement in all 3 esketamine dose groups.
In this study , the same intranasal esketamine doses of 28, 56, and 84 mg will be evaluated to 
establish optimal dose, taking into consideration benefits and tolerability , in young subjects with 
major depressive disorder with imminent suicidality  (MDSI ).A population PK analy sis which 
included esketamine and its active metabolite, norketamine, concentration -time data from 
57pediatric subjects (1.5 to 14 years old) and adults who received IV ketamine indicated that 
estimates were indistinguishable from each other when standardized to a [ADDRESS_462052] allometric scaling was applied using the population pharmacokinetic model developed 
with adult data after intranasal administration of esketamine in order to simulate esketamine 
systemic exposure in pediatric subjects. Simulations (based on standard allometric scaling) of the 
exposure of 56 and 84 mg of esketamine after intranasal administration in the 12 to <18 years of 
age show a similar exposure as in adults .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 75
Status: Approved , Date: 22 November [ZIP_CODE].2.5. Psychoactive Placebo 
Midazolam 
Oral midazolam solution , 0.125 mg/kg, will be used as a psychoactive placebo in a double -dummy 
study  design. Given the transient dissociative and sedative side effects o f esketamine, midazolam 
was selected as a psychoactive placebo in order to maintain blinding.86Midazolam is a short -acting 
benzodiazepi[INVESTIGATOR_368938], with pharmacokinetic characteristics similar to 
those of ketamine; that is, fast onset of action and short elimination half-life. It also possesses 
psychoactive effects such as sedation and disorientation .72,73
The midazolam dose of 0.125 mg/kg is based on a study  ofIV ketamine in adult subjects with 
TRD in which midazolam 0.045 mg/kg IV was used.86Assuming 36% bioavailability  of the oral 
formulation in pedia tric patients,104an oral dose of 0.125 mg/kg was calculated to be equivalent to 
the IV dose of 0.045 mg/kg, approximately  25% of the pediatric dose recommended for pre 
anesthetic use (0.2-0.5 mg/kg) .72,[ADDRESS_462053] 
Characteristics.73
3.2.6. Efficacy Measures
Children’s Depression Rating Scale, Revised (CDRS- R)
The primary  outcome measure in this study  will be the CDRS -R, a validated 17-item, clinician -
rated instrument developed to assess depressive symptomatology  in children that measures the
severit y of a patient’s depressive s ymptoms.69CDRS -R has been used in previous pi[INVESTIGATOR_368943] ( SSRI s)in children and adolescents. It was selected as the 
primary  outcome measure since it reflects the core symptoms of MDD, as defined by [CONTACT_2681]-5, 
including a suicide -related item. The scale has demonstrated good reliability  and validit yin 
adolescents with depression .69
This study  is aimed at evaluating the rapid reduction of sy mptoms of MDD, including suicidality , 
in subjects 12 to <18 years of age who are assessed to be at imminent risk for suicide. Accordingl y, 
the primary  efficacy  endpoint is the change from baseline (Day  1 predose) in the CDRS -R total 
score at [ADDRESS_462054] 24 hours. 
Clinical Global Impression of Severity of Suicidality –Revised (CGI -SS-R)
The CGI-SS was initially created for the International Suicide Prevention Trial (InterSePT), a 
large -scale, long-term prospective study  that evaluated the potential of the antipsy chotic 
medications clozapi[INVESTIGATOR_368944] 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 76
Status: Approved , Date: 22 November 2020or schizoaffective disorder who are known to be at high risk for suicide. The CGI -SS was derived 
from the Clinical Global Impression Severity  Scale (CGI -S), a global rating scale that gives an 
overall measure of the severity of a patient’s i llness. The CGI -SS provided an index to quantify  an 
expert's impression of severity  of suicidality  that helped to confirm the validity of the InterSePT 
Scale for Suicidal Thinking (ISST). 
A revised version of the CGI-SS (CGI -SS-R) with a [ADDRESS_462055] firstdose and through the end of the Double -
Blind Treatment phase , will be used to evaluate other objectives by  [CONTACT_58833]:
Change in severity  of suicidality  at [ADDRESS_462056] dose and through the end of the 
Double- Blind Treatment phase
Resolution of suicidality as measured by [CONTACT_313319] 0 (normal, not at all suicidal) or 
1(questionably  suicidal) of the CGI-SS-R at [ADDRESS_462057] dose on Day  2, and through the end of the Double -Blind Treatment phase
Change in severit y of suicidality  through the end of the follow -up phase
Clinical Global Impression of Imminent Suicid e Risk (CGI-SR-I)
The CGI-SR-I is a scale summarizing the clinician’s best assessment of the likelihood that the 
subject will attempt suicide in the next 7 day s (Section 9.2.2 ). 
The CGI -SR-I will be used to evaluate other objectives by [CONTACT_58833]:
Change in imminent suicide risk at 4 hours postdose on Day 1, 24 hours postdose on Day 2, 
and through the end of the Double- Blind Treatment phase
Montgomery -Asberg Depression Rating Scale (MADRS)
The MADRS has been used as an efficacy  outcome parameter in several adolescent treatment 
trials.32,113A 10 -item clinician -administered scale that was designed to be used in subjects with 
MDD to measure the overall severit y of depressive sy mptoms in adults.74,75Further, the MADRS 
is sensitive to rapid changes in depression s ymptoms and suicidal thoughts, and has been included 
as a key outcome parameter in published studies of ketamine for depression and suicidal 
ideation5,31,60,87,100,101as well as in the sponsor’s Phase 2 adult studies of esketamine in MDD with 
imminent risk for suicide (ESKETINSUI2001) and in TRD (ESKETINTRD2003 and the Phase [ADDRESS_462058]). 
Although not validated in children, the MADRS has been included in previous pediatric trials of 
antidepressants.19,33,51The MADRS will be used to evaluate the change from baseline in MADRS 
total score at [ADDRESS_462059] dose,through the end of the Double-
Blind Treatment phase (Day  25), and through the 6-month Post-Treatment Follow- Up phase .The 
MADRS is included as an additional efficacy  measure because in previous trials of esketamine 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 77
Status: Approved , Date: 22 November 2020and ketamine in depression, it has been shown to be sensitive to rapid change in symptoms of 
depression and suicidal thoughts.
Suicide Ideation and Behavior Assessment Tool (SIBAT)
The development of treatments with the potential for rapid onset of efficacy  as measured by 
[CONTACT_369014] y measure these attributes. However, these requirements 
correspond with specific deficits in existing suicide assessment scales.  To address these unmet 
needs, a new instrument, the SIBAT, develop edby a team of experts in suicide and psychometrics
will be used . The SIBAT is presently  undergoing validation in adults and children.
The SIBAT is a suicide assessment tool that c aptures suicidal ideation and behavior(s) as reported 
by [CONTACT_369015] -term suicide risk and treatment plans 
(see Section 9.2.2 ). 
The SIBAT is computerized and organized into [ADDRESS_462060] 
awide variet y of demographic, cultural and demographic backgrounds. The 8 modules of the 
SIBAT are divided into patient -reported (Modules 1-5) and clinician -rated (Modules 6-8) sections. 
This modular structure allows for customization, and the administration of specific modules can 
be adjusted to meet clinical needs. Responses less susceptible to change (eg, demographics, 
medical history ) are segregated into modules distinct from those responses more likely to fluctuate 
over shorter time intervals (eg, curr ent suicidal ideation). In general, the patient -reported modules 
document information regarding the severity  of suicidal ideation and risk and protective factors 
associated with suicide risk and specific suicidal behaviors. Information from the patient -reported 
modules, plus a brief semi- structured clinician interview in Module 6, represent a comprehensive 
profile for assessment of the Clinical Global Impressions in Module 7, which includes the CGI-
SS-R, the Clinical Global Impression of Imminent Suicide Risk (CGI -SR-I), the Clinical Global 
Impression of L ong-Term Suicide Risk, and assessment of the frequency  of suicidal thinking. An 
assessment of the Clinical Global Judgment of Optimal Suicide Management is included in 
Module 8.
The SIBAT builds on prior work used to develop scales which are available for assessing 
suicidality ; for example, the ISST,65a 12-item instrument designed for the assessment of current 
suicidal ideation in patients with schizophrenia and schizoaffective disorders, and the Clinical 
Global Impression of Severity  of Suicidality  (CGI-SS). Module 7 (Clinical Global Impressions) 
of the SIBAT includes a revised version of the CGI-SS (CGI -SS-R), as well as a Clinical Global 
Impression of Imminent Suicide Risk (CGI -SR-I), which will be used to evaluate other objectives 
(further details are provided above ). In addition, Module 3 (My  Current Thinking) andModule 5 
(My Risk) Question 3 (patient-reported frequency of suicidal thinking) from the SIBAT will be 
used to evaluate the other objective of assessing patient -reported suicidalit y through the end of the 
Double- Blind Treatment phase and during the [ADDRESS_462061]-Treatment Follow- Up phase .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 78
Status: Approved , Date: 22 November 2020Children’s Depression Inventory 2, Self- Report (Short Form) (CDI 2 :SR[S])
The CDI 2 :SR(S)assessment is apatient rated assessment of depr essive sy mptoms in youth aged 
7to 17 years and an efficient screening measure that contains 12 items andtakes 5to 10 minutes 
to administer. The CD I2:SR (S)has excellent psychometric properties and yields a total score that 
is generally  very comparable to the one produced by [CONTACT_152627]-length version , CDI 2, a validated 
screening instrument for depression in children .59
3.2.7. Safety  Evaluations
Physical examination, nasal examination, nasal symptom questionnaire, body weight, vital signs 
(including measurement of blood pressure, heart rate, respi[INVESTIGATOR_2842], and temperature), 12-lead 
ECG, pulse oximetry, clinical laboratory tests (hematology, chemistry, and urinalysis), pregnancy 
testing (for girls of childbearing potential), urine drug screen, and evaluation of TEAEs and 
concomitant therapi[INVESTIGATOR_368945] y. 
The TEAEs of special interest will be examined separately  grouped in the following Medical 
Dictionary  for Regulatory Activities (MedDRA ) based categories: drug abuse, dependence and 
withdrawal (standardized MedDRA queries [MedDRA SMQ]), transient dizziness/vertigo, 
impaired cognition, anxiety, cystitis, and suicidality. The adverse events of special interest will be 
further listed in the statistical anal ysis plan ( SAP).
Given the potential for treatment -emergent transient elevation in systolic and diastolic blood 
pressure, heart rate and blood pressure will be monitored throughout the study  and at multiple time 
points on dosing days. Specific guidance to be followed on intranasal dosing days is provided in 
Section 6.3.
In order to help investigators identify  signs and events suggestiv e of withdrawal, the sponsor has 
included remote (eg, by [CONTACT_756] )contact [ADDRESS_462062] dose of study  drug to assess
adverse events. 
As described further in Section 2.1.1 , the following assessments will be used at the time points 
defined in the Time & Events Schedule to evaluate safet y and tolerability , assess the severit y and 
duration of any sedation, and detect any treatment -emergent worsening of psychiatric symptoms 
or cognition: MOAA/S ,CADSS , BPRS+, YMRS, and Cogstate computerized cognitive battery . 
ThePWC -20 and TLFB will be used to assess for signs and/or symptoms of withdrawal and abuse, 
respectivel y.A nasal examination and nasal symptom questionnaire will monitor for any  signs of 
adverse effects on the nasal mucosa .
Although the SIBAT will be an efficacy  evaluation, it will also be used as a safet y evaluation to 
detect an y worsening of suicidal idea tion and behavior throughout the stud y.
On all outpatient dosing days, all subjects must remain at the clinical site until study  procedures 
have been completed and the subject is ready for discharge per clinician’s assessment. The 
minimum time required forpost dose monitoring is 1.5hours. Subjects should be accompanied 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 79
Status: Approved , Date: [ADDRESS_462063] a car or work with machines 
for 24 hours after receiving stud y drug.
3.2.8. Pharmacokinetic A ssessments
The concentration -time data to be obtained in the present study  will allow for estimation of 
individual PK parameters of esketamine (and noresketamine, if warranted) in adolescent subjects 
using a population modeling approach. The time and days of plasma sampling were chosen to 
gather maximal information about the PK properties of esketamine while minimizing subject 
burden regarding blood sampling.
3.2.9. Biomarker and Pharmacogenomic (DNA and RNA ) Evaluations 
[IP_ADDRESS]. Biomarker
Increasingl y, it is recognized that psychiatric disorders may be associated with altered 
immune/metabolic activation patterns. Blood samples will be collected to explore biomarkers 
related to immune system activity , HPA axis activation, and neurotropic factors (including but not 
limited to growth factors, inflammation, or endocrine markers). Biomarker samples (plasma, and 
serum) will be collected to evaluate the mechanism of action of esketamine or help to explain inter-
individual variability  in clinical outcomes or may help to identify  population subgroups that 
respond differently  to a drug. In addition, biomarker samples may be combined with samples 
collected from other sources to understand the biomarker correlates of suicidal behavior including 
but not limited to high ideation state versus low ideation state versus noideation and to understand 
the MDD disease mechanism.
[IP_ADDRESS]. Pharmacogenomic/ Epi[INVESTIGATOR_18193] (DNA  and RNA )
It is recognized that genetic variation can be an important contributory  factor to inter-individual
differences in drug distribution and response and can also serve as a marker for disease 
susceptibility  and prognosis. Pharmacogenomic research may help to explain inter-individual
variability  in clinical outcomes and may help to identify  population subgroups that respond 
differentl y to a drug. The goal of the phar macogenomic component is to collect DNA and RNA to 
allow the identification of genetic and/or epi[INVESTIGATOR_368946] (PK), pharmacod ynamics (PD), efficacy , safet y, or tolerability  of esketamine
and to identify  genetic factors associated with MDD and suicidalit y in patients with MDD assessed 
to be at imminent risk for suicide.
The DNA, RNA, protein and metabolic biomarker samples may be used to help address emerging 
issues and to enable the development of safer, more effective, and ultimately  individualized 
therapi[INVESTIGATOR_014].
4. SUBJECT POPULA TION
Screening for eligible subjects will be performed within [ADDRESS_462064] administration 
of intranasal study  drug (if possible, screening should occur within [ADDRESS_462065] 
administration of intranasal study  drug).Note: Subjects with acute alcohol intoxication or other 
ingestion should not be screened but can be screened once sober. Requests to rescreen an individual 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 80
Status: Approved , Date: [ADDRESS_462066] satisfy all of the following criteria to be enrolled in the study :
1. Male and female adolescents (12 to <18years of age) 
2. Subject must meet DSM -5 diagnostic criteria for MDD, without psychotic 
features, based upon clinical assessment and confirmed by [CONTACT_369016] 
(MINI -KID).[ADDRESS_462067] current suicidal thinking with intent at the time of 
screening , confirmed by “Yes” response sto both MINI-KID Question B3 
(Think about hurtin g yourself with the possibility that you might die. Or did 
youthink about killing yourself? )  AND Question B10 (Expect to go through 
with a plan to kill yourself ?). 
Note: the response to B3 must refer to the present, whereas the response to 
B10 may reflect the past [ADDRESS_462068] be repeated to 
confirm eligibilit y.
4. In the physician’s opi[INVESTIGATOR_1649], acute psychiatric hospi[INVESTIGATOR_368947]’s imminent risk of suicide.
5. Subject must have a CDRS -R total score of ≥[ADDRESS_462069] agree to be hospi[INVESTIGATOR_368948] a recommended period of 5 day s after randomization (may  be 
shorter or longer if clinically  warranted in the investigator’s opi[INVESTIGATOR_1649]) .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 81
Status: Approved , Date: 22 November [ZIP_CODE]. Criterion modified per Amendment 2:
7.[ADDRESS_462070] agree to take one of the prescribed non-investigational 
antidepressants medications (fluoxetine, escitalopram, sertraline) at least 
during the Double- Blind Treatment phase (Day  25).
8. As part of standard of care treatment, subject must agree to participate in a 
specific psychological intervention (individual cognitive behavioral therapy 
[CBT], interpersonal therapy , family  therap y or psychody namic 
psychothe rapy) at least through the initial 8-week post-treatment follow -up 
period (Day  81).
9. Subject is comfortable with self-administration of intranasal medication and 
able to follow instructions provided.
10. Subject must be medically stable on the basis of physical examination, medical 
history , vital signs, and 12-lead ECG performed at screening. If there are 
abnormalities, the subject may  be included only  if the investigator judges the 
abnormalities to be not clinically  significant. This determination must be 
recorded in the subject's source documents and initialed by  [CONTACT_093] .
Note: Subjects recovering from a recent suicide attempt may be eligible 
provided they  are medically  stable.
11. Subject must be medically  stable on the basis of clinical laboratory  tests 
performed by [CONTACT_313352]. If the results of the serum 
chemistry  panel, hematology , or urinal ysis are outside the normal reference 
ranges, the subject may be included only if the investigator judges the 
abnormalities or deviations from normal to be not clinically  significant . This 
determination must be recorded in the subject's source documents and initialed 
by [CONTACT_093] .
Incidental exclusionary  laboratory  values ("incidental" refers to duplicate 
results from a separate blood sample analyzed at the central laboratory  that 
become available after the subject has satisfied the inclusion and exclusion 
criteria based on the local laboratory  values) will be handled on a case-by-case 
basis to det ermine if the subject should be withdrawn from the stud y.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 82
Status: Approved , Date: [ADDRESS_462071] dose of study  drug, contraception is required. Sexual abstinence 
is strongly  recommended; however heterosexually  active female 
subject smust practice a highl y effective method of contraception 
(failure rate of <1% per year when used consistently  and correctl y).
Examples of highl y effective contraceptives include: implantable 
progestogen-onl y hormone contraception associated with inhibition of 
ovulation; intrauterine device (IUD); intrauterine hormone -releasing 
system (IUS); vasectomized partner; combined (estrogen and 
progestogen- containing) hormonal contr aception associated with 
inhibition of ovulation: oral, intravaginal, and transdermal; 
progestogen-onl y hormone contraception associated with inhibition of 
ovulation: oral and injectable. For each subject, the reliability  of sexual 
abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifesty le of the subject.
During the Double- Blind Treatment phase (from Day [ADDRESS_462072] dose of study  drug) and fora minimum of 1spermatogenesis 
cycle, define d as approximately  90daysafter receiving the last dose of 
study  drug, sexual abstinence is strongl y recommended ; however,
heterosexually  active male subject smust:
-practice a highly  effective method of contraception with his female 
partner from those listed above (see examples of highl y effective 
methods of contraception provided for female subjects).
-use a condom if his partner is pregnant.
-agree not to donate sperm .
Contraceptive use b y males or females should be consistent with local 
regulations regarding the use of contraceptive methods for subject 
participating in clinical studies and should be discussed in detail with 
the subject by  [CONTACT_154976] . 
13. A female subject of childbearing potential must have a negative urine 
pregnancy  test at screening , baseline, and end of double -blind phase.
14. Subject must be willing and able to participate in all study  activities and to 
adhere to the prohibitions and restrictions specified in this protocol
(Section 4.3).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 83
Status: Approved , Date: [ADDRESS_462073]’s parent (s)or legally  acceptable representative (s)[(LAR(s)]
must sign an informed consent form (ICF) indicating that he or she 
understands the purpose of and procedures required for the study  and is 
willing to allow the subject to participate in the study .Assent is also 
required of subjects as described in Section 16.2.3 , Informed 
Consent /Pediatric Assent .
16. Criterion modified per Amendment [ADDRESS_462074] ’s parent (s)or legally  acceptable representative(s) [(LAR(s)]
must sign a separate informed consent form if he or she agrees to have 
the subject provide an optional DNA/RNA  sample for research (where 
local regulations permit). Assent is also required from the subject as 
described in Section 16.2.3 Informed Consent/Pediatric Assent. Refusal 
to give consent/assent for the optional DNA /RNA research sample does 
not exclude a subject from participation in the study .
4.2. Exclusion Criteria
Any potential subject who meets any  of the following criteria will be excluded from participating 
in the study :
1. Subject has a current DSM -5 diagnosis of bipolar (or related disorders), intellectual 
disability , autism spectrum disorder, conduct disorder, anorexia nervosa, oppositional 
defiant disorder, or obsessive compulsive disorder. 
2. Subject currentl y meets DSM -[ADDRESS_462075] meets the DSM -5 severit y criteria for moderate or severe substance or 
alcohol use disorder (except for nicotine or caffeine )within the 6 months before 
screening.
-A history  (lifetime) of ketamine, phency clidine (PCP), lysergic acid 
diethy lamide (LSD), or 3, 4 -methy lenediox y-methamphetamine (MDMA) 
hallucinogen -related use disorder is exclusionary .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 84
Status: Approved , Date: [ADDRESS_462076] has a history  or current signs and/or symptoms of liver or renal 
insufficiency ; has a current diagnosis of clinically  significant cardiac 
(eg,congenital heart disease, cardiomy opathy , ortachyarrh ythmias), vascular, 
pulmonary , gastrointestinal, endocrine (including uncontrolled 
hyperthy roidism), neurologic, hematologic, rheumatologic, or metabolic 
(including severe dehydration/hy povolemia) disease based on investigator 
judgment.
7. Criterion modified per Amendment [ADDRESS_462077] has uncontrolled hypertension (SBP and/or DBP that is greater than or 
equal to the 95thpercentile for sex, age, and height) despi[INVESTIGATOR_154867], exercise or a stable 
dose of an allowed anti- hypertensive treatment at screening; or any  past history  of 
hypertensive crisis. See Attachment 2for pediatric blood pressure tables with 
percentile ranking b y age, sex, and height for determination of hy pertensive status.
Criterion modified per Amendment 3
7.2.On Day -1 (screening) or Day  1 of the double -blind phase prior to randomization, 
a supi[INVESTIGATOR_1662] -supi[INVESTIGATOR_368895]/or DBP ≥ the 95thpercentile for sex, age and 
height is exclusionary (see Attachment 3). Subjects who fall below the 5thor above 
the 95thpercentile for their age, sex, and height should be evaluated using the 
parameters for the 5thor 95thpercentile. Note that subjects whose SBP and/or DBP 
values are≥ the 95thpercentile for sex, age and height may be reevaluated with a 
repeated measure once after [ADDRESS_462078] to assess eligibility .
Subjects with conditions in which blood pressure elevation could pose a serious 
risk (including severe cardiovascular disease, recent cerebral injury , increased 
intracranial pressure / intracranial mass lesion, intracranial bleeding or acute 
stroke, primary developmental or secondary acquired glaucoma or perforating eye 
injury ) are excluded.
8. Criter ion modified per Amendment [ADDRESS_462079] result(s) for phency clidine (PCP), cocaine, 
methamphetamines, or amphetamines/3,4 -methylenedioxy -methamphetamine 
(MDMA) at screening. Subjects known to be using heroin should be excluded 
from the study .
Note: Subjects who have a positive test due to the appropriate use of prescribed 
opi[INVESTIGATOR_858], methadone, benzodiazepi[INVESTIGATOR_1651], barbiturates, or attention -deficit 
hyperactivit y disorder (ADHD) medications may be eligible for study 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 85
Status: Approved , Date: [ADDRESS_462080] of opi[INVESTIGATOR_858], benzodiazepi[INVESTIGATOR_1651], or barbiturates used without a prescription, may 
be considered eligible per clinician judgment and in consultation with the 
sponsor ’s medical monitor .
Subje cts who have a positive test due to cannabinoids may  be eligible provided 
they do not meet DSM -[ADDRESS_462081] a positive testdue to opi[INVESTIGATOR_858], including benzodiazepi[INVESTIGATOR_1651], or 
barbiturates taken in a suicide attempt (eg, overdose) may  be eligible for study  
participation per clinician judgment and in consultation with the sponsor ’s 
medical monitor .
9. Subject has a history of malignancy within 5 years before screening , with the exception 
of amalignancy  that,in the opi[INVESTIGATOR_368949]'s medical monitor, is considered to have minimal risk of recurrence.
10. Subject has anatomical or medical conditions that may impede delivery  or absorption 
of intranasal study  medication.
11. Subject has an abnormal or deviated nasal septum with any  1 or more of the following 
symptoms: blockage of 1 or both nostrils, nasal congestion (especially  1-sided), 
frequent nosebleeds, and frequent sinus infections (and at times has facial pain, 
headaches, and postnasal drip with the sinus infection).
12. Subject has known allergies, hypersensitivity , intolerance or contraindications to 
midazolam, esketamine or ketamine, or their excipi[INVESTIGATOR_840]. 
13. Subject has taken any disallowed therap y(ies) as noted in Section 8, Prestudy and 
Concomitant Therap y and Attachment 1.
14. Subject has received an investigational drug (including esketamine, ketamine, or 
investigational vaccines) or used an invasive investigational medical device within 
60days before the first dose of study  drug or is currentl y enrolled in an investigational 
study .
15. Subject is a female who is pregnant, breast feeding , or planning to become pregnant 
while enrolled in this study or within [ADDRESS_462082] (eg, compromise the well -
being) or that could prevent, limit, or confound the protocol- specified assessments .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 86
Status: Approved , Date: [ADDRESS_462083] oyees or the 
investigator .
NOTE: Investigators should ensure that all study enrollment criteria have been met at screening. 
If a subject's clinical status changes (including any available laboratory  results or receipt of 
additional medical records) after screening but before the first dose of study  drug is given such 
that he or shenolonger meet sall eligibility  criteri a, then the subject should be excluded from 
participation in the study . Section 17.4, Source Documentation, describes the required 
documentation to support meeting the enrollment criteria.
4.3. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and restrictions 
during the course of the study  to be eligible for participation:
1. Refer to Section 4.1, Inclusion Criteria for information regarding contraception/birth 
control requirements and sperm donation restrictions.  
2. On all outpatient intranasal dosing days, all subjects must remain at the clinical site until 
study  procedures have been completed and the subjec t is ready for discharge per 
clinician’s assessment. Subjects should be accompanied by a responsible adult when 
released from the clinical study  site. Subjects must not drive a car or work with 
machines for 24 hours after study  drug dosing.
3. Refer to Section 8, Prestudy  and Concomitant Therap y,andAttachment 1(Prohibited 
Therapi[INVESTIGATOR_014]) for details regarding prohibited and restricted therapy  during the study .
4. Subjects may not receive electroconvulsive therapy  (ECT ), trans -cranial magnetic 
stimulation (TMS), ketamine or other antidepressant therapi[INVESTIGATOR_014] (aside from those 
allowed) during the study .
5. Agree to follow all requirements that must be met during the study  as noted in the 
Inclusion and Exclusion Criteria .
5. TREA TMENT ALLOCA TION AND BLINDING
Treatment Allocation and Randomization
Central randomization will be implemented in this study . Subjects will be randomly assigned to 1 
of 4treatment groups ,in a 1:1:1:2 ratio, based on a computer -generated randomization schedule 
prepared before the study  by [CONTACT_43754]. The randomization will be 
balanced by [CONTACT_369017]. The interactive 
web response system (IWRS) will assign a unique treatment code, which will dictat e the treatment 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 87
Status: Approved , Date: [ADDRESS_462084].
Blinding
Because the routes of administration differ between the active study  drug and the psychoactive 
placebo, t o maintain the study  blind, 2 matching placebo formulations (intranasal and oral) will be
used. A designated pharmacist (or other qualified healthcare professional) , who has no 
involvement otherwise with either the stud y conduct or data collection, will be unblinded in order 
to prepare the oral study  drug. Further details can be found in the investigational product 
preparation instructions, as part of the pharmacy  manual. When possible, it is requested that 
different raters perform safet y and efficacy ratings.
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality  to allow the investigator to break the blind for an 
individual subject.
Data that may potentiall y unblind the treatment assignment (ie, study  drug plasma concentrations, 
treatment allocation) will be handled with special care to ensure that the integrit y of the blind is 
maintained and the potential for bias is minimized. This can include making special provisions, 
such as segregating the data in question from view by  [CONTACT_473], clinical team, or others as 
appropriate until the time of database lock and unblinding .
Under norm al circumstances, the blind should not be broken until all subjects have completed the 
study  and the database is finalized. Otherwise, the blind should be broken only if specific 
emergency  treatment/course of action would be dictated by [CONTACT_369018]. In such cases, the investigator may, in an emergency , determine the identity  of the 
treatment by  [CONTACT_154946] I WRS. It is recommended that the investigator contact [CONTACT_3160] ,if possible ,to discuss the particular situation, before breaking the blind. Telephone 
contact [CONTACT_97500] [ADDRESS_462085] be documented in the appropriate section of the electronic case 
report form (eCRF), and in the source document. The documentation received from the IWRS 
indicating the code break must be retained with the subject's source documents in a secure manner.
Subjects who have had their treatment assignment unblinded should continue to return for
scheduled early termination and follow -up contacts and visits.
In general, randomization codes will be disclosed fully  onlyif the study is completed and the 
clinical database is closed. However, an analysis is planned after the last subject completes the 
Day 25visit. Randomization codes will be disclosed to the sponsor in order to plan for Phase [ADDRESS_462086] 
completes the Day  200 visit.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 88
Status: Approved , Date: 22 November 2020To maintain the blinding of intranasal study  medication, the esketamine and placebo intranasal 
devices will be indistinguishable. Please refer to Section 14(Study  Drug Information) for 
information on the p hysical characteristics of the study  drugs and devices.
To maintain the blinding of oral study  medication, the midazolam and placebo solution swill be 
indistinguishable. Additionally , the final dose of midazolam or equivalent oral placebo volume 
will be pr epared b y a designated pharmacist (or other qualified healthcare professional) .
To maintain the integrity of the study  blind, a urine drug screen (UDS) should not be performed 
during the DB period unless medically  necessary . Ifdeemed medicall y necessary , the medical 
monitor should be contact[CONTACT_369002].
6. DOSA GE A ND A DMINISTR ATION
All subjects will be treated in the context of comprehensive standard clinical care, including the 
initiation or optimization of antidepressant treatment with one of 3 antidepressants allowed per 
protocol during double -blind treatment: fluoxetine, escitalo pram, and sertraline. Treatment with a 
psychological intervention is also required, at least through the initial 8-week Post-Treatment 
Follow -Up phase (Day  81). The specific antidepressant and type of psychological intervention 
selected for a given subject will be based on the treating physician(s) clinical judgment, knowledge 
of the subject’s prior treatment history , and practice guidelines. Acceptable types of psychological 
interventions include individual cognitive behavioral therap y (CBT) , interpersonal therap y, family 
therap y,and psychody nami c psychotherapy . Other evidence- based psychotherapi[INVESTIGATOR_368950].  The frequency  of psychotherap y visits should 
be determined based on clinical need ,at the discretio n of the treatment team . Unless clinical 
judgment dictates otherwise, it is recommended that subjects who have not previously  been treated 
with an antidepressant receive standard of care antidepressant treatment with fluoxetine, as this is 
the only antidep ressant approved in both the US and EU. Antidepressant medication should be 
initiated or optimized on Day 1.However ,initiating standard of care antidepressant medication up 
to [ADDRESS_462087] dose of study  medication (Day 1), is permitted if starting two medications 
simultaneously  is not consistent with local clinical practice.
All study  medication will be self-administered under the direct supervision of the investigator or 
designee. Instructions for use of the intranasal spray  device will beprovided as a separate
document. On Day 1of the Double- Blind Treatment phase , subjects will be randomized in a 
1:1:1:2 ratio to treatment with one of 3 doses of intranasal esketamine (28, 56, or 84 mg) or oral 
psychoactive placebo (midazolam 0.125 mg/kg ), administered 2times per week for [ADDRESS_462088] receiving 1dose of oral study drug 
followed closel y by i ntranasal study  drug (3 devices) as described below (Table 1) for each dosing 
event. Thus, subjects randomized to intranasal esketamine will also receive an oral placebo, and 
subjects randomized to oral midazolam will also be administered an intranasal placebo (3 devices).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 89
Status: Approved , Date: 22 November 2020See Section 9.1.3 for further details on dosing procedures during the Double -Blind Treatment 
phase .
6.1. Oral Study  Drug
Oral mida zolam solution (2mg/ml) will be provided as a psychoactive placebo at a dose of 
0.125 mg/kg to all subjects randomized to intranasal placebo. A designated pharmacist (or other 
qualified healthcare professional) will be unblinded in order to prepare the oral study  drug. 
Subjects randomized to oral psychoactive placebo (midazolam) will receive a weight -based dose 
using a 2 mg/m Lsolution; those randomized to intranasal esketamine will receive an oral placebo 
solution in an equivalent volume to that which they would receive if randomized to the 
psychoactive placebo .
6.2. Intranasal Study  Drug
All intranasal doses of study  medication will be self -administered under the direct supervision of 
the investigator or designee. Instructions for use of the device will be provided as a separate 
document (see Section 15, Study -specific Materials). Details regarding study  drug administration 
will be recorded in the source documents and the eCRF. On all study  medication dosing days, a 
site staff member with basic life support training that is up to date per local regulatio ns must be 
present with the subject during the dosing of study  medication and the postdose observation period. 
In addition, a hand -held bag valve mask (Ambu bag) for manual ventilation support must be 
available. 
Prior to the first intranasal dose on Day 1, subjects will practice spraying (into the air, not 
intranasall y) a demonstration intranasal device that is filled with placebo solution. For each 
intranasal esketamine or placebo dose, subjects will self -administer 1 spray into each nostril (ie, a 
total of 2 spray s using 1 intranasal device) at each of the following 3 time points: t = 0, 5 minutes 
and 10 minutes; time = [ADDRESS_462089] 100-μl spray . Spray s to each nostril 
should be delivered in rapid succession at each of the 3 scheduled time points. Table 1describes 
how esketamine or placebo will be administered in the Double -Blind Trea tment phase . A total of 
3 devices will be used b y all subjects to administer 3 doses of esketamine or placebo.
A phy sical description of the study  drugs is provided in Section 14.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 90
Status: Approved , Date: 22 November 2020Table 1: Dose administration of Intranasal Esketamine 28, [ADDRESS_462090] 
intranasal device. 
bone device will be used at each time point. Each individual intranasal device contains 2 sprays. The intranasal 
devices containing esketamine deliver 14 mg per spray, for a total of 28 mg per individual device (ie, 2 
sprays).
6.3. Guidance on Blood Pressure Monitoring on Study  Medication Dosing Day s
Elevated blood pressure in children is defined as SBP and/or DBP ≥ the 95thpercentile for sex, age 
and height. Attachment 2(Growth Charts: Stature -for-Age Percentiles for Use in Blood Pressure 
Assessments ) and Attachment 3(95thPercentile Blood Pressure Levels For Sex by [CONTACT_368977]) will be used to determine the 95thpercentile for both the systolic (SBP) and diastolic blood 
press ures (DBP) b y sex, age and height percentile (refer to Attachment 3for instructions).
If the predose SBP and/or DBP is elevated on any dosing day, blood pressure measurement should 
be repeated after the subject rests for at least 5 minutes in a supi[INVESTIGATOR_1662] -supi[INVESTIGATOR_368951]. If SBP and/or DBP remain ≥ the 95thpercentile for sex, age and height 
(Attachment 3), dosing should be postponed and rescheduled on the following day or within the 
given visit window. If blood pressure elevation persists at the next visit, the subject should be 
scheduled fora consultation by [CONTACT_154908], other specialist, or primary  care physician prior to 
further dosing. Any elevation in blood pressure after dosing is expected to be transient. If an 
elevat ion is observed, continue monitoring until blood pressure returns to normal .
On any dosing day , if either the postdose SBP or DBP levels are equal to or greater than the sex, 
age and height values in Attachment 4(Postdose Blood Pressure: Withdrawal Criteria Levels for 
Sex by [CONTACT_46855] ), the blood pressure should be repeated after the subject rests forat least 
5minutes (ie, sitting or supi[INVESTIGATOR_050]). If the values are stillequal to or greater than the sex, age and 
height values in Attachment 4, the subject should be withdrawn from the study  and appropriate 
follow -up clinical care should be initiated.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 91
Status: Approved , Date: [ADDRESS_462091] dose of stud y drug through the final visit. 
All therapi[INVESTIGATOR_014] (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements; non-pharmacologic therapi[INVESTIGATOR_23719], acupuncture, special 
diets, exercise regimens) different from the study  drug must be recorded in the eCRF . Modification 
of an effective pre-existing therapy  should not be made for the explicit purpose of entering a 
subject into the study .
A list of concomitant therapi[INVESTIGATOR_368904], permitted, and permitted with restrictions is 
provided in Attachment 1for general guidance for the investigator; however, this list is not all-
inclusive. Please contact [CONTACT_369019][INVESTIGATOR_53301] a subject.
Subjects may not receive electroconvulsive therapy  (ECT), TMS, ketamine orother antidepressant 
therapi[INVESTIGATOR_014] (aside from those allowed) during the study .The sponsor must be notified in advance (or 
as soon as possible thereafter) of an y instances in which prohibited therapi[INVESTIGATOR_23730].
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule summarizes the frequency  and timing of efficacy , PK, biomarker, 
pharmacogenomic (DNA and RNA) , and safet y measurements applicable to this study .
If multiple assessments are scheduled for the same time point, it is recomme nded that procedures 
be performed in the sequence provided by [CONTACT_456] (see Section 9.1.3 ). Actual dates and times 
of assessments will be recorde d in the source documentation and eCRF.
Additional serum or urine pregnancy  tests may be performed, as determined necessary  by [CONTACT_41011], to establish the absence of pregnancy  at any time 
during the subject's particip ation in the study .
Additional drug or alcohol tests may be performed as determined necessary  by [CONTACT_369020] b y local regulation.
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 93
Status: Approved , Date: [ADDRESS_462092] 
completed/discontinued study  drug.
If a subject dies, the date and cause of death will be collected and documented on the eCRF.
9.1.2. Screening Phase
Prior to conducting any study  procedure, the investigator (or designated study  personnel) will 
review and explain the written pediatric assent to each potential subject ,and the ICF to the
subject ’sparent (s) ortheir legally  acceptable representative (s)/[LAR(s)] . Potential subjects are 
aged 12 to <18 yearswith MDD presenting to an ER, psychiatric unitor other permitted setting 
and assessed to be at imminent risk for suicide (See Section 16.2.3). 
After the ICFis signed by [CONTACT_423]’s LAR , and the subject’s assent is obtained , potential subjects 
will be screened under close supervision within 48hours of intranasal dosing on Day [ADDRESS_462093] a CDRS -R 
total score of ≥58 predose on Day 1, and in the physician’s opi[INVESTIGATOR_1649], acute psychiatric 
hospi[INVESTIGATOR_313288]’s imminent risk of suicide. Refer to 
Section 4(Subject Population) for all inclusion and exclusion criteria that will be used to determine 
subject eligibility . Eligible subjects may or may not be receiving antidepressants at the time of 
study  entry .
Refer to the Time and Events Schedule for a complete list of study  procedures that will be 
performed at screening.
The clinician -administered assessments at screening can be performed in the order preferred by 
[CONTACT_977]. However, if the screening phase is longer than 24 hours, Question B3 and B10 
from MINI -KID (current status) must be repeated to confirm eligibility .
All adverse events and special reporting situations, whether serious or non-serious, will be reported 
from the time a signed and dated ICF is obtained until completion of the subject's last study -related 
procedure (which may  include contact [CONTACT_20687] -up of safet y).
9.1.3. Double -Blind Treatment Phase
Following completion of all required screening procedures and confirmation of subject eligibility, 
subjects will enter the Double -Blind Treatment phase .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 94
Status: Approved , Date: 22 November 2020On Day 1 of the Double- Blind Treatment phase , approximately  145 subjects will be randoml y 
assigned in a 1:1:1:2 ratio to 1 of 3 doses of intranasal esketamine (28, 56 or 84 mg) or a 
psychoactive placebo (oral midazolam 0.125 mg/kg), with approximately  29 subjects assigned to 
each dose of intranasal esketamine and approximately  58 subje cts assigned to psychoactive 
placebo. Study  drug will be administered two times per week for 4 weeks (Day s 1, 4, 8, 11, 15, 
18, 22, and 25). Study  medication dosing should not take place on consecutive day s.
All subjects will be treated in the context of comprehensive standard clinical care, including 
hospi[INVESTIGATOR_368952] 
3antidepressants allowed per protocol during double -blind treatment: fluoxetine, escitalopram, 
and sertraline . Treatm ent with a psychological intervention isalso required ,at least through the 
initial 8-week post-treatment phase (Day  81). The specific antidepressant and type of 
psychological intervention selected for a given subject will be based on the treating physician(s) 
clinical judgment, knowledge of the subject’s prior treatment history ,and practice guidelines. 
Acceptable types of psychological interventions include individual CBT, interpersonal therapy , 
family  therap y, and psychody nami c psychotherapy . Other evidence-based psychotherapi[INVESTIGATOR_368953]. The frequency  of psychotherap y visits 
should be determined based on clinical need ,at the discretion of the treatment team. Unless clinical 
judgment dictates otherwise, it is recommended that subjects who have not previously  been treated 
with an antidepressant receive standard of care antidepressant treatment with fluoxetine, as this is 
the only antidepressant approved in both the US and EU. Antidepressant medication should be 
initiated or optimized on Day 1.However ,initiating standard of care antidepressant medication up 
to [ADDRESS_462094] dose of study  medication (Day 1), is permitted if starting two medications 
simultaneously  is not consistent with local clinic al practice. 
Dose titration/adjustments of newl y initiated or optimized standard of care antidepressant 
treatment should occur during the first 2 weeks of double -blind treatment (ie, by [CONTACT_2006] 15), with 
doses remaining stable thereafter through the end of the double -blind phase (Day  25). Subjects 
who are currentl y taking a recently  initiated antidepressant treatment (initiated <2 weeks prior) 
may continue taking the antidepressant at the current dose through the end of the double -blind 
phase (Day  25), if deem ed clinicall y appropriate by [CONTACT_1963]. During the Double-
Blind Treatment phase , the investigator should consult with the sponsor’s medical monitor in
advance if additional changes on antidepressant treatment are clinicall y indicated. Any chan ges to 
the standard of care antidepressant treatment, that is different from what was planned at the time 
of randomization, should be clearly documented including the reason for the change.
The first dose of study  medication will be administered in the ER,inpatient psychiatric unit or 
other permitted setting that has appropriate staffing to manage acutel y suicidal subjects and 
perform postdose study -related procedures . If the first dose is administered in the ER, it is 
recommended that the subject not be transferred from the ERto the inpatient psychiatric unit or 
other permitted setting until after the postdose assessments (approximately  4 hours in length) are 
completed. Subjects who have been admitted directly  into the inpatient psychiatric unit or other
permitted setting due to imminent risk for suicide or transferred from a medical unit (following 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 95
Status: Approved , Date: 22 November 2020medical stabilization for recent suicide attempt) will receive their first dose of study medication in 
the inpatient psy chiatric unit or other permitted setting. 
Subjects will remain in the inpatient ps ychiatr y unit or other permitted setting for a recommended 
duration of 5 days(4 nights) from randomization, with shorter or longer hospi[INVESTIGATOR_368954]. The decision to discharge a subject from the 
hospi[INVESTIGATOR_368955]’s judgment that the subject is no longer imminently 
suicidal and meets standard discharge criteria per local practice . Discharge before [ADDRESS_462095] be 
discussed and approved by [CONTACT_456]’s medical monitor. The investigator must discuss the need 
for continued hospi[INVESTIGATOR_313289] 10 day s and thereafter on a weekly  basis with the sponsor’s 
medical monitor. Following discharge from the inpatient psychiatric unit or other permitted 
setting , subsequent visits for the Double- Blind Treatment phase will be conducted twice -weekl y 
at an outpatient psy chiatric facility  through Day  25. 
On all outpatient dosing days, subjects must remain at the clinical site until study  proce dures have 
been completed and the subject is ready for discharge, per the clinician’s assessment. The 
minimum time required for postdose monitoring is 1.[ADDRESS_462096] intranasal dose on Day 1, subjects will practice spraying (into the air, not 
intranasall y) a demonstration intranasal device that is filled with placebo solution. All subjects will 
self-administer the study medication under the direct supervision of the investigator or designee 
(Refer to Section 6, Dosage and Administration).
The 4-hour assessments at the Day 1 visit should be performed within ±30 minutes of the 4 -hour 
postdose time point. The 24 -hour assessments at the Day  2 visit should be performed ±[ADDRESS_462097] dose on Day 1, whole blood samples (up to [ADDRESS_462098]) 
will be collected from a peripheral vein using an indwelling intravenous catheter at the time point s 
specified in the TIME AND EVENTS SCHEDULE – Double- Blind Treatment Phase .The 
concentrations of esketamine and noresketamine in plasma will be measured using a validated 
bioanaly tical method under the super vision of the sponsor ’s bioanal ytical laboratory .
Efficacy , safet y, pharmacokinetic, biomarker, and pharmacogenomics (DNA and RNA) 
evaluations will be performed as described in the TIME AND EVENTS SCHEDULE –Double -
Blind Treatment Phase . When multiple patient -reported outcomes and clinician -administered 
assessments are scheduled for the predose time point ,it is recommended they be performed in the 
following sequence :
SIBAT
Patient Portion
Clinician Portion
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 96
Status: Approved , Date: 22 November 2020MADRS and CDRS -R 
CDI 2-SR(S)
Subjects and site staff will complete the clinician -administered assessments and patient -reported 
outcomes using an electronic tablet device provided for this study  or using a paper version if 
electronic entry  is not functioning (refer to Section 15, Study -Specific Materials).
MADRS and CDRS -R will be performed at both predose and 4-hour postdose assessments on 
Day 25 (visit 10) of the Double- Blind T reatment phase .
9.1.4. Post -Treatment Follow -up Phases
Upon completion of the double -blind phase, subjects will enter a Post-Treatment Follow -Up phase . 
Visits will continue to occur twice a week for the first 2 weeks (Day s 28, 32, 35, 39), after which 
visits will occur weekl y (Days 46 and 53) , then every  2 weeks (Da ys 67 and 81). The Day  [ADDRESS_462099]-
Treatment Follow -Up phase (Day s 81-200), during which they will have monthl y visits to assess 
safety. Investigators may  add follow -up visits as dictated by  [CONTACT_423]’s clinical condition and the 
investigator’s clinical judgment. Evaluations will be performed as described in the TIME AND 
EVENTS SCHEDULE –Post-Treatment Follow -Up Phase .
9.1.5. Early  Withdrawal
Subjects who discontinue D ouble -Blind Study treatment for reasons other than withdrawal of 
consent /assent , lost to follow -up or death will have the DB EW visit conducted at the time of 
discontinuation. I n addition, if the DB EW visit occurs on Day [ADDRESS_462100] visit 
(eg, by [CONTACT_756]) will be conducted 5 day s (+/-2 day s) after the last dose of study  medication. If 
remote contact D+5 occurs within 2 day s of the early  withdrawal visit, +[ADDRESS_462101] D+[ADDRESS_462102] visit will also be conducted on Day 
25 to assess PWC -20, CDRS -R and MADRS, and for collection of concomitant therapi[INVESTIGATOR_368897]. 
If the DB EW visit occurs on or after Day 22 (assuming dose administered), D25 RC visit is not 
required, however, RC D+5 ([ADDRESS_462103] dose) should be performed.
Subjects who discontinue from the Post-Treatment Follow -Up phase for reasons other than 
withdrawal of consent /assent , lost to follow -up or death will have the Post-Treatment Early 
Withdrawal visit conducted at the time of discontinuation. In addition, if the PT EW visit occurs 
prior to completion of the Day  [ADDRESS_462104] (eg, by [CONTACT_756]) will be performed on 
Day 81 for PWC -20, CDRS -RandMADRS ,and for collection of concomitant therapi[INVESTIGATOR_368897] .
If the PT EWvisit occurs within ±5 day s window of Day  81 (Visit 18), then earl y withdrawal visit 
will be adequate, and the Day 81RCvisit is not required. If subjects discontinue an ytime between 
Day 25 postdose and Day 28 RC of the PT phase, the PT EW visit is notrequired; however, Day [ADDRESS_462105] is appropriately  transitioned and/or followed for any 
additional care required when a subject discontinues participation in the study  for any  reason.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 97
Status: Approved , Date: [ADDRESS_462106] by 
[CONTACT_8786], concomitant therapi[INVESTIGATOR_368956], and CDRS -R 
and MADRS assessment swill be performed b y appropriatel y qualified staff. 
9.2. Efficacy Evaluations
9.2.1. Children’s Depression Rating Scale, Revised (CDRS- R)
The primary  outcome measure in this study  will be the CDRS -R, a validated 17-item, clinician-
rated instrument developed to assess depressive symptomatology  in children that measures the 
severit y of a patient’s depressive symptoms. The scale has demonstrated good reliability  and 
validity  in adolescents with depression.69
The typi[INVESTIGATOR_368911] -R is 7 days. In this study , the CDRS -R will be administered 
using 4 recall periods: a 7-day recall on Day 1(predose) ; a 4-hour recall at the 4-hour postdose 
assessment on Day s1 and 25; a 24-hour recall at the postdose assessment on Day  2;and a “since 
last assessment” recall predose on Day 4 through Day 25 dosing days. “Since last assessment” 
recall will also be used in Post-Treatment Follow -up assessments on Days 28, 32, [ADDRESS_462107] to calculate the total score. 
9.2.2. Suicide Ideation and Behavior Assessment Tool (SIBA T)
The SIBAT has two major divisions: a patient -rated section and a clinician -rated section. The 
patient -rated section has modules of demographics and suicide history , risk/protective factors, 
suicidal thinking, suicide behavior, and suicide risk. The information generated in this section will
be summarized and used to support the clinical decision- making of the second section. The 
clinician -rated section has modules for a semi -structured interview, clinical global impressions of 
current severity  of suicidality  and imminent suicide risk, clinic al global impression of long-term 
suicide risk, and clinical judgment of optimal suicide management. 
The SIBAT will be provided in an electronic format for use by  [CONTACT_369021] . Refer to the SIBAT Time and Events Schedule fo r an outline of which modules will be 
performed at each scheduled time point. 
One module of the SIBAT includes a revised version of the Clinical Global Impression –Severity 
of Suicidality . The CGI-SS-R rating is scored on a 7-point scale from 0 (normal, not at all suicidal) 
to 6 ( among the most extremel y suicidal patients) and will be based on the totality  of information 
available to the clinician, including information from the SIBAT. The CGI -SS-R summarizes the 
clinician’s overall impression of severity of suicidality  and will be used to assess the reduction of 
suicidal ideation endpoint in this study  (see Section 2.1.2 ). This rating operates likenumerous 
other CGI -severit y scales that have been used in other psychiatric studies. These instruments have 
shown clinical validity  and sensitivity  to change. Also included in this module is the CGI-SR-I, 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 98
Status: Approved , Date: 22 November 2020which summarizes the clinician’s best assessment of the likelihood that a patient will attempt 
suicide in the next [ADDRESS_462108] consists of 
10items, each of which is scored from 0 (item not present or normal) to 6 (severe or continuous 
presence of the s ymptoms), for a total possible score of 60. Higher scores represent a more severe 
conditio n. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, 
appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts. The 
test exhibits high inter -rater reliability . 
The typi[INVESTIGATOR_368957] 7 days. In this study , the MADRS will be administered 
using 4 recall periods :a 7-day recall on Day 1(predose) ; a 4-hour recall at the 4-hour postdose 
assessment on Day s 1 and 25; a 24-hour recall at the postdose assessment on Day 2; and a “since 
last assessment” recall predose on Day 4 through Day 25 dosing days. “Since last assessment” 
recall will also be used in Post-Treatment Follow -up assessments on Days 28, 32, 35, and 39. A 
7-day recall will be used for Post-Treatment Follow -up assessments on Days 46-200. The sleep 
item score is not assessed at the 4-hour postdose time point on Day [ADDRESS_462109] to calculate the 
total score .
Whenever possi ble, all efforts should be made to use the same raters for the MADRS at each site 
to assess the same subjects throughout the study . If this is not possible, review of the appropriate 
prior assessments and communication with prior raters should be conducted as needed.
9.2.4. Children’s Depression Inventor y 2: Self -Report (Short) 
The CDI 2:SR(S) assessment is based on the Children’s Depression Inventory  2 (CDI 2) and 
Children’s Depression I nventory  2 Self -Report (CDI 2:SR). 
The CDI 2:SR is a 12-item self-reported assessment that yields a total score, 2 scale scores 
(emotional problems and functional problems), and 4 subscale scores (negative mood, negative 
self-esteem, ineffectiveness, interpersonal problems). 
The CDI 2 SR(S ), which will be used in this study , is a shortened version of the CDI 2:SR and is 
an efficient screening measure that contains 12 items and takes about half the time of the full-
length version to administer (5–10 minutes). The CDI 2:SR(S) has excellent psychometric 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 99
Status: Approved , Date: 22 November 2020properties and yields a total score that is generally  very comparable to the one produced by [CONTACT_369022]-length version.1
9.3. Pharmacokinetics
Whole blood samples will be used to evaluate the PK of esketamine (and noresketamine, if 
warranted) .Plasma collected for PK may additionally  be used to evaluate safety  or efficacy  aspects 
that address concerns arising during or after the study  period. Genetic analyses will not be 
performed on these plasma samples. Subject confidentiality  will be maintai ned.
9.3.1. Evaluations
Venous blood samples of approximately  2mL will be collected for measurement of plasma 
concentrations of esketamine , noresketamine, and other metabolites (if warranted) at the time 
points specified in the Time and Events Schedule. The exact dates and times ofpharmacokinetic 
blood sampling must be recorded.
Samples collected for analy ses of esketamine plasma concentration may additionally  be used to 
evaluate safety or efficacy aspects that address concerns arising during or after the st udy period or
for the evaluation of additional relevant biomarkers . Genetic analy ses will not be performed on 
these plasma samples. Subject confidentialit y will be maintained. Additional information about 
the collection, handling, and shipment of biologica l samples can be found in the Laboratory 
Manual.
9.3.2. Analytical Procedures
Pharmacokinetics
Plasma samples will be analyzed to determine concentrations of esketamine and noresketamine 
using a validated, specific, and sensitive achiral liquid chromatograph y/mass spectrometry /mass 
spectrometry  (LC-MS/MS) method by  [CONTACT_43754]. 
If required, some plasma samples may be analy zed to document the presence of circulating 
esketamine metabolites or midazolam using a qualified research method. In addition, plasma PK 
samples may  be stored for future anal ysis of the metabolite profile.
The bioanaly tical report, including a description of the assay  and a summary  of the assay  
performance data, will be included in the final study report as an addendu m.
9.3.3. Pharmacokinetic Parameters
The plasma concentration -time data of esketamine (and noresketamine, if warranted) will be 
analyzed using population PK modeling. 
Based on the individual plasma concentration -time data, using the actual dose taken and the act ual 
sampling times, PK parameters and exposure information of esketamine will be derived using 
population PK modelling. Baseline covariates (eg, body  weight, age, sex, CrCL , race) may be 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 100
Status: Approved , Date: 22 November 2020included in the model, if relevant. The results of population PK analyses may be reported 
separately . 
9.4. Pharma cokinetic/Pharmacody namic Evaluations
The relationship between CDRS -R total score (and possibly  other efficacy  endpoints such as 
MADRS and selected adverse events and additional pharmacod ynamic parameters), and PK 
metrics of esketamine may be evaluated. The results of such analyses may be reported separately.
9.5. Biomarker and Pharmacogenomic (DNA and RNA ) Evaluations
Biomarker Evaluations
Blood samples will be collected as indicated in the Time and Events Schedule for exploratory 
analysis of biomarkers (protein andmetabolites) related to immune system activity , HPA axis 
activation, neurotrophic and metabolic factors. Exploratory  analyses may be performed for 
additional biomarkers as well. Results may  be presented in a separate biomarkers report.
If possible, b lood samples should be collected under fasting conditions (minimum 8 hours prior to 
biomarker sample collection, water is permitted). When fasting is not feasible, subjects should 
follow a low fat dietfor at least 8 hours prior to sample collection , if possible. Subjects should 
refrain from exercise/strenuous physical activity  and the use of non-steroidal anti-inflammatory 
drugs(NSAIDs) for 24 hours prior to b lood collection. Not following these recommendations wi ll 
not constitute a protocol violation.
Biomarkers may be added or deleted based on scientific information or technical innovations under 
the condition that the total volume of blood collected will not be increased. 
All biomarker data obtained during this study  may  be included in ongoing cross- study  analy ses to 
investigate the relationship between depression severity and phenot ypes and biomarkers.
Per the Time and Events Schedule, information on menstrual cycle (date of first day of last period, 
average le ngth of cy cle) will be recorded at each visit when blood samples for biomarker anal ysis 
are collected.
Pharmacogenomic s, Epi[INVESTIGATOR_7009], and Gene Transcription Evaluations
Subject participation in pharmacogenomics/epi[INVESTIGATOR_18193] /gene transcription evaluations is optional. 
Whole blood sample sfor DNA and RNA analy ses will be collected from all subjects who provide 
consent /assent for pharmacogenomic research at the time points indicated in the Time and Events 
Schedule.
DNA and RNA samples will be anal yzed for the assessment of genetic variation and transcription 
ofgenes in pathways relevant to MDD and suicidality . Additional anal yses may  be conducted if it 
is hy pothesized that this may  help resolve issues with the clinical data. 
DNA and RNA samples will be used for research related to esketamine or MDD. They  may also 
be used to develop tests/assay s related to esketamine and MDD. Pharmacogenomic research may  
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 101
Status: Approved , Date: [ADDRESS_462110] of the analysis of one or more candidate genes or of the analysis of genetic markers 
throughout the genome (as appropriate) in relation to esketamine or MDD clinical endpoints.
All genetic data obtained during this study  may be included in ongoing cross- study  analyses to 
investigate the relationship between depressi on severity  and phenot ypes and biomarkers.
9.6. Safety  Evaluations
Details regarding the IDMC are provided in Section 11.7.
Any clinicall y relevant chan ges occurring during the study  must be recorded on the Adverse Event 
section of the eCRF.
Any clinically  significant abnormalities persisting at the end of the stud y/early  withdrawal will be 
followed b y the investigator until resolution or until a clinical ly stable endpoint is reached. 
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in the Time and Events Schedule:
Adverse Events
AEswill be reported by [CONTACT_423] (or, when appropriate, by a caregiver, surrogate, or the subject's 
LAR ) for the duration of the study . Adverse e ventswill be followed by [CONTACT_369023] 12, Adverse Event Reporting.
The TEAEs of special interest will be examined separatel y (refer to Section 3.2.7 and Section 11.6
for further details).
Clinical Laboratory Tests
Blood samples forserum chemistry  and hematology  and a urine sample for urinal ysis will be 
collected. The investigator must review the laboratory  results, document this review, and record 
any clinicall y relevant changes occurring during the study  in the adverse event section of the eCRF. 
The laboratory  reports must be filed with the source documents. 
A local laboratory  will be used at screening to ensure results are available in enough time to 
determine subject eligibility . If standard of care clinical laborator y tests areperformed within 
72hours prior to the screening visit (ie, signing of the ICF), results for those laboratory  tests 
required per protocol at screening can be used for determination of subject eligibility . A local 
laboratory  can also be used in any  instance where safet y follow -up is time -critical and the central 
laboratory  results are not expected to be available before actions need to be taken for safet y 
reasons.
At Day  -1 (screening), following ICF process , central laboratory  samples must also be c ollected.
A central laboratory  will be used at screening and during the stud y.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 102
Status: Approved , Date: 22 November 2020The following tests will be performed:
Hematology  Panel
-hemoglobin -platelet count
-hematocrit
-red blood cell (RBC) count
-white blood cell (WBC) count with differential
Serum Chemistry  Panel
-sodium -alkaline phosphatase
-potassium -creatine phosphokinase (CPK)
-chloride -lactic acid deh ydrogenase (LDH)
-bicarbonate -uric acid
-blood urea nitrogen (BUN) -calcium
-creatinine -phosphate
-glucose -albumin
-aspartate aminotransferase (AST) -total protein
-alanine aminotransferase (ALT)
-gamma -glutam yltransferase (GGT)
-total bilirubin
Urinaly sis 
Dipstick performed at central laboratory
-specific gravit ySediment (if central laboratory dipstick result 
is abnormal)
-pH
-glucose -red blood cells
-protein -white blood cells
-blood -epi[INVESTIGATOR_1663]
-ketones -crystals
-bilirubin -casts
-urobilinogen -bacteria
-nitrite
-leukocy te esterase
If dipstick result is abnormal, flow cytometry  will be used to measure sediment. I n case of 
discordance between the dipstick results and the flow cy tometric results, the sediment will 
be examined microscopi[INVESTIGATOR_897] .
Specific gravity , pH, glucose, protein, blood, ketones, bilirubin, and urobilinogen will be 
determined using a dipstick. Red blood cells, white blood cells, epi[INVESTIGATOR_1663], crystals, casts, and 
bacteria will be measured using flow cytometry . If there is discordance between the dipstick results 
and the flow cy tometric result s, the sediment will be examined microscopi[INVESTIGATOR_897] .
The following additional clinical laboratory assessments will be performed at the study  site:
Urine Pregnancy  Testing (for female subjects of childbearing potential only)
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 103
Status: Approved , Date: 22 November 2020Urine drug test will screen for amphetamine, barbiturates, benzodiazepi[INVESTIGATOR_1651], cocaine, 
marijuana (THC), methadone, methamphetamine, methy lenedioxymethamphetamine 
(MDMA), opi[INVESTIGATOR_858], phency clidine, and tricyclicantidepressants. To maintain the integrit y of 
the study  blind, a urine drug screen (UDS) should not be performed during the DB period 
unless medically  necessary . If deemed medically  necessary , the medical monitor should be 
contact[CONTACT_369024] s. 
Electrocardiogram (ECG) 
A single, 12-lead ECG will be performed at each time point specified in the Time and Events 
Schedule.
During the collection of ECGs, subjects should be in a quiet setting without distractions 
(eg,television, cell phones). Subjects should rest in a supi[INVESTIGATOR_1662]-supi[INVESTIGATOR_368958] 
5minutes before ECG collection and should refrain from talking or moving arms or legs. If blood 
sampling or vital sign measurement is scheduled for the same time point as ECG recording, the 
procedures should be performed in the following order: ECG (s), vital signs, blood draw.
All ECG tracings will be sent to a central ECG laboratory . The ECGs will be read at the scheduled 
time points and summarized by a central ECG laboratory . The central ECG laboratory  will send 
the sponsor an electronic copy  of the data for inclusion in the clinical database. In addition, the 
investigator or sub-investigator is required to review all ECGs at the study  visit to assess for any 
potential safet y concerns or evidence exclusionary conditions prior to dosing. 
At screeni ng, the ECG tracing will be sent to the central ECG laboratory  but the investigator or 
sub-investigator is required to review the ECG locally  todetermine subject eligibility .
Physical Examination, Body Weight and Height
Physical examinations and measureme nt of body  weight and height will be performed per the Time 
and Events Schedule.
Young Mania Rating Scale (Y MRS) 
YMRS will be administered to assess treatment -emergent occurrence and severit y of manic 
epi[INVESTIGATOR_1841]. The YMRS is an eleven -item multiple choice questionnaire which is used to measure 
the severit y of manic epi[INVESTIGATOR_368959]. It is based on the patient’s subjective 
report of his or her clinical condition over the previous hours. Additional information is based 
upon clinical observ ations made during the clinical interview. The scale is completed by a clinician 
or other trained rater and takes 15–30 minutes to complete. The symptom items were selected 
based upon published descriptions of the core symptoms of mania; the YMRS is a reliable, valid 
and sensitive rating scale to measure the severit y of mania.[ADDRESS_462111] (PWC -20)
The PWC -20 will be administere d by [CONTACT_369025]. The PWC -20 is a 20-item simple and 
accurate method to assess potential development of discontinuation symptoms after stoppi[INVESTIGATOR_31081] 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 104
Status: Approved , Date: 22 November 2020study  medica tion. The PWC -20 is a reliable and sensitive instrument for the assessment of 
anxioly tic discontinuation symptoms .106Discontinuation symptoms occu r early  and disappear 
rather swiftl y, depending upon speed of taper, daily  medication dose, and drug elimination half-
life.106
Cogstate computerized cognitive battery
The Cogstate computerized cognitive battery  is a validated set of assessments which will be 
performed to assess verbal learning and memory  and evaluate cognitive function.12,28,64There are 
4 in-study  assessment times for these: between Day 4 and Day 8 (prior to discharge ; predose if 
perfo rmed on dosing day), Day 25 pre dose, DB EW, Day 81, Day  200, PT EW .
The battery  will provide assessment of multiple cogni tive domains, including attention, visual 
learning and memory , and executive function. The tests use culture neutral stimuli, enabling use 
in multilingual/multicultural settings. The computerized battery  includes:
Simple and choice reaction time tests; scored for speed of response:
oDetection (DET; Ps ychomotor Function)
oIdentification (IDN; Attention)
Visual epi[INVESTIGATOR_10682] ; visual recall test:
oOne Card Learning (OCL; Visual Learning)
Working memory  (n back task); scored for seed of correct response:
oOne Back (ONB; Working Memory )
Verbal learning and memory  assessment 
oInternational Shoppi[INVESTIGATOR_96063] (I SLT)
Executive function; maze/sequencing test, scored for total number of errors:
oThe Groton Maze Learning Test (GML; Executive Function)
All measures in the cognitive battery  have been validated against traditional neurops ychological 
tests and are sensitive to the effects of various drugs on cognitive performance, including a lcohol 
and benzodiazepi[INVESTIGATOR_1651]. The subject completed Cogstate compute rized cognitive battery  has been 
used for cognitive assessment in several child and adolescent research trials including attention 
deficit hyperactivity  disorder ,7and demonstrates good reliability  and validity  in child and 
adolescent populations.6The ISLT has also been used in adolescent trials, demonstrating 
sensitivity , reliabilit y and validity . The subject completed cognitive battery requires approximately 
25minutes; the clinician administered I SLT requires approximately  15 minutes in total.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 105
Status: Approved , Date: [ADDRESS_462112] will also complete a series of other tasks for 15 -20 minutes, before being 
asked to recall the 12 words from the IS LT again –this is called a Delayed Recall trial. The subject 
will also be shown a list of words and asked to recognize previousl y presented words, a Word 
Recognition trial.
Timeline Follow -Back ( TLFB )
The TLFB will be used to assess the potential for ketamine and PCP abuse during the follow -up 
phase. The Timeline Follow -Back (TLFB) ,35a clinical and research tool used to obtain a variety 
of quantitative estimates of alcohol and drug use, will be used to evaluate the potential for ketamine 
or PCP abuse during the follow -up. The Timeline Follow -Back method has been used in studies 
to quantify  ketamine use in adults, as well as to evaluate substance use in various adolescent 
populations.62
Dosing Day Assessments
Vital Signs (Temperature, Pulse /Heart Rate , Respi[INVESTIGATOR_13581], Blood Pressure)
Vital signs will be performed per the Time and Events Schedule. Blood pressure and pulse/heart 
rate measurements will be assessed with a completely  automated device. Manual techniques will 
be used onl y if an automated device is not available.
Blood pressure and pulse/heart rate measurements should be preceded b y at least [ADDRESS_462113] 
ina quiet setting without distractions (eg, television, cell phones). Blood pressure, heart rate, and 
respi[INVESTIGATOR_368960] (should be performed between t = -15 min and t = 0) and at 
t = 40 mins, 1 hr, and 1.5 hrs postdose; temperature at pr edose only .
For further details regarding blood pressure monitoring, please see Guidance on Blood Pressure 
Monitoring on Study  Medication Dosing Days (Section 6.3).
Tympanic temperature is recommended. The method used for obtaining temperature should be 
documented.
Pulse Oximetry
Pulse oximetry  will be used to measure arterial oxygen saturation (SpO 2). On each dosing da y, the 
device will be attached to the finger, toe, or ear, and SpO 2should be monitored and documented 
once predose between t = -15 minutes and t = 0 ( first spray )and then every  15 minutes postdose
for approximately 1.5 hours. I f oxygen saturation levels are <93% at an y time during the 1.5hour 
postdose interval, pulse oximetry  will be recorded every  5 minutes until levels return to 93% or 
until the subject is referred for appropriate medical care, if clinicall y indicated. If oxygen saturation 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 106
Status: Approved , Date: 22 November 2020levels are <95% predose, dosing should be postponed, and the subject should be evaluated by [CONTACT_369026] .
Targeted Nasal Examination and Nasal Symptom Questionnaire
Targeted nasal examinations (including the upper respi[INVESTIGATOR_53121]/t hroat) will be conducted by a 
qualified healthcare practitioner. The objective of the examination at screening is to rule out any 
subjects with anatomical or medical conditions that may  impede drug delivery  or absorption. 
Subsequent examinations will consist of a visual inspection of the nostrils, nasal mucosa, and 
throat for nasal ery thema, rhinorrhea, rhinitis, capi[INVESTIGATOR_1396] /blood vessel disruption and epi[INVESTIGATOR_3940] ,and 
the presence and severity  of symptoms will be graded. Any treatment- emergent change or 
worse ning from baseline examination will be recorded as an adverse event.
In addition, a clinician or designated study  staff will complete a nasal s ymptom questionnaire.
Modified Observer's Assessment of Alertness/Sedation (MOAA/S)
The MOAA/S will be used to measure treatment -emergent sedation with correlation to levels of 
sedation defined by [CONTACT_313364] y of Anesthesiologists (ASA) continuum.96The MOAA/S 
scores range from 0 (no response to painful stimulus; ASA continuum = general anesthesia) to 5 
(readil y responds to name [CONTACT_154992] [awake]; ASA continuum = minimal sedation).
On each dosing day, the MOAA/S should be performe d once predose between t = -15 minutesand 
t = 0 (first spray), and every  15 minutes for approximately  1.5 hours postdose (or longer, if 
necessary ).
If the score is ≤3 at any time during the 90-minute postdose interval, the MOAA/S should be 
performed every  5  m inutes until a score of 4 is reached (at which point a frequency  of every  
15 minutes can be resumed until t = 90 minutes postdose). 
If a subject does not have a score of at least 5 at t = [ADDRESS_462114] should 
continue to be monitored. For subjects with a score of 4, the assessment should be repeated every 
15 minutes. And for subjects with a score of ≤3, the assessment should be repeated every  5minutes 
until the score returns to [ADDRESS_462115] is referred for appropriate medical care, if clinically 
indicated.
Clinician -Administered Dissociative States Scale (CADSS)
The CADSS is an instrument for the measurement of present -state dissociative symptoms13and 
will be administered to assess treatment -emergent dissociative symptoms. On each dosing day, the 
CADSS should be performed predose, and at 40 minutes and 1.5 hours postdose. If any CADSS 
items are scored zero at 40 minutes, these ite ms will not be repeated at 1.5 hours postdose.
The CADSS consists of 23 subjective items, divided into 3 components: depersonalization (items 3 
to 7, 20, and 23), derealization (items 1, 2, 8 to 13, 16 to 19, and 21) and amnesia (items 14, 15, 
and 22). Thesubject’s responses are coded on a 5 -point scale (from 0=not at all to 4=extremely ). 
The CADSS has excellent inter- rater reliability  and internal consistency .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 107
Status: Approved , Date: 22 November 2020Brief Psychiatric Rating Scale , Positive Symptom Subscale (BPRS+)
The BPRS+ is an instrument that uses a 4-item positive symptom subscale (consisting of: 
suspi[INVESTIGATOR_23703], hallucinations, unusual thought content, and conceptual disorganization) to assess 
psychosis -like side effects. On each dosing day, BPRS+ to be performed predose and at 40 minutes 
and 1.5 hours postdose.
9.7. Other Evaluations
MINIInternational Neuropsychiatric Interview for Children and Adolescents (MINI -KID )
The MINI-KIDis a short, structured diagnostic interview developed for the fifth edition of the 
Diagnostic and Statistical Manua l of Mental Disorders (DSM -5) and 10th revision of the 
International Statistical Classification of Diseases and Related Health Problems (ICD-10) 
psychiatric disorders. The MINI-KID follows the structure and format of the adult version of the 
interview (MIN I) but was revised and validated for use in children aged 6 to 17 years. Itis 
administered to the child or adolescent together with their parents(s), or can be administered 
without a parent present for adolescents .108It has an administration time of approximately  15 to 
30 minutes and provides an accurate structured psychiatric interview for multicenter clinical trials. 
The MINI-KIDis used to confir m the diagnosis of MDD with current suicidal ideation and to 
determine if there are other ps ychiatric conditions present.
Questions B3 and B10 from the MINI -KID
Current suicidal ideation with intent will be evaluated at screening using Question B3 (Think about 
hurting yourself with the possibility that you might die. Or did you think about killing yourself?)
AND B10 (Expect to go through with a plan to kill yourself?) from the MINI-KID. Subjects will 
be asked to answer these questions (Yes or No) relative to their current state. The response to B3 
must refer to the present, whereas the response to B10 may  reflect the past 24hours. If screening 
is longer than [ADDRESS_462116] be recorded in the eCRF or laboratory 
requisition form. If blood samples are collected via an indwelling cannula, an appropriate amount 
(1 mL) of serosanguineous fluid slightl y greater than the dead space volume of the lock will be 
removed from the cannula and discarded before each blood sample is taken. After blood sample 
collection, the cannu la will be flushed with 0.9% sodium chloride, [LOCATION_002] Pharmacopeia 
(USP) (or equivalent) and charged with a volume equal to the dead space volume of the lock.
Refer to the T ime and Events Schedule for the timing and frequency  of all sample collectio ns.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory  manual that will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the laboratory  manual.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 108
Status: Approved , Date: [ADDRESS_462117] COMPLETION/DISCONTINUA TION OF STUDY TREATMENT/ 
WITHDRA WAL FROM THE STUDY
10.1. Completion
A subject will be considered to have completed treatment if he or she has completed assessments 
up to and including Day 25of the Double- Blind Treatment phase . Subjects who prematurel y 
discontinue study  treatment for any reason before completion of the Double -Blind Treatment 
phase will not be considered to have completed the study treatment .
A subject will be considered to have completed the study  if he or she has completed assessments 
up to and including Week 29 (Day  200).
10.2. Discontinuation of Study Treatment/Withdrawal from the Study
Discontinuation of Study Treatment During the Double- blind Phase 
A subje ct's study  treatment will bediscontinue d for an y of the following reasons:
Lost to follow -up
Withdrawal of consent/assent
Death 
Subjects whose postdose SBP or DBP measures areequal to or greater than the sex, age and 
height values in Attachment 4(after a repeated measurement ).
Lack of efficacy , per the investigator’s judgment
The investigator believes that for safety  reasons or tolerability  reasons (eg,adve rse event or 
worsening of underl ying condition) it is in the best interest of the subject to discontinue stud y 
treatment
The subject becomes pregnant during the Double- Blind Treatment phase
Blind is broken
Violation of protocol procedures, per the investig ator’s judgment and in consultation with the 
sponsor
Change in the in-patient hospi[INVESTIGATOR_313295] a result of a 
judicial or other legal administrative order.
Refer to Section 9.1.[ADDRESS_462118] is appropriately  transitioned and/or followed for any 
additional care required when a subject discontinues participation in the study  for any  reason.
Withdrawal from the Study During the Post -Treatment Follow -Up Phase
A subject will be withdrawn from the study  during the follow -up phase for any of the following 
reasons:
Lost to follow -up
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 109
Status: Approved , Date: 22 November 2020Withdrawal of consent/assent
Death
Violation of protocol procedures, per the investigator’s judgment and in consultation with the 
sponsor
Change in the in-patient hospi[INVESTIGATOR_313295] a result of a 
judicial or other legal administr ative order.
Requires treatment with ECT, TMS, ketamine or esketamine
Refer to Section 9.1.[ADDRESS_462119] is appropriately  transitioned and/or followed for any 
additional care required when a subject discontinues participation in the study  for any  reason .
10.3. Withdrawal from the Use of Research Samples
A subject who withdraws from the study  will have the following options regarding the optional 
research sample (s):
The collected sample will be retained and used in accordance with the subject and 
parent(s)/LAR(s) original separate pediatric assent /informed consent form for optional 
research sample (s).
The subject or parent (s)/LAR(s) may withdraw pediatric assent /informed consent for optional 
research sample (s), in which case the sample (s)will be destroy ed and no further testing will 
take place. To initiate the sample destruction process, the investigator must notify  the sponsor 
study  site contact [CONTACT_369027] /informed consent for the optional research 
sample (s)and to request sample destruction. The sponsor study  site contact [INVESTIGATOR_1318], in turn, 
contact [CONTACT_90805]. If requested, the 
investigator will receive written confirmation from the sponsor that the sample has been 
destroy ed.
Withdrawal from the Optional Research Samples While Remaining in the Main Study
The subject or parent(s )/LAR(s) may withdraw pediatric assent / informed consent for optional 
research sample (s)while remaining in the study . In such a case, the optional research sample (s)
will be destroyed. The sample destruction process w ill proceed as described above.
Withdrawal from the Use of Samples in Future Research
The subject or parent (s)/LAR(s) may withdraw pediatric assent/ informed consent for use of 
samples for research (refer to Section 16.2.5 , Long-Term Retention of Samples for Additional 
Future Research). In such a case, samples will be destroyed after they are no longer needed for the 
clinical study . Details of the sample retention for research are presented in the main I CF and in the 
separate ICF for optional research samples.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 110
Status: Approved , Date: [ADDRESS_462120] completes the25-day 
Double-b lind Treatment Period (Day  25).This analy sis will enable selection of a dose for the 
planned Phase [ADDRESS_462121] Information
The primary  efficacy  and safet y analysis sets are defined belo w.
Full analy sis set: The full analysis set will include all randomized subjects who receive at least 
[ADDRESS_462122] both a baseline and a postdose evaluation 
for the CDRS -R total score.
Safety  analysis set: The safet y analysis set will include all randomized subjects who receive 
at least one dose of double- blind study  medication.
11.2. Sample Size Determination
The sample size for this study was calculated assuming an effect size of 0.65 between an y dose of 
esketamine and psychoactive placebo for the change from baseline at 24 hours postdose for the 
CDRS -R total score and a 2-sided significance level of 0.05. Atotal of 145 subjects will be 
randomized in this study. Using a 1:1:1:2 randomization ratio (esketamine 28 mg: esketamine 
56mg: esketamine 84 mg: psychoactive placebo), approximately  58subjects will need to be 
randomized to psychoactive placebo and 29 subjects will need to be randomized to each 
esketamine treatment group to achieve 94% power for the comparison ofthe pooled doses of 
esketamine 56 mg andesketamine 84 mg versus psy choactive placebo and 92% power for at least 
one of the 2 esketamine higher doses(56-mg and 84 -mg) versus psy choactive placebo. The effect 
size of 0.65 is based on results from study  ESKETINSUI 2001 (mean difference between treatment 
groups of -7.2 and a pooled SD of 11.02) for MADRS total score .[ADDRESS_462123] to be estimated in the study , is defined 
by [CONTACT_716] 3 components:
Population: subjects with MDD who are at imminent risk of suicide
Endpoint: change from baseline to [ADDRESS_462124] dose (Day  2) in the CDRS -R total score 
Measure of Intervention: the effect of the initiall y randomized treatment that would have been 
observed had all subjects remained on their treatment until Day  2 of the double -blind phase. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 111
Status: Approved , Date: 22 November 2020The primary  analysis will be b ased on the full analy sis set and the CDRS -R total scores collected 
at Day 2([ADDRESS_462125] dose) .
Primary Efficacy Analysis
The primary  analysis will be based on the full analy sis set. The primary  efficacy  variable, change 
from baseline in CDRS -R total score at [ADDRESS_462126] dose, will be analyzed using an anal ysis 
of covariance (ANCOVA) model. The model will include factors for treatment and center ,and 
baseline CDRS -R total score as a covariate. A pooled sequential multiple testing procedure will 
be implemented to control for Type I error. The esketamine 56 mg and 84 mg treatment groups 
will be pooled and compared with psychoactive placebo at the2-sided significance level of 0.05. 
If this comparison achieves statistical significance in favor of esketamine, the 56-mgdose and 
84-mg dose will be simultaneously  tested versus psychoactive placebo at the 2-sided significance 
level of 0.05 based on the closed testing procedure. The 28 -mg dose will be tested only if both the 
56-mg and 84-mg dosesareshown to be significant. Point estimates and 95% confidence intervals 
for treatment differences will be provided. Since subjects are hospi[INVESTIGATOR_313296], it is anticipated that missing data will be infrequent. However, if a subject has a CDRS -
R total score at a time earlier than [ADDRESS_462127] 
dose and at Day 25 will be conducted with various dose response models being explored. Details 
of the dose response analysis will be provided in the S AP.
Changes from baseline over time in CDRS -R total score, MADRS total score, and CDI 2:SR (S)
score will be anal yzed based on last observation carried forward (LOCF) data using an ANCOVA 
model with treatment and center as factors and baseline value as a covariate. Additionally , the 
change from baseline in CDRS -R total score at Day  25 will be analy zed using a mixed model for 
repeated measures (MMRM) analy sis with baseline CDRS -R total score as a covariate, and 
treatment, center, day, and day-by-treatment interaction as fixed effects, and a random subject 
effect. Comparison of each esketamine dose versus placebo will be performed using the 
appropriate contrast. Point estimates and 95% confidence intervals for treatment differences will 
be provided. Missing data will be closel y monitored and additional sensitivity  analyses will be 
specified in the SAP, if necessary .
The ranks of changes from baseline over time for both CGI-SS-R and CGI -SR-Iwill be analy zed 
using an ANCOVA model using last observation carried forward data with factors for treatment 
and center and baseline CGI -SS-R and CGI-SR-I (unranked) as a covariate. Treatment differences 
will be estimated using the Hodges- Lehmann estimate, which is the median of all possible paired 
differences for t he change from baseline for CGI -SS-R and CGI-SR-I.
SIBAT Module 3 (My Current Thinking ) andModule 5 (My Risk)Question 3 (patient -reported 
frequency  of suicidal thinking) will be summarized over time.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 112
Status: Approved , Date: 22 November 2020Additionally , scores of all efficacy  endpoints will besummarized for all visits. Descriptive 
statistics (N, mean, standard deviation, median, minimum and maximum) will be provided for 
continuous variables and frequency  distributions will be provided for categorical variables.
Details of the other anal yses wi ll be provided in the S AP.
11.4. Pharmacokinetic A nalyses
Data will be listed for all subjects with available plasma concentrations per treatment group. 
Subjects will be excluded from the PK analy sis if their data do not allow for accurate assessment 
of the PK (eg, incomplete administration of the study  drug; missing information of dosing and 
sampling times; concentration data not sufficient for PK parameter calculation). Concentrations 
below the lowest quantifiable concentration or missing data will be labeled as such in the 
concentration database. All subjects and samples excluded from the analy sis will be clearl y 
documented in the study report.
The plasma concentration -time data of esketamine (and noresketamine, if warranted) will be 
analyzed using population PK modeling. Data may be combined with those of other selected 
studies to support a relevant structural model. Available baseline subject characteristics 
(demographics, laboratory  variables, genot ypes, race, etc.) will be tested as potential covariates 
affecting PK parameters. 
Details will be given in a population PK analysis plan and the results of the population PK analysis 
will be presented in a separate report. In addition to the final population PK parameter estimates, 
the corresponding standard error s and 95% confidence intervals will be provided.
The relationship between CDRS -R total score (and possibly  other efficacy  endpoints such as 
MADRS and selected adverse events and additional pharmacod ynamic parameters), and PK 
metrics of esketamine may be ev aluated. The results of such analy ses may  be reported separately .
11.5. Biomarker and Pharmacogenomic Analyses
Changes in biomarkers over time will be summarized by [CONTACT_1570]. Associations between 
baseline levels and changes from baseline in selected bioma rkers and clinical endpoints will be 
explored.
Exploratory  analy ses may  be performed for additional biomarkers. Results may  be presented in a 
separate Biomarkers report. 
Pharmacogenomic anal yses (DNA and RNA) may include candidate gene analyses ,genome -wide 
association analyses, and gene transcription analysesin relation to treatment response, 
non-response, and MDD. Additional exploratory  analy ses may  be performed.
Details of the analy sis plan and summary  of results from both biomarker and pharm acogenomic 
analyses will be reported separately .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 113
Status: Approved , Date: [ADDRESS_462128] one dose of double -blind study  medication. The safet y data from the follow -up phase wil l be 
summarized separatel y.
Adverse Events
The verbatim terms used in the eCRF by [CONTACT_23820] (MedDRA). Treatment -emergent adverse 
events are adverse events with onset during the Double- Blind Treatment phase orthat are a 
consequence of a pre-existing condition that hasworsened since baseline .All reported adverse 
events with onset during the Double- Blind Treatment phase (ie, TEAEs and adverse events that 
have worsened since baseline) will be included in the analy sis. For each adverse event, the 
percentage of subjects who experience at least 1occurrence of the given event will be summarized 
by [CONTACT_1570] . In addition, comparisons between treatment groups will be provided if 
appropriate. Adverse events during the follow -up phase will be summarized separately .
The TEAEs of special interest will be examined separatel y (refer to Section 3.2.7 for further 
details); adverse events of special interest will be further listed in the SAP. Subjects who die, who 
discontinue treatment due to an adverse event, or who experience a serious ad verse event will be 
summarized separatel y.
Clinical Laboratory Tests
Laboratory  data will be summarized by [CONTACT_23821]. Markedly  abnormal results 
(specified in the SAP) will be used in the summary  of laboratory  data. Descriptive statistics will
be calculated for each laboratory  analyte at baseline and for observed values and changes from 
baseline at each scheduled time point. A listing of subjects with any markedly  abnormal laboratory 
results will also be provided.
Electrocardiogram (ECG)
The effects on cardiovascular variables will be evaluated by [CONTACT_23822]. These tables will include observed values and changes from baseline values.
Electrocardiogram data will be summarized by [CONTACT_105292] . Descri ptive statistics will be 
calculated at baseline and for observed values and changes from baseline at each scheduled time 
point. Frequency  tabulations of the abnormalities will be made.
The ECG variables that will be analy zed are heart rate, PR interval, QRS interval, QT interval, and 
corrected QT (QTc) interval using the following correction methods: QT corrected according to 
Bazett's formula (QT cB), QT  corrected according to Fridericia's formula (QT cF).8,44,47,109
Descriptive statistics of QTc intervals and changes from baseline will be summarized at each 
scheduled time point. The percentage of subjects with QTc interval >450 milliseconds, 
>480 milliseconds, or >500 milliseconds will be summarized, as will the percentage of subjects 
with QT c interval increases from baseline >30 milliseconds or >60 milliseconds.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 114
Status: Approved , Date: 22 November 2020All clinically  relevant abnormalities in ECG waveform that are changes from the baseline readings 
will be reported (eg, chan ges in T -wave morphology  or the occurrence of U -waves.)
Vital Signs , Pulse Oximetry and Body Weight
Descriptive statistics of temperature, pulse/heart rate, respi[INVESTIGATOR_2842], pulse oximetry 
measurements, bod y weight measurements, and blood pressure (s ystolic and diastolic) values and 
changes from baseline will be summarized at each scheduled time point. The percentage of 
subjects with values beyond clinically  important limits will be summarized.
Nasal Examination and Nasal Symptom Questionnaire
Changes in findings from the baseline nasal examination (including the upper respi[INVESTIGATOR_53075]/throat) will be listed by [CONTACT_1570]. Examinations will provide ratings of severity that 
are based on a visual inspection of the nostrils, nasal mucosa, and throat for nasal erythema, 
rhinorrhea, rhinitis, capi[INVESTIGATOR_1396] /blood vessel disruption and epi[INVESTIGATOR_3940]. A shift table for changes from 
baseline in ratings for each examination will be presented by [CONTACT_369028].
Scoring from the nasal symptom questionnaire will be summarized descriptively  by [CONTACT_6490].
MOAA/S and CADSS
Sedation data from the MOAA/S and dissociative symptoms data from the CADSS will be 
summarized descriptively at each scheduled visit by  [CONTACT_17673].
SIBAT, BPRS+, and YMRS
Suicidal ideation and behavior data from the SIBAT, psychosis -like side effect data from the 
BPRS+, and potential treatment -emergent symptoms of mania data from the YMRS will be 
summarized descriptively at each scheduled visit by [CONTACT_1570].
Cogstate Computerized Cognitive B attery 
Cognitive function data from the Cogstate computerized cognitive battery  will be summarized 
descriptivel y at each scheduled visit by  [CONTACT_1570].
PWC -20
Withdrawal symptoms data from the PWC -20will be summarized descriptively  at designated
scheduled visit by  [CONTACT_1570] .106
Time Line Follow -Back (TLFB)
The TLFB, a clinical and researc h tool used to obtain a variet y of quantitative estimates of 
ketamine and PCP abuse, will be summarized descriptively  at each scheduled visit by [CONTACT_6490].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 115
Status: Approved , Date: [ADDRESS_462129] Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by [CONTACT_369029] t hose procedures.
Method of Detecting Adverse Events and Serious Adverse Events
Care will be taken not to introduce bias when detecting adverse events or SAEs . Open -ended and 
nonleading verbal questioning of the subject is the preferred method to inquire about adverse event
occurrence. For some studies, subjects are not alway s able to provide valid verbal responses to 
open -ended questions. In these circumstances, certain adverse events are solicited by [CONTACT_369030] y assessments (see Section 3.2.6 andSection 3.2.7 ).
Solicited Adverse Events
Solicited adverse events are predefined local and systemic events for which the subject is 
specificall yquestioned.
Unsolicited Adverse Events
Unsolicited adverse events are all adverse events for which the subject is specifically  not 
questioned.
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An adverse event is any untoward medical occurrence in a clinical study  subject administered a 
medic inal (investigational or non -investigational) product. An adverse event does not necessaril y 
have a causal relationship with the treatment. An adverse event can therefore be any  unfavorable 
and unintended sign (including an abnormal finding), sy mptom, or d isease temporally  associated 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 116
Status: Approved , Date: 22 November 2020with the use of a medicinal (investigational or non -investigational) product, whether or not related 
to that medicinal (investigational or non-investigational) product. (Definition per International 
Conference on Harmonisation [ICH])
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects adverse events starting with the signing of the ICF (refer to 
Section 12.3.[ADDRESS_462130] adverse event recording).
Serious Adverse Event
Aserious adverse event based on ICH and EU Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dose:
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe.)
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or significant disability /incapacity
Is a congeni tal anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situation s, such as important medical events that may not be immediatel y 
life-threatening or result in death or hospi[INVESTIGATOR_66816]. These should 
usually  be considered serious.
If a serious and unexpected adverse event occurs for which there is evidence suggesting a causal 
relationship between the study drug and the event (eg, death from anaph ylaxis), the event must be 
reported as a serious and unexpected suspected adverse reaction even if it is a component of the 
study  endpoint (eg, all -cause mortality ). 
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An adverse event is considered unlisted if the nature or severit y is not consistent with the applicable 
product reference safet y information. For esketamine , the expectedness of an adverse event will 
be determined by [CONTACT_83408]'s Brochure.48,49,50For midazolam,
with a marketing authorization, the expectedness of an adverse event will be determined by 
[CONTACT_369031] .72,73
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 117
Status: Approved , Date: 22 November 2020Adverse Event Associated With the Use of the Drug
An adverse event is considered associated with the use of the drug if the attribution is possible, 
probable, or very  likel y by [CONTACT_23826] 12.1.2 , Attribution Definitions .
12.1.2. Attribution Definitions
Not Related
An adverse event that is not related to the use of the drug.
Doubtful
An adverse event for which an alternative explanation is more likely, eg,concomitant drug(s), 
concomitant disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An adverse event that might be due to the use of the drug. An alternative explanation, 
eg,concomitant drug(s) , concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable
An adverse event that might be due to the use of the drug. The relationship in time is suggestive 
(eg,confir med b y dechallenge). An alternative explanation is less likel y, eg, concomitant drug(s), 
concomitant disease(s).
Very Likely
An adverse event that is listed as a possible adverse reaction and cannot be reasonabl y explained 
by [CONTACT_4867], eg,concomitant drug(s), concomitant disease(s). The relationship in 
time is very  suggestive (eg, it is confirmed b y dechallenge and rechallenge).
12.1.3. Severity Criteria
An assessment of severity grade will be made using the following general categorical descript ors:
Mild : Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate : Sufficient discomfort is present to cause interference with normal activity .
Severe : Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 118
Status: Approved , Date: [ADDRESS_462131] on a sponsor study  drugthat may require expedited reporting or safet y 
evaluation include, but are not limited to:
Overdose of a sponsor study  drug
Suspected abuse/misuse of a sponsor study  drug
Accidental or oc cupational exposure to a sponsor study  drug
Medication error involving a sponsor product (with or without subject/patient exposure to the 
sponsor study  drug , eg, name [CONTACT_2976])
Exposure to a sponsor study  drug from breastfeeding
Special reporting situatio ns should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of a serious adverse event should be recorded on the serious adverse event page 
of the eCRF.
12.3. Procedures
12.3.1. All Adverse Events
All adverse events and special reporting situations, whether serious or non-serious, will be reported 
from the time a signed and dated ICF is obtained until completion of the subject's last study -related 
procedure, which may include contact [CONTACT_20687] -up o f safety , with the exception of pregnancy  
which will be reported up to [ADDRESS_462132] dose of study  medication (females) or [ADDRESS_462133] dose of study  medication (partners of male subjects. Serious adverse events, including 
those spontane ously  reported to the investigator from the time a signed and dated I CF is obtained 
until completion of the subject ’s last study -related procedure, must be reported using the Serious 
Adverse Event Form. The sponsor will evaluate any safet y information that is spontaneousl y 
reported b y an investigator bey ond the time frame specified in the protocol.
One of the principal aims of this trial is to define safet y of intranasal esketamine use in the 
adolescent population. Anticipated events will not be applied to this adolescent trial. There are no 
common causes of hospi[INVESTIGATOR_368961] y in this age group. There is not 
enough information in this age group to define anticipated events due to major depression or major 
depression with suicidal intention at this time.
All events that meet the definition of a serious adverse event will be reported as SAEs , regardless 
of whether they  are protocol -specific assessments.
All adverse events, regardless of seriousness, severity , or presumed relationship to study  drug, 
must be recorded using medical terminology  in the source document and the eCRF. Whenever 
possible, diagnoses should be given when signs and symptoms are due toa common etiology 
(eg,cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respi[INVESTIGATOR_23739]"). Investigators must record in the eCRF their opi[INVESTIGATOR_154890] y. All measures required for adverse event 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 119
Status: Approved , Date: [ADDRESS_462134] be recorded in the source document and reported according to sponsor 
instructions.
The sponsor assumes responsibility  for appropriate reporting of adverse events to the regulatory  
authorities. The sponsor will also report to the investigator (and the head of the investigational 
institute where required) all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) . The 
investigator (or sponsor where required) must report S[LOCATION_003]Rs to the appropriate IEC/ IRB that 
approved the protocol unless otherwise required and documented by  [CONTACT_6179]/I RB.A S[LOCATION_003]R will 
be reported to regulatory  authorities unblinded. Participating investigators and IEC/I RB will 
receive a blinded S[LOCATION_003]R summary , unless otherwise specified.
For all studies with an outpatient phase, including open -label studies, the subject must be provided 
with a "wallet (study )card" and instructed to carry  this card with them for the duration of the study  
indicating the following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name [INVESTIGATOR_1238] 24-hour contact [CONTACT_23828]
Local sponsor's name [INVESTIGATOR_1238] [ADDRESS_462135] telephone number (for medical staf f onl y)
Site number
Subject number
Any other information that is required to do an emergency  breaking of the blind
12.3.2. Serious A dverse Events
All SAEs occurring during thestudymust be reported to the appropriate sponsor contact [CONTACT_184932] -site personnel within [ADDRESS_462136] be completed and signed by  a physician from the study  site, and transmitted to 
the sponsor w ithin 24 hours. The initial and follow-up report s of a serious adverse event should be 
made b y facsimile (fax) .
All SAEs that have not resolved by [CONTACT_2054] , or that have not resolved upon 
discontinuation of the subject's participation in the study , must be followed until any of the 
following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the stud y dru g or to factors unrelated to stud y 
conduct
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 120
Status: Approved , Date: 22 November 2020It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration of 
due diligence with follow -up efforts)
Suspected transmission of an infectious agent b y a medicinal product will be reported as a serious 
adverse event. An y event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) that occurs 
during the course of a subject's participation in a study  must be reported as a serious adverse event , 
except hospi[INVESTIGATOR_368962]:
Inpatient hospi[INVESTIGATOR_368963] -recommended 5 days (not due to 
adverse event; e.g.clinical worsening)
Hospi[INVESTIGATOR_23742] (eg, social reasons such
as pending placement in long- term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the eCRF ). 
Note: Hospi[INVESTIGATOR_23743], and where the 
underly ing condition for whic h the hospi[INVESTIGATOR_23744] ,will not be 
considered serious adverse events. Any adverse event that results in a prolongation of the 
originall y planned hospi[INVESTIGATOR_23745] a new serious adverse event.
The cause of death of a subject in a study  from the time a signed and dated ICF is obtained until 
completion of the subject's last study -related procedure , whether or not the event is expected or 
associated with the study drug , is considered a serious adve rse event.
12.3.3. Pregnancy
All initial reports of pregnancy in female subjects or partners of male subjects must be reported to 
the sponsor by  [CONTACT_1758] -site personnel within 24 hours of their knowledge of the event using the 
appropriate pregnancy  notification f orm. Abnormal pregnancy  outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomal ies, ectopic pregnancy ) are considered serious 
adverse events and must be reported using the Serious Adverse Event Form. Any subject who 
becomes pregnant during the study  must be promptly  withdrawn from the study  and discontinue 
further stud y treatment.
Because the effect of the study  drug on sperm is unknown, pregnancies in partners of male subjects 
included in the study  will be reported as noted above.
Follow-up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required .
12.4. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_369032](s), which will be provided as a separate document.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 121
Status: Approved , Date: [ADDRESS_462137] qualit y complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliabilit y of a product, including its labeling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy  of the p roduct. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor , and are mandated b y regulatory  agencies worldwide. The sponsor has established 
procedu res in conformity with regulatory requirements worldwide to ensure appropriate reporting 
of PQC information; all studies conducted by [CONTACT_43765].
13.1. Procedures
All initial PQCs must be r eported to the sponsor by  [CONTACT_1758] -site personnel within [ADDRESS_462138] report the 
PQC to the sponsor according to the serious adverse eve nt reporting timelines (refer to 
Section 12.3.2, Serious Adverse Events). A sample of the suspected product should be maintained 
for further investigation if requested b y the sponsor.
13.2. Contact[CONTACT_23834] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23835](s ), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drug(s)
Study  drug will be manufactured and provided under the responsibility  of the sponsor .Refer to the 
Investigator's Brochure for a list of excipi[INVESTIGATOR_368964] ,48and to the midazolam product 
label72,73for a list of excipi[INVESTIGATOR_368965].
Intranasal Esketamine and Placebo Solution
The esketamine supplied for this study  is available as a clear, colorless intranasal solution of 
esketamine hydrochloride (16.14% weight/volume [w/v]; equivalent to 14% w/v of esketamine 
base) in a nasal spray  pump. The solution will consist of 161.4 mg/mL esketamine hy drochloride 
(equivalent to140 mg of esketamine base) formulated in 0.12 mg/mL  EDTA and 1.5 mg/mL citric 
acid at pH of 4.5. It is provided in a nasal spray  pump, which delivers 16.14 mg esketamine 
hydrochloride (14 mg esketamine base) per 100 μL spray. Each individual nasal spray  pump 
(device) contains a total of 28 mg (ie, 2 spray s).
The intranasal placebo solution will be provided as a clear, colorless intranasal solution of water 
for injection with a bittering agent (denatonium benzoate [Bitrex®] at a final concentration of 
0.001 mg/mL) added to simulate the taste of the intranasal solution with active drug. The placebo 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 122
Status: Approved , Date: 22 November 2020solution will be provided in matching nasal spray pump devices. Benzalkonium chloride is added 
as a preservative at a concentration of 0.3 mg/mL. Each individual nasal spray  pump (device) 
contains 2 sprays.
Oral Midazolam and Placebo
The oral midazolam supplied for this study  is available as a clear, colorless solution of midazolam -
ratiopharm®2 mg/ml. Other ingredients include raspberry  flavoring , sodium benzoate, sodium 
cyclamate, hydrochloric acid (0.8%) and distilled water. It is provided in a glass bottle with dropper 
and child- proof plastic cap, measuring cap, and application sy ringe.
The oral placebo solution will be provided as a clear, colorless oral solution of purified water with 
a preservative (sodium benzoate) at a concentration of 2.36 mg/mL  with a buffer (citric acid) at 
3.00 mg/mL. Sucralose (sweetener) is added at a concentration of 1.00 mg/mL and artificial 
raspberry  flavor is added at a concentration of 1.00 mg/mL . The oral placebo solution is provided 
in 30 -mL amber glass bottles with a child -resistant cap.
14.2. Packaging
All study  drug will be administered under the supervision of site staff.
Intranasal Esketamine and Placebo Solution
Study  drug (ie, intranasal esketamine and placebo solution) will be supplied by [CONTACT_104222] a 
bi-dose nasal spray  device. The devices will contain 230 µL (of which ~30 µL is the residual 
volume). Each device delivers 16.14 mg esketamine hydrochloride (14 mg esketamine base) or 
0.1µg of denatonium benzoate per [ADDRESS_462139] kit, labeled with a unique 
medication kit number.
Device for Practicing Intranasal Study Drug Administration
The demonstration intranasal device will also be supplied by [CONTACT_369033]. Subjects will practice spray ing into the air and will not spray  intranasall y.
Oral Midazolam and Placebo
The oral midazolam (2mg/ml) and oral placebo solutions will be provided in 30-mL amber glass 
bottles with a child- resistant cap andpackaged in cartons. Storage conditions are as indicated on 
the label.
14.3. Labeling
Study  drug labels will contain information to meet the applicable regulatory requirements.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 123
Status: Approved , Date: [ADDRESS_462140] specific 
labeling. 
Refer to the pharmacy  manual/ study  site investigational product and procedures manual for 
additional guidance on study  drug preparation ,handling , and storage .
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study . The dispensing of study  drug to the subject, and the return 
of study  drug from the subject (if applicable), must be documented on the drug accountability  
form. All study  drug will be stored and disposed of according to the sponsor's instructions. S tudy-
site personnel must not combine contents of the st udy drug containers.
Study  drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. The return to t he sponsor of unused study  drug, or used returned study  
drug for destruction, will be documented on the drug return form. When the study  site is an 
authorized destruction unit and study  drug supplies are destro yed on -site, this must also be 
documented on the drug return form.
Potentially  hazardous materials such as used ampules, needles, syringes and vials containing 
hazardous liquids, should be disposed of immediately  in a safe manner and therefore will not be 
retained for drug accountability  purposes. 
Study drug should be dispensed under the supervision of the investigator or a qualified member of 
the study -site personnel , or by a hospi[INVESTIGATOR_307]/clinic pharmacist. Study  drug will be supplied only to 
subjects participating in the study . Returned study drug must not be dispensed again, even to the 
same subject. Study  drug may not be relabeled or reassigned for use by [CONTACT_23837]. The 
investigator agrees neither to dispense the study  drug from, nor store it at, any site other than the 
study  sites agreed upon wi th the sponsor.
15. STUDY -SPECIFIC MATER IALS
The investigator will be provided with the following supplies:
Investigator 'sBrochure for esketamine
SmPC or Package Insert for midazolam
Pharmacy  manual/ study  site investigational product and procedures manual
Study  medication “Instructions for Use” documents for subject and clinical site staff
Practice/demonstration intranasal devices and ancillary  supplies
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 124
Status: Approved , Date: 22 November 2020Central laboratory  manual and materials
ECG manuals and materials
Clinician -administered and subject -completed/patient -reported outcome assessments 
-Paper versions if applicable
-Electronic devices and associated materials
IWRS Manual 
Electronic data capture (eDC) manual
Information for clinician regarding dosing, switching, and augmenting antidepressant 
treatments
Guidance for minimum requirements for site staff and equipment on dosing day s
Visit procedures checklist
Study  awareness and support materials (ie, to facilitate subject identification and retention)
Any updates to these documents that occur during the study  will also be provided.
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
Clinical Study in Subjects with MDD Assessed to be at Imminent Risk of Suicide
Major depressive disorder is the most prevalent mental health condition and the psychiatric
diagnosis most commonly associated with suicide.54,91Epi[INVESTIGATOR_368917] 12 -
month prevalence of MDD is 2% in children and 4% to 8% in adolescents,2that MDD is the main 
predictor of suicidal ideation among children and adolescents,37,93and that 40% to 80% of 
adolescents meet the diagnostic criteria for depression at the time of suicide attempt.10,37There is 
no approved treatment for patients with MDD assessed to be at imminent risk for suicide. The 
current standard of care is hospi[INVESTIGATOR_368966] . However, these therapi[INVESTIGATOR_368967]. Thus, subjects remain at risk for 
suicide ,with up to 13.9% of subjects reattempt ingsuicide within the [ADDRESS_462141] on reducing suicidal ideation within hours of 
administration.31,60,101,103,123Furthermore, a Phase 2 study  (ESKETINSUI 2001) recentl y 
completed by [CONTACT_369034][INVESTIGATOR_2478] y reduced symptoms of 
depression and suicidality  in subjects with MDD at imminent risk for suicide and that intranasal 
esketamine was tolerated in this population. Thus, esketamine treatment for [ADDRESS_462142] therapi[INVESTIGATOR_368968].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 125
Status: Approved , Date: 22 November 2020Selection of Subjects
The primary  aim of the study  is to evaluate the efficacy  of intranasal esketamine for the rapid 
reduction of the sy mptoms of MDD , including suicidal ideation, in young subjects assessed to be 
at imminent risk for suicide. Thus, the study  cannot be completed in healthy subjects or depressed 
patients who are not at imminent risk for suicide.
While a patient’s decisional capacity  can be impacted by [CONTACT_369035] , this 
becomes an ethical concern when the patient refuses medicall y necessary  treatment. However, the 
subjects and parent (s)/LAR(s) in this trial will be providing voluntary  pediatric assent /informed 
consent to participate in the study  of a potentiall y efficacious treatment, given in the context of 
standard of care treatme nt (ie, hospi[INVESTIGATOR_059], antidepressant treatment and psychological 
therap y). Thus, ethical concerns regarding subjects’ decision to participate are minimal.
Subjects and parent (s)/LAR(s) may participate in the study  only if they have adequate capacit y to 
give assent and after fully understanding the potential risks and giving a pediatric assent/ informed 
consent . Determination of capacity  to provide assent will be made by [CONTACT_154976]. 
Subjects may discontinue the study  at any time. The probabilit y of receiving placebo and the 
concept of random assignment will be explained to the subject. Potential disadvantages and 
adverse events of participating in the study  and alternative treatment options will be discussed. 
Further each subject’s parent(s)/ LAR (s), as required by [CONTACT_427], must give written consent .
Justification for Using Psychoactive Placebo
Assessment of the potential efficacy  of a new compound for the treatment of MDD requires 
adequate and well -controlled clinical studies. As there are no approved treatments for the rapid 
reduction of symptoms of MDD, including suicidal ideation, a psychoactive placebo -controlled 
study  conducted in the context of comprehensive standard of care treatment (ie, acute psy chiatric 
hospi[INVESTIGATOR_059], the initiation of optimization standard of care antidepressant treatment, 
psychological therap y and close outpatient follow up) is ethically  appropriate. 
The rationale for use of a psychoactive placebo to protect the blind of study  medication is discussed 
in Section 3.2.3 . Asits pharmacokinetic characteristics and transient psychoactive effects are 
similar to ketamine, midazolam has been used as a psy choactive control in studies of ketamine .85
It will be used in doses approximately  25% of those recommended for use in pediatric 
populations.72,[ADDRESS_462143] of care antidepressant medication 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 126
Status: Approved , Date: [ADDRESS_462144] dose of study  medication (Day  1) may be permitted if starting two 
medications simultaneously  is not consistent with local clinical practice.
Subjects will be followed closel ythroughout the study : twice a week during the 25-daytreatment 
period, followed by [CONTACT_369036] 8, visits every [ADDRESS_462145]’s condition and possible intervention.
If subjects do not respond during the study  and are not willing or able to receive additional study 
drug treatment, clinical care will be arranged between the study  investigator and or their physician.
The investigator will ensure that subjects who withdraw from the study  prior to completion are 
appropriatel y followed and/or transitioned for an y additional care required.
Only  qualified and experienced investigators will participate in the study .
Potential subjects and their parent(s) or LAR (s) will be full y informed of the risks and requirements 
of the study  and, during the study , subjects will be given any new information that may  affect their 
decision to continue participation. They  will be told that their respective assent andconsent to 
participate in the study  is voluntary  and may be withdrawn at any time with no reason given and 
without penalt y or loss of benefits to which they would otherwise be entitled. Only subjects and 
parent (s)/LAR(s) who are fully able to understand the risks, benefits, and potential advers e events of 
the study , and provide their pediatric assent /informed consent voluntaril y will be enrolled.
When referring to the signing of the ICF, the terms legal guardian and legall y acceptable 
representative refer to the legall y appointed guardian of thechild with authorit y to authorize 
participation in research. For each subject, his or her parent(s) (preferabl y both parents, if available) 
or LAR (s), as required by [CONTACT_427], must give written consent (permission) according to 
local requirements after the nature of the stud y has been full y explained and before the performance 
of any study -related assessments. Assent must be obtained from children (minors) capable of 
understanding the nature of the study , typi[INVESTIGATOR_1306] y subjects [ADDRESS_462146] provided 
consent (and assent as applicable) refers to the subjects and his or her parent(s) or the subject's legal 
guardian(s) or LAR (s) who have provided consent according to this process. Minors who assent to 
a study  and later withdraw that assent should not be maintained in the study  against their will, even 
if their parents still want them to participate.
The total blood volume to be collecte d is considered to bean acceptable amount of blood to be 
collected over this time period from the population in this study  based upon E uropean Medicines 
Agency and Food and Drug Administration ( FDA )requirements and strategies for pediatric drug 
developme nt.124Weight and age charts for 12-year-olds in the 5th percentile, show a weight of 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 127
Status: Approved , Date: 22 November 2020approximatel y 30 kg for both girls and boys.26,45,34,111Assuming a conservative phlebotom y protocol 
that is 1% of total blood volume drawn within 24 hours and a total of 3% total blood volume drawn 
over 30 day s, total blood volume for the study  population was calculated based on an assumption of 
80 mL/kg, as follows:
Maximum total blood volume per 24 hours = 30 kg x 80 mL/kg x 0.01 = 24 mL
Maximum total blood volume per 30 day s = 30 kg x 80 mL/kg x 0.03 = 72 mL
Compensation for any procedure will be fair per local standards and approved by [CONTACT_155120]/I RBs 
for participating sites in order not to offer an y undue incentive to participate in the study .
The blood volumes estimated for this study  (Section 9.1.1 ,Table 2) are lower than maximum 
recommended blood volumes.
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki ,andthat the study  data are credible.
The risks and inconveniences related to Study  ESKETIN SUI2002 participation will be minimal. 
Any risk or inconvenience will be mitigated through strict adherence to study  procedures by [CONTACT_1275], and compliance with study  procedures by [CONTACT_423]/guardians. To that end, the 
investigator is responsible for ensuring precise study  conduct as specified by [CONTACT_760], which 
will be achieved through training on the study  protocol, review of important supporting document s 
pertaining to risks (see Section 15, Study -Specific Materials), and compliance with all aspects of 
study  conduct.
The following are the foreseeable risks to be monitored by [CONTACT_23528] , 
and the associated mitigations, as defined in respective protocol sections:   
Voluntary c onsent/assent 
For this study , both parental consent and subject assent is required. Subjects may  participate only  if 
their parent(s) /LAR(s) have adequate capacit y to give consent and fully understand the potential 
risks. While a patient’s decisional capacit y can be impacted by [CONTACT_369037] y, 
this becomes an ethical concern when the patient refuses medicall y necessary  treatment. 
Determination of capacit y will be made by [CONTACT_1704]. See Section 4.1, Inclusion Criteria. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 128
Status: Approved , Date: [ADDRESS_462147] 
clinical care, in cluding hospi[INVESTIGATOR_059] ,the initiation or optimization of antidepressant treatment and 
psychological therapy . Additionall y, close outpatient follow upwill occur, consistent with practice 
guideline recommendations from the National Institute for Health and Clinical Excellence (NICE)
and the American Academ y of Pediatrics (AAP ).90Subjects will remain hospi[INVESTIGATOR_80529] a 
recommended period of 5 day s, which is consistent with the t ypi[INVESTIGATOR_368969], and may stay longer or shorter if clinicall y 
warranted. Very  frequent clinical visit and assessments monitoring symptoms of the subjec t’s MDD, 
including suicidal ideation, occur throughout the study , thus optimizing early identification of 
changes in depressive status. See Section 9.1, Study Procedures.
Post- treatment follow -up period
After the [ADDRESS_462148] visits conducted weekl y through Day 53, then every  
other week until Day 81, then monthly  safety appointments for the remainder of the 6 months 
(Day 81-200). The duration of follow -up in this study  covers the period of greatest risk for 
recurrent suicidali ty post initial attempt and/or hospi[INVESTIGATOR_059].11,102The follow -up through 
Day 200will allow for appropriate outpatient monitoring and the exploration of the continued 
effects of esketamine on depression and suicidal sy mptoms .
Study discontinuation and follow -up
Subjects may discontinue the study  at any time for a variet y of reasons, including withdrawal of 
consent . If subjects do not respond during the study  and are not willing or able to receive additional 
study  drug treatment, clinical care will be arranged between the study  investigator and/or their 
physician. The investigator will ensure that subjects who withdraw from the study  prior to 
completion are appropriately  followed and/or transitioned for any additional care required. See 
Section 10.
Safety during study
All phlebotomy  volumes for this study  have been minimized to adhere to the Committee for 
Human Medicinal Products ( CHMP )and Paediatric Committee (PDCO )guideline 
recommendations.26To increase subject comfort, an indwelling catheter has been recommended.
Study  requirements for frequent and close follow -up,coupled with use of recommended 
pharmacologic and psychological therapi[INVESTIGATOR_368970],assures that adolescents 
participating in the study receive care consistent with recognized guidelines for care of subjects 
with MDD and suicidal ideation .
Based on previous studies, it is known that certain adverse drug reactions occur postdose , peak 
around 40 minutes, and then dissipate, usually within 4 hours. The study  includes careful 
monitoring following study  drug dosing . Vital signs areperformed atpredose (should be 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 129
Status: Approved , Date: 22 November 2020performed between t = -15 minutes and t = 0) and at 40 minutes, 1 hour, and1.5 hours postdo se.
Oxygenation should bemonitored predose (performed between t = -15 minutes and t = 0), and 
every  15minutes thereafter through to approximat ely 1.5 hours postdose, or longer, if necessary . 
Additionally , other known side effects of esketamine (eg, dissociation, sedation, conceptual 
disorientation, hallucinogenic behavior, and abnormal thought content) are monitored closel y 
during this time using specific assessment tools like CADSS, MOAA/S, and BPRS+. On each 
dosing day, CADS S and BPRS+ should be performed predose and at 40 minutes and 1.5 hours 
postdose; MOAA/S should be performed predose (between t = -15 minutes and t = 0) and every 
[ADDRESS_462149] safet y;eg, specific guidance 
provided regarding management of elevated blood pressure , pre-and postdose (Section 6.3), and 
intensive post -administration monitoring on outpatient day s(Section 10). In addition, an external 
IDMC will be established to monitor unblinded safet y data on an ongoing basis to ensure the 
continuing safet y of the subjects enrolled in this study . The committe e will meet regularl yto 
review safet y data and determine if it is appropriate for the study  to continue (Section 11.7). 
16.2.2. Independent Ethics Committ ee or Institutional Review  Board
Before the start of the study , the investigator (or sponsor where required) will provide the IEC/I RB 
with current and complete copi[INVESTIGATOR_23747] (as required by  [CONTACT_427]) :
Final protocol and, if applicable, amendments
Sponsor -approved ICF(and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensatio n for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as documented 
by [CONTACT_6179]/IRB)
Information regarding funding, name [CONTACT_8152], institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/IRB has given full approval of the final protocol, 
amendments (if any, excluding the ones that are purely  administrative, with no consequences for 
subjects, data or study  conduct , unless required locally ), the ICF, applicable recruiting materials, 
and subject compensation programs, and the sponsor has received a copy of this approval. This 
approval letter must be dated and must clearly  identify  the IEC/I RB and the documents being 
approved.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 130
Status: Approved , Date: [ADDRESS_462150] 
be obtained from the IEC/IRB. Approval for the protocol can be obtained independent of this 
optional research component . 
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their revi ew and approval, where appropriate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision(s) to ICFand any  other written materials to be provided to subjects
If applicabl e, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochure and amendments/ad denda
Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of adverse events that are serious, unlisted/unexpected, and associated with the study 
drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct) , the amendment and applicable ICFrevisions 
must be submitted promptly to the IEC/IRB for review and approval before implementation of the 
change(s).
At the end of the study , the investigator (or sponsor where required) will notify the IEC/I RB about 
the study  completion (if applicable, the notification will be submitted through the head of 
investigational institution) .
16.2.3. Informed Consent /Pediatric Assent Form
Subject’s parent(s) or LAR (s) must give written consent, granting permission forhis/her child to 
participate in the stud y according to local requirements after the nature of the study has been full y 
explained. Written assent must be obtained from the subject.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 131
Status: Approved , Date: [ADDRESS_462151] explain to potential subjects and their parent (s)/LAR (s), the methods, reasonabl y 
anticipated benefits, and potential hazards of the study , and any discomfort participation in the 
study  may entail. This discussion should be documented. Subjects and parent (s)/LAR(s)will be 
informed that their participation is voluntary  and that they  may  withdraw consent to participate at 
any time. They  will be informed that choosing not to participate will not affect the care the subject 
willreceive for the treatment of his or her disease. Subjects and parent(s)/ LAR (s)will be told that 
alternative treatments are available if they refuse to take part and that such refusal will not 
prejudice future treatment. Finally , the subject and parent/ LAR will be told that the investigator 
will maintain a subject ID register for the purposes of long-term follow -up if needed, and that their 
records may be accessed by [CONTACT_369038], to the extent permitted by [CONTACT_6983](s) or regulations. 
By [CONTACT_369039]/ICF the subject and parent/ LAR are authorizing such access, 
including permission to obtain information about his or her survival status, and agree to allow their 
study  physician to recontact [CONTACT_43774], if needed, and subsequent disease -related treatment, or to obtain information about 
his or her survival status. The subject and parent/ LAR will be given sufficient time to read the ICF 
and the opport unity  to ask questions. Parent/LAR ICF(s) and the pediatric assent form(s) must be 
signed before performance of any study -related activity . The ICF(s) and assent form (s)that are 
used must be approved by [CONTACT_8135]/I RB and bein a language 
that the parent/ LAR and subject can read and understand. The informed consent/assent should be 
in accordance with principles that originated in the Declaration of Hel sinki, current I CH and GCP 
guidelines, applicable regulatory  requirements, and sponsor policy . After having obtained the 
consent and assent, a copy both must be g iven to the subject and parent/ LAR.
Children (minors) who reach the age of majorit y during thestudy  will be reconsented using a 
provided adult written ICF per applicable local regulations and the I RB/IEC requirements. 
Subjects and parent (s)/LAR(s) will be asked for consent to provide optional samples for research 
(where local regulations permit). After informed consent for the study  is appropriatel y obtained, 
the subject and his or her parent (s)/LAR (s)will be asked to sign and personally  date a separate 
ICF indicating agreement to participate in the optional research component. Refusal to participate 
in the optional research will not result in ineligibility  for the study . A copy of this signed 
ICF(s)/assent(s) will be given to the subject and paren t(s)/LAR(s).
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be limited 
to those data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized disclosures 
or access, accide ntal or unlawful destruction, or accidental loss or alteration must be put in place. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 132
Status: Approved , Date: 22 November 2020Sponsor personnel whose responsibilities require access to personal data agree to keep the identity 
of subjects confidential.
The informed consent /pediatric assent obtained from the subject and his or her parent(s)/LAR(s)
includes explicit consent for the processing of personal data and for the investigator /institution to 
allow direct access to his or her original medical records (source data/documents) for study -related 
monitoring, audit, IEC/IRB review, and regulatory  inspection. This consent also addresses the 
transfer of the data to other entities and to other countries.
The subject (s) or their parent(s)/LARs has the right to request through the investigator access to 
his or her personal data and the right to request rectification of any data that are not correct or 
complete. Reasonable steps will be taken to respond to such a request, taking into consideration 
the nature of the request, the conditions of the study , and t he applicable laws and regulations.
Exploratory  DNA, biomarker andPK research is not conducted under standards appropriate for 
the return of data to subjects. In addition, the sponsor cannot make decisions as to the significance 
of any findings resulting from exploratory  research. Therefore, exploratory research data will not 
be returned to subjects or investigators, unless required by [CONTACT_23844] . Privacy  and 
confidentiality  of data generated in the future on stored samples will be protected by [CONTACT_67828].
16.2.5. Long -Term Retention of Samples for Additional Future Research 
Samples collected in this study  may be stored for up to 15 y ears (or according to local regulations) 
for additional research. Sample s will only be used to understand esketamine , to understand 
depression and suicidality , to understand differential drug responders, and to develop tests/assays 
related to esketamine and depression and suicidality . The research may begin at any time during 
the study  or the post study  storage period. 
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects or their parent(s)/LAR (s)may withdraw their consent 
for their /their child’s samples to be stored for research ( refer to Section 10.3, Withdrawal from the 
Use of Research Samples).
16.2.6. Country Selection
This study  will only be conducted in those countries where the intent is to launch or otherwise help 
ensure access to the developed product if the need for the product persists , unless explicitly  
addressed as a specific ethical consideration in Section 16.1, Study -Specific Design 
Considerations.
17. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify this protocol without a formal amendment b y 
the sponsor. All protocol amendments must be issued by  [CONTACT_369040] 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 133
Status: Approved , Date: [ADDRESS_462152] not be implemented withou t prior IEC/IRB approval, or 
when the relevant competent authority  has raised any grounds for non-acceptance, except when 
necessary  to eliminate immediate hazards to the subjects, in which case the amendment must be 
promptly  submitted to the IEC/IRB and relevant competent authorit y. Documentation of 
amendment approval b y the investigator and IEC/IRB must be provided to the sponsor. When the 
change(s) involves only logistic or administrative aspects of the study , the IEC/IRB (where 
required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact [CONTACT_90814] (s), which will be provided as a separate document . Except 
in emergency  situations, this contact [CONTACT_90815]. In all cases, contact [CONTACT_369041] a nd agree on an appropriate course of action. The data recorded in the eCRF and source 
documents will reflect any departure from the protocol, and the source documents will describe 
this departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory  
requirements are met.
17.2.2. Requir ed Prestudy  Documentation
The following documents must be provided to the sponsor before shipment of study  drug to the 
study site:
Protocol and amendment(s), if an y, signed and dated by [CONTACT_458]
A copy of the dated and signed (or sealed, where appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by [CONTACT_23850] (or sealed, where appropriate per local 
regulations) by [CONTACT_23851].
Name [CONTACT_23875]/IRB, including a current list of the I EC/I RB members and their 
function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, from 
the IEC/IRB, a general statement may be substituted for this list. If an investigator or a 
member of the study -site personnel isa member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the vote/opi[INVESTIGATOR_66821] .
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 134
Status: Approved , Date: 22 November 2020Documentation of investigator qualifications (eg, curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial agreement, which includes the financial agreement
Any other documentation required by  [CONTACT_43782]:
Completed investigator financial disclosure forms from all subinve stigators
Documentation of sub -investigator qualifications (eg, curriculum vitae)
Name [CONTACT_23876] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by [CONTACT_66886] -site contact [CONTACT_23853].
The subject identification and enrollment log will be treated as confidential and will be filed by 
[CONTACT_23854]. To ensure subject confidentiality , no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by [CONTACT_369042]. In cases where the subject is not randomized into thestudy , the date seen 
and date of birth will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for inclusion in the study .
17.4. Source Documentation
At a minimum, source document s consistent in the type and level of detail with that commonly  
recorded at the study  site as a basis for standard medical care must be available for the following: 
subject identification, eligibility , and study  identification; study  discussion and date of signed 
informed consent /pediatric assent ; dates of visits; results of safet y and efficacy  parameters as 
required by [CONTACT_760]; record of all adverse events and follow -up of adverse events; concomitant 
medication; drug receipt/dispensing/return records; study  drugadministration information ; and 
date of study  completion and reason for early discontinuation of study  drug or withdrawal from 
the study , if applicable. 
The author of an entry  in the source documents should be identifiable.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 135
Status: Approved , Date: 22 November 2020Specific details required as source data for the study  and source data collection methods will be 
reviewed with the investigator before the study and will be described in the monitoring guidelines 
(or other equivalent document).
Subject -and investigator -completed scales and assessments designated by [CONTACT_369043]. The CDRS -R, MADRS, SIBAT, CDI 2:SR(S), MOAA/S, YM RS, 
PWC -20, BPRS+, MINI -KID, Cogstate computerized cognitive battery , TLFB (including paper 
calendar) , nasal sy mptom questionnaire, and C ADSS will be considered source data.
The minimum source documentation requirements for Section 4.1,Inclusion Criteria and 
Section 4.2,Exclusion Criteria that specify a need for documented medical history are as follows:
Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by [CONTACT_41047] (eg, physical examinat ion, 
laboratory  assessment) and documented in the source documents.
An electronic source system may be utilized, which contains data traditionally  maintained in a 
hospi[INVESTIGATOR_23749] (eg, electronic source documents) as well as the 
clinical study -specific data fields as determined by [CONTACT_760]. This data is electronically 
extracted for use b y the sponsor. If the electronic s ource system is utilized, references made to the 
eCRF in the protocol include the electronic source system but information collected through the 
electronic s ource system may not be lim ited to that found in the eCRF. Data in this sy stem may be 
considered source documentation.
17.5. Case Report Form Completion
Case report forms are prepared and provided by  [CONTACT_66888].
All eCRF entries, corrections, and alterations must be made by [CONTACT_170191] -site personnel. The investigator must verify  that all data entries in the eCRF are accurate and 
correct.
Electronic data capture (eDC) will be used for this study. The study  data will be transcribed by 
[CONTACT_3449] -sitepersonnel from the source documents onto an eCRF, and transmitted in a secure manner 
to the sponsor within the timeframe agreed upon between the sponsor and the study  site. The 
electronic file will be con sidered to be the eCRF. 
Worksheets may be used for the capture of some data to facilitate completion of the eCRF. Any 
such worksheets will become part of the subject's source document s. Data must be entered into 
eCRF in English. The CRF must be completed as soon as possible after a subject visit and the 
forms should be available for review at the next scheduled monitoring visit.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 136
Status: Approved , Date: 22 November 2020All subjective measurements (eg, scale information or other questionnaires) will be completed by 
[CONTACT_66890].
The investigator must verify  that all data entries in the eCRF are accurate and correct. All eCRF 
entries, corrections and alterations must be made by [CONTACT_369044] y-site 
perso nnel. If necessary , queries will be generated in the eDC tool. If corrections to an eCRF are 
needed after the initial entry  into the eCRF, this can be done in either of the following ways:
Investigator and study-site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  [CONTACT_66832]) .
Sponsor or sponsor delegate can generate a query  for resolution by [CONTACT_70449] -
site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to betaken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , periodic monitoring visits by[CONTACT_456], and direct 
transmission of clinical laboratory  data from a central laboratory  into the sponsor's data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples. 
Guidelines for eCRF completion willbe provided and reviewed with study -sitepersonnel before 
the start of the stud y.
The sponsor will review eCRF for accuracy  and completeness during on-site monitoring visits and 
after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the study database they  will be verified for 
accuracy  and consistency with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRF 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in I CH/GCP Section 8, Essential Documents for the Conduct of a Clinical 
Trial, and all study  documents as specif ied by [CONTACT_23859](s). The 
investigator/institution will take measures to prevent accidental or premature destruction of these 
documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing applications 
in an I CH region or until at least [ADDRESS_462153]. These documents will be retained for a longer period 
if required by [CONTACT_66891]. It is the 
responsibility  of the sponsor to inform the investigator/institution as to when these documents no 
longer n eed to be retained.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 137
Status: Approved , Date: [ADDRESS_462154] be notified in writing of the name [CONTACT_66903]. Under no circumstance shall the investigator relocate or dispose of any study documents 
before having obtained written approval from the sponsor.
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such reports.
17.8. Monitoring
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will
record dates of the visits in a study  site visit log that will be kept at the study site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compar e the data entered into the eCRF with the source documents
(eg,hospi[INVESTIGATOR_307]/clinic/phy sician’s office medical records) ; a sample may be reviewed . The nature and 
location of all source documents will be identified to ensure that all sources of original data 
required to complete the eCRF are known to the sponsor and study -site personnel and are 
accessible for verification by [CONTACT_43786] -site contact. If electronic records are maintained 
at the study site, the method of verification must be discussed with the study -site personnel . 
Direct access to source document s(medical records) must be allowed for the purpose of verifying 
that the recorded data are consistent with the original source data. Findings from this review will 
be discussed with the study -site personnel . The sponsor expects that, during monitoring visits, the 
relevant study -site personnel will be available, the source document swill be accessible, and a 
suitable environment will be provided for review of study -related documents. The monitor will 
meet with the investigator on a regular basis during the study to provide feedback on the study
conduct.
In addition to on -site monitoring visits, remote contacts can occur. It is expected that during these 
remote contacts, study- site personnel will be available to provide an update on the progress of the 
study  at the site. 
Central monitoring will take place for data identified by  [CONTACT_70467].
17.9. Study Completion/Termination
17.9.1. Study Completion /End of Study
The study  is considered completed with the last study assessment for the last subject participating 
in the study .The final data from the study site will be sent to the sponsor (or designee) after 
completion of the final subject assessment at that study  site, in the time frame specified in the 
Clinical Trial Agreement.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 138
Status: Approved , Date: [ADDRESS_462155] been collected 
and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of a study site by [CONTACT_66892]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  [CONTACT_093]
Discontinuation of further study  drug development
17.10. On-Site A udits
Representatives of the sponsor' s clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study
records, including source documents, for inspection. Subject privacy  must, however, be respected. 
The investigator and study -site personnel are responsible for being present and available for 
consultation during routinely  scheduled study -site audit visits conducted by [CONTACT_66893]. 
Similar auditing procedures may also be conducted by [CONTACT_23865], either as part 
of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submissio n. The investigator should immediately  notify  the sponsor if he or shehas
been contact[INVESTIGATOR_530] b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding esket amine or the sponsor's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by [CONTACT_43787], and any data, including pharmacogenomic or exploratory  biomarker
research data, generated as a result of this study , areconsidered confidential and remain the sole 
propert y of the sponsor. The investigator agrees to maintain this information in confidence and use 
this informatio n only to accomplish this study  andwill not use it for other purposes without the 
sponsor's prior written consent.
The investigator understands that the information developed in the study will be used by [CONTACT_369045] , and thus may  be disclosed 
as required to other clinical investigators or regulatory  agencies. To permit the information derived 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 139
Status: Approved , Date: [ADDRESS_462156] identifiers will not be used in publication o f results. Any  work created in connection with 
performance of the study  and contained in the data that can benef it from copyright protection 
(except any publication by [CONTACT_40999]) shall be the propert y of the 
sponsor as author and owner of cop yright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, t he sponsor shall have the right to publish such primary  (multicenter) data and 
information without approval from the investigator. The investigator has the right to publish study 
site-specific data after the primary  data are published. If an investigator wishes to publish 
information from the study ,a copy of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by [CONTACT_170196], the investigator will withhold such publication for up to an additional 60days to allow for 
filing of a patent application. In the event that issues arise regardin g scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with the investigator. The sponsor will 
not mandate modifications to scientific content and does not have the right to suppress information.
Formulticenter stud y designs and substud y approaches, secondary  results generall y should not be 
published before the primary  endpoints of a study  have been published. Similarly , investigators 
will recognize the integrity  of a multicenter study by [CONTACT_369046], within 12months of the availability  of the final data (tables, listings, 
graphs), or the sponsor confirms there will be no multicenter study  publication. Authorship of 
publications resulting from this study  will be based on the guidelines on authorship, such as those 
described in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, which 
state that the named authors must have made a significant contribution to the design of the study 
or analysis and interpretation of the data, provided critical review of the paper, and given final 
approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as required by 
[CONTACT_2371].
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 140
Status: Approved , Date: 22 November 2020REFERENCES
1. Allgaier A, Frühe, B, Pi[INVESTIGATOR_9245] K, Saravo B, Baethmann M, Schulte- Körne, G.  Is the Children's Depression 
Inventory Short version a valid screening tool in pediatric care? A comparison to its full -length version. 
Journal of Psychosomatic Research .2012 ;75(5),369 -374.
2. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of 
children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007;46:1503 -1526.
3. Ates-Alagoz Z, Adejare A. NMDA receptor antagonists for treatment of depression. Pharmaceuticals. 
2013;6(4):[ADDRESS_462157] ED, Ionescu DF, Vande Vort JL, et al. Improvement in suicidal ideation after ketamine infusion: 
relationship to reductions in depression and anxiety. J Psych Res. 2014;58:[ADDRESS_462158] ED, Luckenbaugh DA, Richards EM, et al. Assessing measures of suicidal ideation in clinical t rials
with a rapid -acting antidepressant. J Psychiatr Res. 2015;68:68 -73.
6. Bangirana P, Sikorskii A, Giordani B, Nakasuija N, Boivin MJ. Validation of the CogState battery for rapid 
neurocognitive assessment in Ugandan school age children. Child Adolesc Psy chiatry Ment Health. 2015: 
9(38).
7. Barnett R, Maruff P, Vance A. An investigation of visuospatial memory impairment in children w ith attention 
deficit hyperactivity disorder (ADHD), combined type. Psychol Med. 2005; 35(10): 1433 -1443.
8. Bazett HC. An analysis of the time -relationship of electrocardiograms. Heart. 1920;7:353 -380.
9. Beardsley PM, Balster RL. Behavioral dependence upon phencyclidine and ketamine in the rat. J Pharmacol 
Exp Ther. 1987;242:203 -211.
10. Beautrais AL, Joyce PR, Mulder RT. Psychiatric illne ss in a New  Zealand sample of young people making 
serious suicide attempts. N Z Med J. 1998;111(1060):44 –48.
11. Bickley H, Hunt IM, Windfuhr K, Shaw  J, Appleby L, Kapur N. Suicide within two weeks of discharge from 
psychiatric inpatient care: a case- control s tudy. Psychiatr Serv. 2013;64(7):653 -659.
12. Bredlau AL, Harel BT, McDermott MP, Dw orkin RH, Korones DN, Dolan JG, Adams HR. Neurocognitive 
Changes after Sustained Ketamine Administration in Children with Chronic Pain . J Palliat Care Med . 2015 : 2; 
pii 215.
13. Bremmer JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM. Measurement of 
dissociative states with the Clinician -Administered Dissociative States Scale (CADSS). J Trauma Stress. 
1998;11(1):125 -136.
14. Brent DA, Baugher M, Bridge J, Chen T , Chiappetta L. Age -and sex -related risk factors for adolescent 
suicide. J Am Acad Child Adolesc Psychiatry. 1999;38(12):1497 -1505.
15. Brent DA, Greenhill LL, Compton S, et al. The Treatment of Adolescent Suicide Attempters study (TASA): 
predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry. 
2009;48(10):987 -996.
16. Briefing Book JNJ -54135419 -AAC (esketamine hydrochloride). Esketamine for Rapid Reduction of 
Symptoms of Major Depressive Disorder, including Suicidality, in Pat ients who are Assessed to be at 
Imminent Risk for Suicide (25 Aug 2016).
17. Centers for Disease Control: Suicide Prevention Available from: 
http://www.cdc.gov/violenceprevention/suicide/youth_suicide html. Accessed 12 January 2016.
18. Chang T, Savory A, Albin M, Goulet R, Glasko AJ. Metabolic disposition of tritium -labelled ketamine 
(Ketalar®, CI-581) in normal human subjects. Clin Res. 1970;18:597.
19. Cheung A, Emslie G, Mayes TL. Review of the efficacy and safety of antidepressants in youth depression. J 
Child Psy chol and Psychiatry. 2005;46(7):735 -754.
20. Cheung A, Zuckerbrot RA, Jensen PS, et al. Guidelines for Adolescent Depression in Primary Care (GLAD -PC): II. 
Treatment and Ongoing Management. PEDIATRICS Volume 120, Number 5, November 2007. e1313 -1326. 
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 141
Status: Approved , Date: 22 November 202021. Cincinnat i Children's Hospi[INVESTIGATOR_29349]. Best Evidence Statement (BESt): Treatment of Children and 
Adolescents With Major Depressive Disorder (MDD) During the Acute Phase. Cincinnati, OH: Cincinnati 
Children's Hospi[INVESTIGATOR_29349]; 2010.
22. Clark MS, Jansen K L, Cloy JA. Treatment of childh ood and adolescent depression. Ame r Fam  Physician. 
2012; 86(5):442 -448.
23. Clinical Study Report ESKETINTRD2003. A Double- Blind, Doubly -Random ized, Placebo -Controlled Study 
of Intranasal Esketamine in an Adaptive Treatment Protocol to Assess Safety and Efficacy in Treatment -
Resistant Depression (29 Apr 2016).
24. Collins GT, Woods JH. Drug and reinforcement history as determinants of the response -maintaining effects of 
quinpi[INVESTIGATOR_313304]. J Pharmacol Exp Ther. 2007;323:599 -605.
25. Collins RJ, Weeks JR, Cooper MM, Good PI, Russell RR. Prediction of abuse liability of drugs using IV self -
administration by [CONTACT_116434]. Psychopharmacology. 1984;82:6 -13.
26. Committee for Medicinal Products for Human Use (CHMP) and Paediatric Committee (PDCO). Guideline on 
the investigation of medicinal products in the term and preterm neonate; London, 25 June 2009. Doc Ref 
EMEA/536810/2008.
27. Critchlow DG. A case of ketamine dependence with discontinuation symptoms. Addiction. 2006;101:[ADDRESS_462159] .2016 : 46(4); 1455 -1463.
29. Curran HV, Morgan C. Cognitive, dissociative and psychotogenic effec ts of ketamine in recreational users on 
the night of drug use and 3 days later. Addiction. 2000;95:575 -590.
30. Deisenhammer EA, Ing CM, Strauss R, Kemmler G, Hinterhuber H, Weiss EM. The duration of the suicidal 
process: how  much time is left for intervention betw een consideration and accomplishment of a suicide 
attempt? J Clin Psychiatry. 2009; 70(1):[ADDRESS_462160] in pat ients with treatment -resistant major depressive disorder. J Clin 
Psychiatry.  2010;71(12):1605 -1611.
32. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and 
adolescents: a placebo -controlled, randomized c linical trial. J Am Acad Child Adolesc Psychiatry. 
2002;41(10):1205 –1215.
33. Emslie GJ, Heiligenstein JH, Wagner KD, et al. Fluoxetine for acute treatment of depression in children and 
adolescents: a placebo -controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 
2002;41(10):1205 -1215.
34. European Medicines Agency. Ethical considerations for clinical trials on medicinal products with the 
paediatric population. Available from: http://ec.europa.eu/health/files/eudralex/vol -
10/ethical_considerat ions_en.pdf. Accessed [ADDRESS_462161] 2015 .
35. Fals-Stewart W, O’Farrell TJ, Freitas TT, McFarlin SK, Rutigliano P. The timeline followback reports of 
psychoactive substance use by [CONTACT_9934] -abusing patients: psychometric properties. J Consul Clin Psychol. 2000: 
68(1); 134-144.
36. Geisslinger G, Hering W, Thomann P, Knoll R, Kamp H -D, Brune K. Pharmacokinetics and 
pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J 
Anaesth. 1993;70:666 -671.
37. Gould MS, King R, Greenwal d S, et al. Psychopathology associated w ith suicidal ideation and attempts among 
children and adolescents. J Am Acad Child Adolesc Psychiatry. 1998;37(9):915 –923.
38. Grant IS, Nimmo WS, McNicol LR, Clements JA. Ketamine disposition in children and adults. Br J Anaesth. 
1983;55(11):1107 -1111 .
39. Haas DA, Harper DG. Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia. 
Anesth Prog. 1992;39:61 -68.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 142
Status: Approved , Date: 22 November 202040. Hagelberg NM, Peltoniemi MA, Saari TI, et al. Clarithromycin, a potent inhibitor of CYP3A , greatly increases 
exposure to oral S -ketamine. Eur J Pain. 2010;14:[ADDRESS_462162] D, Anderson BJ. Ketamine disposition in children presenting for procedural sedation and analgesia in a 
children's emergency department. Paediatr Anaesth. 2007;17(7):[ADDRESS_462163] NH. Modeling the norketamine metabolite in children and the implications 
for analgesia. Paediatr Anaesth. 2007;17(9):831 -840.
43. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N -demethylation of 
ketamine in human liver microsomes. Drug Metab Dispos. 2002;30:853 -858.
44. Hodges M, Salerno D, Erlien D. Bazett’s QT correction review ed: evidence that a linear QT correction for 
heart rate is better. J Am Coll Cardiol. 1983;1:694.
45. How ie SRC, Blood sample volumes in child health research: review  of safe limits. Bull World Health Organ 
2011;89:46 -53.
46. Hurt PH, Ritchie EC. A case of ketamine dependence. Am J Psychiatry. 1994;151:779.
47. International Council for Harmonisation of Technical Requirements for Registr ation of Pharmaceuticals for 
Human Use. ICH Harmonized Tripartite Guideline E14: Clinical evaluation of QT/QTc interval prolongation 
and proarrhythmic potential for non -antiarrhythmic drugs. ICH 12 May 2005.
48. Investigator’s Brochure, JNJ -54135419 -AAC (esket amine hydrochloride). Edition 4 , Janssen Research & 
Development, LLC (12 February 2015) .
49. Investigator’s Brochure, JNJ -54135419 -AAC (esketamine hydrochloride). Edition 4, Addendum 1. Janssen 
Research & Development, LLC (21 June 2016) .
50. Investigator’s Brochur e, JNJ -54135419 -AAC (esketamine hydrochloride). Edition 4, Addendum 2. Janssen 
Research & Development, LLC (14 September 2016) .
51. Jain S, Carmody TJ, Trivedi M, et al. A psychometric evaluation of the CDRS and MADRS in assessing 
depressive symptoms in childr en. J Am Acad Child Adolesc Psychiatry. 2007;46(9):1204 -1212.
52. Jansen KL. Ketamine --can chronic use impair memory? Int J Addict. 1990;25:133 -139.
53. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004;292:338 -343.
54. Kessler R C, Berglund P, Borges G, et al. Trends in suicide ideation, plans, gestures, and attempts in the United
States, 1990 -1992 to 2001 -2003. JAMA. 2005; 293(20):2487 -2495.
55. Ketalar® (ketamine hydrochloride injection, USP) [[LOCATION_002] Prescribing Information]. JHP 
Pharm aceuticals, LLC; March 2012.
56. Ketanest -S [Summary of Product Characteristics]. Ankeveen, Netherlands: Eurocept BV; 2011.
57. Koffarnus MN, Hall A, Winger G. Individual differences in rhesus monkeys’ demand for drugs of abuse. 
Addict Biol. 2011;17:887 -896.
58. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg. 1998;87:1186 -1193.
59. Kovacs M. Children’s Depression Inventory 2 (CDI 2) (2nd edition). J Psychoeducational Assessment. 
2012;30(3)304 -308.
60. Larkin GL, Beautrais AL. A prelimina ry naturalistic study of low -dose ketamine for depression and suicide 
ideation in the emergency department. Int J Neuropsychopharmacol. 2011;14 (8):1127 -1131.
61. Lewandowski RE, Acri,MC, Hoagw ood KE, et al. Evidence for the management of adolescent depression . 
Pediatrics. 2013;132(4):e996 -e100.
62. Lewis -Esquerre JM, Colby [CONTACT_10009], Tevyaw TO, Eaton CA, Kahler CW, Monti PM. Validation of the timeline 
follow -back in the assessment of adolescent smoking. Drug Alcohol Depend. 2005: 79(1); 33 -43.
63. Lim DK. Ketamine associated psychedelic effects and dependence. Singapore Med J. 2003;44:31 -34.
64. Lim YY, Prang K H, Cysique L, Pi[INVESTIGATOR_58628] R H, Snyder PJ, Maruff P.A method for cross -cultural adaptation of 
a verbal memory assess ment. Behavior Research Methods. 2009: 41(4); 1190 -1200.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 143
Status: Approved , Date: 22 November 202065. Lindenmayer JP, Czobor P, Alphs L, et al. InterSePT Study Group. The InterSePT Scale for Suicidal Thinking 
reliability and validity. Schizophr Res. 2003;63(2):161 -170.
66. Malinovsky JM, Servin F, Cozian A, Lepage JY, Pi[INVESTIGATOR_368971] M. Ketamine and norketamine plasma concentrations 
after i.v., nasal and rectal administration in children. Br J Anaesth. 1996;77(2):203 -207.
67. Mathew SJ, Shah A, Lapi[INVESTIGATOR_27562] K, et al. Ketamine for treatment -resistant unipolar depression: current evidence. 
CNS Drugs. 2012;26 (3):189 -204.
68. Mathew SJ , Shah A, Lapi[INVESTIGATOR_27562] K, et al. Ketamine for treatment -resistant unipolar depression: current evidence. 
CNS Drugs. 2012;26:[ADDRESS_462164] BD, Emslie GJ. Psychometric properties of the Children's 
Depression Rating Scale -Revis ed in adolescents. J Child Adolesc Psychopharmacol. 2010;20(6):513 -516.
70. Midazolam Injection USP. [[LOCATION_002] Prescribing Information]. Sagent Pharmaceuticals; September, 2012.
71. Midazolam Syrup. Available at http://www.drugs.com/pro/midazolam -syrup.html.
72. Midazolam -ratiopharm® 2mg/ml Oral Solution: Full Prescribing Information. Ratiopharm GmbH; November, 
2015.
73. Midazolam -ratiopharm® 2mg/ml Oral Solution: Summary of Product Characteristics. Ratiopharm GmbH; 
November 2015.
74. Montgomery SA, Asberg M. A new depres sion scale designed to be sensitive to change. Br J Psychiatry. 
1979;134:[ADDRESS_462165] sizes in depression. Eur Neuropsychopharmacology. 
1994;(4)283 -284.
76. Moore NN, Bostw ick JM. Ketamine dependence in anesthesia provider s. Psychosomatics. 1999;40:356 -359.
77. Moreton JE, Meisch RA, Stark L, Thompson T. Ketamine self -administration by [CONTACT_313374]. J Pharmacol 
Exp Ther. 1977;203:303 -309.
78. Morgan CJ, Muetzelfeldt L, Curran HV. Ketamine use, cognition and psychological wellbeing : a comparison 
of frequent, infrequent and ex -users with polydrug and non -using controls. Addiction. 2009;104:77 -87.
79. Morgan CJA, Curran HV, Independent Scientific Committee on Drugs. Ketamine use: a review. Addiction. 
2012;107:27 -38.
80. Morgan CJA, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. 
Psychopharmacology. 2006;188:408 -424.
81. Morgan CJA, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self -administration upon 
neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction. 
2010;105:[ADDRESS_462166] of intranasal esketamine on cognitive functioning in healthy 
participants: A randomized, double -blind, placebo -controlled study. Poster presented at: S ociety of Biological 
Psychiatry, May, 2016, Atlanta GA. 
83. Muetzelfeldt L, Kamboj SK, Rees H, Taylor J, Morgan CJ, Curran HV. Journey through the K -hole: 
phenomenological aspects of ketamine use. Drug Alcohol Depend. 2008;95:219 -229.
84. Murrough J, Perez, A, Pi [INVESTIGATOR_61628] S, et al. Rapid and longer -term antidepressant effects of repeated ketamine 
infusions in treatment -resistant major depression. Biol Psychiatry. 2013;74(4):250 -256.
85. Murrough JW, Iosifescu MD, Chang L, et al. Antidepressant Efficacy of Ketamine in Treatment- Resistant
Major Depression: A T wo-Site Randomized Controlled Trial. Am J Psychiatry. 2013;170(10):1134 -1142.
86. Murrough JW, Perez AM, Pi[INVESTIGATOR_61628] S, et al. Rapid and longer -term antidepressant effects of repeated ketamine 
infusions in treatment -resistant major depression. Biol Psychiatry. 2013;74(4):250 -256.
87. Murrough JW, Soleimani L, deWilde KE, et al. Ketamine for rapid reduction of suicide ideation: a randomized 
controlled trial. Psychol Med. 2015;45(16);3571 -3580.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 144
Status: Approved , Date: 22 November 202088. Murrough, JW, Burdick KE, Levitch CF, et al. Neurocognitive effects of ketamine and association with 
antidepressant response in individuals with treatment -resistant depression: A randomized controlled trial. 
Neuropsychopharmacology. 2015;40:1084 –1090.
89. Narendran R, Frankle WG, Keefe R, et al. Altered prefrontal dopaminergic function in chronic recreational 
ketamine users. Am J Psychiatry. 2005;162:2352 -2359.
90. National Institute for Health and Clinical Excellence (NICE) Depression in children and young people: 
identification and management. Clinic al Guideline 28. National Collaborating Centre for Mental Health, 
London: March 2015. Available from: https://www.nice.org.uk/guidance/cg28 . Accessed 5 December 2016 .
91. National Institute for Health and Clinical Excellence (NICE) Depression in adults: recogn ition and 
management. Clinical Guideline 90. National Collaborating Centre for Mental Health, London: October 2009. 
https:// www.nice.org.uk/guidance/CG90. A ccessed 16 September 2016.
92. Nock MK, Borges G, Bromet EJ, et al. Cross -national prevalence and risk factors for suicidal ideation, plans, 
and attempts in the WHO World Mental Health Surveys. Br J Psychiatry. 2008;192(2):98 -105.
93. Nock MK, Green JG, Hw ang I, et al. Prevalence, correlates, and treatment of lifetime suicidal behavior among 
adolescents: results from the National Comorbidity Survey Replication Adolescent Supplement. JAMA 
Psychiatry. 2013;70(3):300 -310.
94. Oye I, Paulsen O, Maurset A. Effects of ketamine on sensory perception: evidence for a role of N -methyl -D-
aspartate receptors. J Pharmacol Exp The r. 1992;260:1209 -1213.
95. Pal HR, Berry N, Kumar R, Ray R. Ketamine dependence. Anaesth Intensive Care. 2002;30:382 -384.
96. Pam bianco DJ, Vargo JJ, Pruitt RE, Hardi R, Martin JF. Computer -assisted personalized sedation for upper 
endoscopy and colonoscopy: a comp arative, multicenter randomized study. Gastrointest Endos c.
2011;73(4):765 -772.
97. Papakostas G, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta -
regression of double -blind, randomized clinical trials in MDD. Eur Neur opsy chopharmacol. 2008;19(1):34 -40.
98. Pharm acokinetic Report KET -PK-007. A randomized, open label, single center, single dose, cross -over study 
to determine the absolute bioavailability and the nasopharyngeal absorption of PMI -150 (intranasal ketamine) 
in he althy adult volunteers. Javelin Pharmaceuticals, Inc (31 October 2008 ).
99. Portmann S, Kwan HY, Theurillat R, Schmitz A, Mevissen M, Thormann W. Enantioselective capi[INVESTIGATOR_154894] P450 enzyme s which metabolize 
ketamine and norketamine in vitro. J Chromatogr A. 2010;1217:7942 -7948. 
100. Price RB, Iosifescu DV, Murrough JW, et al. Effects of ketamine on explicit and implicit suicidal cognition: a 
randomized controlled trial in treatment -resistant depression. Depress Anxiety. 2014;31(4):335 -343.
101. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit 
measures of suicidality in treatment -resistant depression. Biol Psychiatry. 2009; 66:522 -526.
102. Prinstein M, Noc k M, Simon V, Aikins JW, Cheah CSL, Spi[INVESTIGATOR_50175] A. Longitudinal trajectories and predictors of 
adolescent suicidal ideation and attempts following inpatient hospi[INVESTIGATOR_059]. J Consult Clin Psychol. 
2008;76(1):92 -103.
103. Rasmussen KG, Lineberry TW, Galardy CW, et al. Serial infusions of low -dose ketamine for major 
depression. J Psychopharmacol. 2013; 27(5):444 -450.
104. Reed MD, Rodarte A, Blumer JL, et al. The single -dose pharmacokinetics of midazolam and its primary 
metabolite in pediatric patients after oral and intr avenous administration. J C lin Pharmacol. 
2001;41(12):1359 -1369.
105. Reich DL, Silvay G. Ketamine: an update on the first twenty -five years of clinical experience. Can J Anaesth. 
1989;36:[ADDRESS_462167] (PWC -20). Journal of 
Clinical Psychopharmacology . 2008; 28(4):[ADDRESS_462168]. 1988;15(3):227 –233.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 145
Status: Approved , Date: [ADDRESS_462169], et al. Reliability and validity of the mini international neuropsychiatric 
interview for children and adolescents (MINI -KID). J Clin Psychiatry. 2010;71( 3):313 -326.
109. Simon GE, Savarino J. Suicide attempts among patients starting depression treatment with medications or 
psychotherapy. Am J Pyschiatry. 2007;164:1029 -1034.
110. Sinner B, Graf BM. Ketamine. In: Schüttler J, Schwilden H, eds. Modern Anesthetics: Hand book of 
Experimental Pharmacology. Berlin: Springer -Verlag; 2008;182:313 -333.
111. Veal GJ. Blood volumes in pediatric clinical trials: a review of current regulations and guidance for research 
studies. Clin Invest (Lond) 2014;4(11):1005 -1011.
112. Vesierra® [Summar y of Product Characteristics]. Sandwich, Kent, [LOCATION_008]: [COMPANY_007] Limited; 2014.
113. Vitiello B, Brent D, Greenhill LL, et al. Depressive symptoms and clinical status during the treatment of 
adolescent suicide attempters study (TASA). J Am Acad Child Adolesc Psychiatry 2009;48(10):997 -1004.
114. Wasserman D, Rihmer Z, Rujescu D, et al. The European Psychiatric Association (EPA) guidance on suicide 
treatment and prevention. Eur Psychiatry. 2012;27:[ADDRESS_462170]. 
1975;24:260 -263.
116. Williams JB, Kobak KA. Development and reliability of a structured interview guide for the Montgomery 
Asberg Depression Rating Scale (SIGMA). Br J Psychiatry. 2008;192:52 -58.
117. World Health Organizati on (WHO 2014). Preventing suicide: A global imperative. Available from: 
http://www. who.int/mental_health/suicide- prevention/w orld_report_2014/en/. Accessed 20 December 2015.
118. Yanagihara Y, Kariya S, Ohtani M, et al. Involvement of CYP2B6 in N- demethylation of ketamine in human 
liver microsomes. Drug Metab Dispos. 2001;29:887 -890.
119. Yanagihara Y, Ohtani M, Kariya S, et al. Plasma concentration profiles of ketamine and norketamine after 
administration of various ketamine preparations to healthy Japanese voluntee rs. Biopharm Drug Disp. 
2003;24(1):37 -43.
120. Young AM, Herling S, Winger GD, Woods JH. Comparison of discriminative and reinforcing effects of 
ketamine and related compounds in the rhesus monkey. NIDA Res Monogr. 1981;34:173 -179.
121. Young AM, Woods JH. Maintenan ce of behavior by [CONTACT_313375] -administration histories. J Pharmacol Exp Ther. 1981,218:720 -727.
122. Young RC, Biggs JT, Ziegler VE, Meyer, DA. A rating scale for mania: reliability, validity and sensitiv ity. 
British Journal of Psychiatry (1978), 133, 429 -435.
123. Zarate C, Brutsche NE, Ibrahim L, et al. Replication of ketamine’s antidepressant efficacy in bipolar 
depression: a randomized controlled add -on trial. Biol Psychiatry. 2012;71: 939 -946.
124. Zisowski J, Krause A, Diingemanse J. Druge development for pediatric populations: Regulatory aspects. 
Available from: http://www.ncbi nlm.nih.gov/pmc/articles/PMC3967144/ . Accessed 20 December 2016.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 146
Status: Approved , Date: 22 November 2020Attachment 1:Prohibited /Permitted Concomitant Medications 
This list of medications is not all -inclusive ; it is intended for general guidance.  Please contact [CONTACT_369047].
The pharmacotherapi[INVESTIGATOR_313307] (Y), permitted with restrictions (Y*) with additional 
guidance or restrictions in the “Comments” column, or excluded (N) due to potential impact on efficacy 
evaluation and/or subject safety, or because they are indicated for exclusionary conditions.
Except where specifically noted in the table below, the prohibited therapi[INVESTIGATOR_313308] 1 day (24 hours) after the last dose of study medication.
Drug ClassEpi[INVESTIGATOR_170407] (as 
needed)Continuous 
Use Comments
ADHD medications
Atomoxetine N N
Amphetamines N Y On dosing days, should be held until at least [ADDRESS_462171] the medical 
monitor to discuss an alternate plan regarding the 
timing of dosing of these medications ,relative to 
study drug. Methylphenidate N Y
Clonidine Y Y Dose as usual
Guanfacine Y Y Dose as usual
Aldehydes and Derivatives
Chloral hydrate N N
Anorexiants 
Phentermine N N
Phendimetrazine N N
Anticonvulsants Y* N Use of anticonvulsants as adjunctive treatment 
for major depressive disorder (MDD) is 
prohibited. 
-Note: Anticonvulsants used for indications 
other than seizures (eg valproate for 
migraine) may be perm itted upon discussion 
with medical monitor 
Antidepressants 
(other than the three (3) 
specific antidepressants 
permitted as SoC per 
protocol )N N Taper and/ or Washout from prohibited 
antidepressant(s) will be per cli nician’s judgment 
on or before screening visit day. Antidepressants 
that are not perm itted during the double -blind
period may be started on Day [ADDRESS_462172] 
assessment (eg, 4-hour postdose assessment).
Note the exception of the use of Monoam ine 
Oxidase Inhibitors (MAOIs see below).
Antidepressant medications used for indications 
other than depression (eg trazodone for sleep) 
may be permitted upon discussion with the 
medical monitor. Trazodone should not be used 
within 8 hours prior to the start of study drug 
administration.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 147
Status: Approved , Date: 22 November 2020Drug ClassEpi[INVESTIGATOR_170407] (as 
needed)Continuous 
Use Comments
Antidepressants
Monoamine Oxidase 
InhibitorsN NProhibited from within [ADDRESS_462173] Generation Y* Y*Should not be used within 8 hours prior to study 
drug administration.
Second Generation 
Non-sedatingY Y
Antihypertensive Agents
Ketanserin N N
Antipsychotics Y N Low dose antipsychotic medications used for 
indications other than psychosis, bipolar disorder 
or antidepressant augmentation (eg,quetiapi[INVESTIGATOR_89913]) may be perm itted upon discussion with the 
Medical Monitor; however, they may not be used 
prior to the completion of Day [ADDRESS_462174] assessment 
(eg, 4 -hour postdose assessment).
Antivertigo Products 
Scopolamine N N
Antivirals
Amantadine N N
Anxiolytics and Sleep Aids
Benzodiazepi[INVESTIGATOR_1651] 
(at dosages equal to or 
less than the equivalent of 
6mg/day lorazepam) Y* Y*
Anxiolytics and Sleep Aids should not be used 
within 8 hours prior to study drug administration 
and/orcognitive testing. On Day 2, should not be 
used within 8 hours ofassessments.Hydroxyzine Y* Y*
Diphenhydramine Y* Y*
Zolpi[INVESTIGATOR_6730], Zaleplon, 
Eszopi[INVESTIGATOR_11123], and 
Ramelteon)Y* Y*
Melatonin Y Y
Cyamemazine 
(maximum of 
75mg/day, in doses no 
larger than 50 mg at a time)Y* Y*
Cardiac Preparations
Metyrosine N N
Centrally Acting Alpha Agonists
Clonidine Y Y
Methyldopa N N
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 148
Status: Approved , Date: 22 November 2020Drug ClassEpi[INVESTIGATOR_170407] (as 
needed)Continuous 
Use Comments
Corticosteroids Y* Y* Intermittent and continuous use of inhaled, 
intranasal, topi[INVESTIGATOR_2855], and ophthalmic 
corticosteroids are permitted.
Continuous use of oral corticosteroids may be 
acceptable for maintenance of stable chronic 
disease states (eg, rheumatologic and respi[INVESTIGATOR_195925]) but must be discussed w ith the 
medical monitor. Likewise, intermittent use of 
IM steroid must be discussed with the medical 
monitor.
Intermittent and continuous use of IV 
corticosteroid use is not permitted. 
Cough/cold 
Preparations/Nasal 
Solutions Containing 
Vasoconstrictors, 
Decongestants (Excluding 
Dextromethorphan) Y* Y* Intranasally -administered decongestants 
(vasoconstrictors) or saline solution / spray 
should not be used from 1 hour prior to study 
drug administration.
Pseudoephedrine -containing oral products should 
not be used within 12 hours prior to study drug 
administration.
Herbal Supplements (eg, 
Valerian, St. John’s Wort)N N
Mood Stabilizers
Lithium N N
Non-Opi[INVESTIGATOR_368972] N N
Opi[INVESTIGATOR_2438] Y* Y* Continuous use of oral opi[INVESTIGATOR_368973] (eg, sickle cell disease, 
rheumatologic conditions) but must be discussed 
with the medical monitor.
Illicit use is prohibited if criteria for moderate or 
severe substance use disorder are met. 
Oral Anti -Acne Retinoids 
Isotretinoin N Y* May only be used in consultation with the 
medical monitor .
Other Psychostimulants
Armodafanil N N
Modafinil N N
Rauwolfia Alkaloids 
Reserpi[INVESTIGATOR_050] N N
Thyroid hormone 
supplement for treatm ent 
of thyroid condition only 
(not for depression)N Y
Abbreviations: ADHD: attention -deficit/hyperactivity disorder, IM:intramuscular ,IV:intravenous , N: Prohibited ,
Y:permitted ,Y*:perm itted with restrictions (in the case of “permitted with restrictions”, please refer to the 
column labeled “Comments” for additional guidance or restrictions).
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 149
Status: Approved , Date: 22 November 2020Attachment 2:Growth Charts : Stature -for-Age Percentiles for Use in Blood Pressure 
Assessments
(Boys, 2 to 20 Years)
To be used to determine individual blood pressure thresholds for eligibility , predose and 
postdose withdra wal criteria .
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 150
Status: Approved , Date: 22 November 2020Growth Charts: Stature -for-Age Percentiles for Use in Blood Pressure A ssessments
(Girls, 2 to 20 Years)
To be used to determine individual blood pressure thresholds for eligibility , predose and 
postdose withdra wal criteria.
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 151
Status: Approved , Date: 22 November 2020Attachment 3: 95thPercentile Blood Pressure Levels For Sexby [CONTACT_369048]
1. Use Attachment 2to determine the height percentile. Subjects who fall below the 5thor above the 95th
percentile for their age, sex, and height should be evaluated using the parameters for the 5thor 95th
percenti le.
2. Measure and record the blood pressure of the child or adolescent.
3. Use the table below to identify the 95thpercentile for both systolic and diastolic blood pressure, by [CONTACT_4321], 
according to age and height .
Boys’ 95thPercentile Blood Pressure Levels by [CONTACT_369049] (mmHg) Diastolic BP (mmHg)
Age 
(Year)Percentile of Height  Percentile of Height 
5th10th25th50th75th90th95th5th10th25th50th75th90th95th
9 113 114 116 118 119 121 121 76 77 78 79 80 81 81
10 115 116 117 119 121 122 123 77 78 79 80 81 81 82
11 117 118 119 121 123 124 125 78 78 79 80 81 82 82
12 119 120 122 123 125 127 127 78 79 80 81 82 82 83
13 121 122 124 126 128 129 130 79 79 80 81 82 83 83
14 124 125 127 128 130 132 132 80 80 81 82 83 84 84
15 126 127 129 131 133 134 135 81 81 82 83 84 85 85
16 129 130 132 134 135 137 137 82 83 83 84 85 86 87
17 131 132 134 136 138 139 140 84 85 86 87 87 88 89
95thpercentile for blood pressure level is 1.645 SD over the mean.
Adapted from “The fourth report on the diagnosis, evaluation and treatment of high blood pressure in 
children and adolescents. National Institutes of Health. May 2005.”
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 152
Status: Approved , Date: [ADDRESS_462175] the blood pressure of the child or adolescent.
3. Use the table below to identify the 95thpercentile for both systolic and diastolic blood pressure, by [CONTACT_4321], 
according to age and height .
Girls’ 95thPercentile Blood Pressure Levels by [CONTACT_369050] (mmHg) Diastolic BP (mmHg)
Age 
(Year)Percentile of Height  Percentile of Height 
5th10th25th50th75th90th95th5th10th25th50th75th90th95th
9 114 114 115 117 118 119 120 76 76 76 77 78 79 79
10 116 116 117 119 120 121 122 77 77 77 78 79 80 80
11 118 118 119 121 122 123 124 78 78 78 79 80 81 81
12 119 120 121 123 124 125 126 79 79 79 80 81 82 82
13 121 122 123 124 126 127 128 80 80 80 81 82 83 83
14 123 123 125 126 127 129 129 81 81 81 82 83 84 84
15 124 125 126 127 129 130 131 82 82 82 83 84 85 85
16 125 126 127 128 130 131 132 82 82 83 84 85 85 86
17 125 126 127 129 130 131 132 82 83 83 84 85 85 86
95thpercentile is 1.645 SD over the mean.
Adapted from “The fourth report on the diagnosis, evaluation and treatment of high blood pressure in 
children and adolescents. National Institutes of Health. May 2005.”
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 153
Status: Approved , Date: 22 November 2020Attachment 4:Postdose Blood Pressure: Withdrawal Criteria Levels for Sex by A ge and Height
Postdose Blood Pressure: W ithdrawal Criteria Levels for Boys
If, postdose , either the s ystolic or diastolic BP levels are equal to or greater than the age and height 
values in the table below, measure blood pressure again after at leas t five minutes of relaxation (i e, sitting 
or supi[INVESTIGATOR_050]). If the values are still equal to or greater than the age and height values in the table, the 
subject should be withdrawn from the study and appropriate follow -up clinical care should be initiated.
Subjects who fall below the 5thor above the 95thpercentile for their age, sex, and height should be 
evaluated using the parameters for the 5thor 95thpercentile.
Blood pressure withdrawal values below 
represent the 99thpercentile for age and 
height plus 1.28 SD over the meanBlood pressure withdrawal values below 
represent the 99thpercentile for age and 
height plus 1.28 SD over the mean
Systolic BP (mmHg) Diastolic BP (mmHg)
Age 
(Year)Percentile of Height  Percentile of Height 
5th10th25th50th75th90th95th5th10th25th50th75th90th95th
9 158 159 161 163 164 166 166 111 112 113 114 115 116 116
10 160 161 162 164 166 167 168 112 113 114 115 116 116 117
11 162 163 164 166 168 169 170 113 113 114 115 116 117 117
12 164 165 167 168 170 172 172 113 114 115 116 117 117 118
13 166 167 169 171 173 174 175 114 114 115 116 117 118 118
14 169 170 172 173 175 177 177 115 115 116 117 118 119 119
15 171 172 174 176 178 179 179 116 116 117 118 119 120 120
16 174 175 177 179 180 182 182 117 118 118 119 120 121 122
17 176 177 179 181 183 184 185 119 120 121 122 122 123 124
Adapted from “The fourth report on the diagnosis, evaluation and treatment of high blood pressure in 
children and adolescents. National Institutes of Health. May 2005.”
[STUDY_ID_REMOVED]
JNJ-54135419 (esketamine)
Clinical Protocol ESKETINSUI2002 Amendment 4
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 154
Status: Approved , Date: 22 November 2020Postdose Blood Pressure: W ithdrawal Criteria Levels for Girls
If, postdose , either the s ystolic or diastolic BP levels are equal to or greater than the age and height 
values in the table below, measure blood pressure again after at least five minutes of relaxation (ie, sitting 
or supi[INVESTIGATOR_050]). If the values are still equal to or greater than the age and height values in the table, the 
subject should be withdrawn from the study and appropriate follow -up clinical care should be initiated.
Subjects who fall below the 5thor above the 95thpercentile for their age, sex, and height should be 
evalu ated using the parameters for the 5thor 95thpercentile.
Blood pressure withdrawal values below 
represent the 99th percentile for age and 
height plus 1.28 SD over the meanBlood pressure withdrawal values below 
represent the 99th percentile for age and 
height plus 1.28 SD over the mean
Systolic BP (mmHg) Diastolic BP (mmHg)
Age 
(Year)Percentile of Height  Percentile of Height 
5th10th25th50th75th90th95th5th10th25th50th75th90th95th
9 159 159 160 162 163 164 165 111 111 111 112 113 114 114
10 161 161 162 164 165 166 167 112 112 112 113 114 115 115
11 163 163 165 166 167 168 169 113 113 113 114 115 116 116
12 164 165 166 168 169 170 171 114 114 114 115 116 117 117
13 166 167 168 169 171 172 173 115 115 115 116 117 118 118
14 168 168 170 171 172 174 174 116 116 116 117 118 119 119
15 169 170 171 172 174 175 176 117 117 117 118 119 120 120
16 170 171 172 173 175 176 177 117 117 118 119 120 120 121
17 170 171 172 174 175 176 178 117 118 118 119 120 120 121
Adapted from “The fourth report on the diagnosis, evaluation and treatment of high blood pressure in 
children and adolescents. National Institutes of Health. May 2005.”
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]
CONFIDENTIAL –FOIA Exemptions Apply in U.S.
Status: Approved ,Date: 16 July 2020Janssen Research & Development *
COVID -19 Appendix
A Double -blind, Randomized, Psychoactive Placebo -controlled, Study to Evaluate the 
Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in 
Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of 
Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Subjects Assessed to 
be at Imminent Risk for Suicide
Protocol ESKETINSUI2002; Phase 2b
JNJ-54135419 (esketamine)
*Janssen Research & Development is a global organization that operates through different legal entities in
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development
studies may vary, such as, but not limited toJanssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics,
BV; Janssen- Cilag International NV; Janssen Pharmaceutica NV; Janssen, Inc; Janssen Sciences Ireland
UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout the protocol to
represent these various legal entities; the sponsor is identified on the Contact [CONTACT_369051].
This study  will be conducted under US Food & Drug Administration I NDregulations (21 CFR 
Part 312).
EudraCT NUMBER: 2016 -004422 -42
Status: Approved
Date: 16 July 2020
Prepared by: [CONTACT_12945] & Development, LLC  
EDMS number: EDMS- RIM-100193, 1.0
THIS APPENDIX APPLIES TO ALL CURRENT APPROVED VERSIONS , INCLUDING 
COUNTRY -SPECIFIC VERSIONS, OF THE PROTOCOL
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and 
may not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed 
by [CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as 
privileged or confidential.
[STUDY_ID_REMOVED]
COVID -19 Appendix
JNJ-54135419 (esketamine) Clinical Protocol ESKETINSUI2002
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 2COVID -[ADDRESS_462176] during the COVID -19 Pandemic
This Appendix applies to all current versions, including country -specific versions, of Protocol 
ESKETINSUI2002.
It is recognized that the Coronavirus Disease 2019 (COVID -19) pandemic may  have an impact on 
the conduct of this clinical study  due to, for example, self-isolation/quarantine by [CONTACT_1130] s and 
study site personnel; travel restrictions/limited access to public places, including hospi[INVESTIGATOR_600]; study 
site personnel being reassigned to critical tasks.
In alignment with recent health authority  guidance, the sponsor is providing options for study -
related subject management in the event of COVID -related disruption to the conduct of the stud y. 
This guidance does not supersede any  local or government requirements or the clinical judgment
of the investigator to protect the health and well- being of subjects/ guardians andsite staff. If, at 
any time, a subject’s safety  is considered to be at risk, study  participation will be discontinued, and 
study  follow -up will be conducted according tothe “Guidance Specific To This Protocol ” section 
of this document .
Every  effort should be made to adhere to protocol -specified assessments . Modifications addressed 
in the “Guidance Specific To This Protocol ”section should be discussed with the subjects / 
guardians , and documented as described in section entitled “Subject Agreement to Modified 
Study Procedures ”.
Additional modifications to protocol -required assessments not addressed in this document may be 
permitted in response to the pandemic emergency  after consultation between the subject / guardian
and investigator ,and with the agreement of the sponsor or designee . Missed assessments/visits 
will be captured as protocol deviations.
If re-consenting of subjects/guardians is required during the COVID -[ADDRESS_462177] as a 
result of the COVID -19 pandemic will be summarized in the clinical study report.
[STUDY_ID_REMOVED]
COVID -19 Appendix
JNJ-54135419 (esketamine) Clinical Protocol ESKETINSUI2002
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 3GUIDANCE SPECIFIC TO THIS PROTOCOL
These provisions are meant to minimize the risk of exposure to COVI D-[ADDRESS_462178] / guardian travel limitations are compromised 
by [CONTACT_4113] -19-related restrictions. As restrictions are lifted, sites should revert to original protocol 
conduct as soon a s feasible.
The safet y of study  subjects and site staff is priority. Each subject ’s circumstances and potential 
restrictions should be evaluated by [CONTACT_079] . If there isdoubt regarding the 
risk/benefit assessment of the participant in relation to these COVI D-related modifications , the 
investigator should contact [CONTACT_1034]’s Medical Monitor for discussion and / or discontinue the 
participant from the study.
All modifications described in this Appendix should be instituted in accordance with applicable 
(including local) laws, regulations, guidelines, and procedures.
SCREENI NG AND ENROLLMENT:
Potential study  candidates who arecurrently  known to bepositive for the COVID -19 virus 
will not be screened for the study .
Potential study  candidat es who have any symptoms related to the COVID -19 virus or who 
are suspected to be infected with the COVID -19 virus will not be screened for the stud y.
Potential study  candidates who have had the COVID -[ADDRESS_462179] fully  recovered may 
be considered for enrol lment following a discussion with the Sponsor’s Medical Monitor.
Prior to enrollment, s ite should assess current capability  for subject /guardian tocomplete in -
person do sing visits (D ouble -blind Treatment Phase ).
If known travel / site restrictions constrain or prohibit thecompletion of the Double -blind 
Treatment Phase , the potential candidate s hould not bescreened or enrolled .
DOUBLE -BLIND TREATMENT PHASE :
If needed for COVID -[ADDRESS_462180] may remain as inpatient for the entire 
25 day s of the Double -blind Treatment Phase provided that :
Subject and guardian agree
Principal investigator [INVESTIGATOR_368974]
Inpatient bed is available
If subject has been discharged and is an outpatient during the D ouble -blind Treatment Phase , 
andsubject/ guardian isrestricted from coming back for dosing visits ,OR,if the site cannot 
conduct adosing visit, site should consult the Sponsor’s Medical Monitor to discuss. G eneral 
guidelines are as follows:
Assess risk/benefit of subject remaining in the study
[STUDY_ID_REMOVED]
COVID -19 Appendix
JNJ-54135419 (esketamine) Clinical Protocol ESKETINSUI2002
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 4If >14days elapse since last dose, subject should be discontinued from the study
 If ≤14days elapse since last dose , dosing should resume .If possible ,all 8 doses should 
be administered .
If adosing visit is missed ,the site should call the subject and remotel y conduct the following
assessments as applicable and feasible for that Visit Day :
Suicide Ideation and Behavior Assessment Tool (SIBAT ), including both patient modules 
and clinician modules
Children’s Depression Rating Scale -Revised (CDRS -R) / Montgomery -Asberg 
Depression Rating Scale ( MADRS )
Physician W ithdrawal C hecklist (PWC -20)
International Shoppi[INVESTIGATOR_96063] ( ISLT)(from the Cogstate Battery )
Children’s Depression I nventory  (CDI)
Evaluation of adverse events ( AEs)and concomitant medications
These assessments should be placed in an “Unscheduled Assessment” folder.
If a dosing visit is missed, the Study  Visitupon return in the Double- blind treatment phase 
should beresumed as the next visit in the schedule . For example :ifVisit Day [ADDRESS_462181] returns , and dosing for the remain der
of the 8 total doses in the Double- blind Treatment Phase would be administered follow ingthe 
twice -weekl y dosing schedule .
Outpatient standard of care psy chological therap y should be initiated/continued per protocol. 
It is recognized that during this time, standar d of care psy chological therapy  sessions may  be 
constrained or interrupted. Continued psycho logical therapy  remotely  via telephone is 
acceptable/encouraged in this case.
POST -TREATMENT FOLLOW -UP PHASE
The table below provides information on modifications for remote performance of assessments
during the Post-treatment Follow -up Phase .
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]
COVID -19 Appendix
JNJ-54135419 (esketamine) Clinical Protocol ESKETINSUI2002
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 6VISIT DAY 200
To accommodate potential restrictions, thewindow for the Day 200 protocol visit may be extended 
by [CONTACT_369052] +7 days . The current protocol window is +/-7 day s; this effectivel y allows for a
– 7/+14 day  visit. I f neither an in -person or remote Day  200 visit are feasible within the extended 
window of +[ADDRESS_462182] should be discontinued.
GENERAL :
COVID -19 Related:
If a subject contract sthe virus during the Screening or Double -blind Treatment Phase :
PI [INVESTIGATOR_368975]’s Medical Monitor to discuss the best course of action
based on a risk/ benefit assessment .
If a subject contract sthe virus during the Post- Treatment Follow -up Phase :
PI [INVESTIGATOR_368975]’s Medical Monitor; if feasible, the subject, may  complete 
assessments remotel y until recovered.
Additional Assessment Information:
Clinical lab tests that cannot be performed at the site may be performed locally , for safet y, per 
Principal Investigator [INVESTIGATOR_368976] a risk/benefit assessment which should be recorded 
in source documentation.
ECGs and other physical assessments (eg,PE, body  weight, vital signs ) that cannot be 
performed in person at the site will be recorded as ‘missing’ and documented per conventions.
At each contact, subjects (and guardians as necessary ) will be interviewed to collect AEs and 
concomitant medication data. Subjects will be quest ioned regarding their general health status.
Early Withdrawal Information:
Discontinuation of study treatment and withdrawal from the study  due to COVID -19 AEs/ 
serious adverse events (SAEs) should be documented as discontinuation due to“Adverse 
Event” . The specific COVID -19-related AE should then be chosen from the corresponding AE 
logline. If a subject dies due to COVID -19, “death” should be selected as the reason for 
discontinuation and the cause of death should be specified as COVID -19-related . 
Discontinuations for other COVID -19 reasons should be documented with the prefix “COVID -
19-related” in the CRF.
Early Withdrawal visit assessments should be conducted as feasible, remotely  or in -person .
As a reminder, the investigator must ensure the subject is appropriately  transitioned and/or 
followed for any additional care required when a subject discontinues participation in the study  for 
any reason .
[STUDY_ID_REMOVED]
COVID -19 Appendix
JNJ-54135419 (esketamine) Clinical Protocol ESKETINSUI2002
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 7Subject Agreement to Modified Study  Procedures
Specific guidance provided in this Appendix in response to t he global COVID -[ADDRESS_462183]’s and legal guardian(s)’s willingness to continue participating in the study . 
Below is general guidance for an oral consent. Documentation of this should be made within the 
subject’s source documentation (one-time per subject).
General guidance for oral consent is listed below :
Who assented / consented: Name [CONTACT_369056], the legall y 
authorized representative(s ).
When they assented / consented: The time and date the conversation took place .
What they were told at the time: What changes or new aspects of the study were agreed 
due to the COVID -19 pandemic (example script: To simplify study participation during 
the COVID -19 pandemic, some of your previously completed and upcoming sc heduled 
study visits may be conducted by [CONTACT_369053]’s office. 
Your study doctor will explain which visits you can do by [CONTACT_369054]. ).
How they consented: The consent result (e.g., all subject / legal authorized representative 
questions were reviewed and answered , they understand and agree to the modifications) , 
the method used (eg, telephone ).
Who captured the oral / verbal consent: name [CONTACT_369057] t he Investigator or staff 
member who captured the assent / consent from the subject and legally  authorized 
representative(s).
Impartial Witness (if applicable): Who was present as impartial witness and how the 
impartial witness was selected .
Sites should refer to their continuity  plans and local HA/I RB/EC guidance for appropriate methods 
of documenting evidence for verbal and/or other alternate consent methods. Additionally , 
acceptability  of alternate consenting methods will vary  by [CONTACT_369055]/country 
guidance, laws, and regulations , and take precedence over the above general guidance.
Statistical Analy sis
The sponsor will evaluate the totality  of the impact of COVID -19 on collection of key  study  data . 
Additional data anal yses, if any , will be outlined in the statistical analy sis plan.
[STUDY_ID_REMOVED]
COVID -19 Appendix
JNJ-54135419 (esketamine) Clinical Protocol ESKETINSUI2002
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 8Attachm ent 1: Cogstate COVID- 19 Rem ote ISLT Administration Guidelines for ESKETINSUI2002
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]
[STUDY_ID_REMOVED]